GB2070016A - 17-acyloxy-5-corticoids and 17-acyloxy-5-corticoids - Google Patents
17-acyloxy-5-corticoids and 17-acyloxy-5-corticoids Download PDFInfo
- Publication number
- GB2070016A GB2070016A GB8101407A GB8101407A GB2070016A GB 2070016 A GB2070016 A GB 2070016A GB 8101407 A GB8101407 A GB 8101407A GB 8101407 A GB8101407 A GB 8101407A GB 2070016 A GB2070016 A GB 2070016A
- Authority
- GB
- United Kingdom
- Prior art keywords
- dione
- clme
- compound according
- pregnane
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 459
- 229940070710 valerate Drugs 0.000 claims description 124
- 238000000034 method Methods 0.000 claims description 105
- XMRPGKVKISIQBV-UHFFFAOYSA-N (+-)-5- Pregnane-3,20-dione Natural products C1CC2CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 XMRPGKVKISIQBV-UHFFFAOYSA-N 0.000 claims description 101
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 62
- 239000001488 sodium phosphate Substances 0.000 claims description 62
- 239000001257 hydrogen Substances 0.000 claims description 55
- 229910052739 hydrogen Inorganic materials 0.000 claims description 55
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 49
- 150000003431 steroids Chemical class 0.000 claims description 35
- XMRPGKVKISIQBV-BJMCWZGWSA-N 5alpha-pregnane-3,20-dione Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 XMRPGKVKISIQBV-BJMCWZGWSA-N 0.000 claims description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- 239000000460 chlorine Substances 0.000 claims description 22
- 229910052801 chlorine Inorganic materials 0.000 claims description 22
- 230000008569 process Effects 0.000 claims description 22
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 19
- 229910052731 fluorine Inorganic materials 0.000 claims description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 15
- 239000011737 fluorine Substances 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- -1 p-carboxyphenyl Chemical group 0.000 claims description 11
- 239000003054 catalyst Substances 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 8
- 239000004593 Epoxy Substances 0.000 claims description 6
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 229910052744 lithium Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 5
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- AQRHTGSVDQECPZ-UHFFFAOYSA-N azane;lithium Chemical compound [Li].N AQRHTGSVDQECPZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- 102220090095 rs1042713 Human genes 0.000 claims 3
- AHRWWYGWQKBKBF-PCHYHQBZSA-N (5r,8s,9s,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-2,4,5,6,7,8,9,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,11-dione Chemical compound C([C@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O AHRWWYGWQKBKBF-PCHYHQBZSA-N 0.000 claims 2
- AHRWWYGWQKBKBF-MUGXHADPSA-N (5s,8s,9s,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-2,4,5,6,7,8,9,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,11-dione Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O AHRWWYGWQKBKBF-MUGXHADPSA-N 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical group OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 240000008042 Zea mays Species 0.000 claims 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 235000005822 corn Nutrition 0.000 claims 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 129
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 95
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 64
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 61
- FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 description 53
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 238000002360 preparation method Methods 0.000 description 50
- 239000000243 solution Substances 0.000 description 45
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- 239000000741 silica gel Substances 0.000 description 40
- 229910002027 silica gel Inorganic materials 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 239000002244 precipitate Substances 0.000 description 28
- 238000010828 elution Methods 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 238000002425 crystallisation Methods 0.000 description 20
- 230000008025 crystallization Effects 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 18
- 238000005984 hydrogenation reaction Methods 0.000 description 18
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 16
- 239000003246 corticosteroid Substances 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 16
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 15
- 229960001334 corticosteroids Drugs 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000011736 potassium bicarbonate Substances 0.000 description 14
- 235000015497 potassium bicarbonate Nutrition 0.000 description 14
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 14
- 239000005457 ice water Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 230000003110 anti-inflammatory effect Effects 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 239000006260 foam Substances 0.000 description 11
- 230000000699 topical effect Effects 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 239000012141 concentrate Substances 0.000 description 9
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 8
- FGWYWKIOMUZSQF-UHFFFAOYSA-N 1,1,1-triethoxypropane Chemical compound CCOC(CC)(OCC)OCC FGWYWKIOMUZSQF-UHFFFAOYSA-N 0.000 description 7
- JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 235000011181 potassium carbonates Nutrition 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000011877 solvent mixture Substances 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 4
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 4
- 235000019800 disodium phosphate Nutrition 0.000 description 4
- DLLJVQNYBYOKGS-UHFFFAOYSA-N ethoxyethane;pentane Chemical compound CCCCC.CCOCC DLLJVQNYBYOKGS-UHFFFAOYSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- IECKAVQTURBPON-UHFFFAOYSA-N trimethoxymethylbenzene Chemical compound COC(OC)(OC)C1=CC=CC=C1 IECKAVQTURBPON-UHFFFAOYSA-N 0.000 description 4
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical group C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 3
- 239000003810 Jones reagent Substances 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000003470 adrenal cortex hormone Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000002905 orthoesters Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- FDJABJJEKWDNQO-UHFFFAOYSA-N pentane;propan-2-one Chemical compound CC(C)=O.CCCCC FDJABJJEKWDNQO-UHFFFAOYSA-N 0.000 description 3
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- KOPMZTKUZCNGFY-UHFFFAOYSA-N 1,1,1-triethoxybutane Chemical compound CCCC(OCC)(OCC)OCC KOPMZTKUZCNGFY-UHFFFAOYSA-N 0.000 description 2
- XUXVVQKJULMMKX-UHFFFAOYSA-N 1,1,1-trimethoxypentane Chemical compound CCCCC(OC)(OC)OC XUXVVQKJULMMKX-UHFFFAOYSA-N 0.000 description 2
- VOYADQIFGGIKAT-UHFFFAOYSA-N 1,3-dibutyl-4-hydroxy-2,6-dioxopyrimidine-5-carboximidamide Chemical class CCCCn1c(O)c(C(N)=N)c(=O)n(CCCC)c1=O VOYADQIFGGIKAT-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- RYPRIXSYXLDSOA-UHFFFAOYSA-L chromium(2+);sulfate Chemical compound [Cr+2].[O-]S([O-])(=O)=O RYPRIXSYXLDSOA-UHFFFAOYSA-L 0.000 description 2
- 229910000334 chromium(II) sulfate Inorganic materials 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- CNTIXUGILVWVHR-UHFFFAOYSA-N diphosphoryl chloride Chemical compound ClP(Cl)(=O)OP(Cl)(Cl)=O CNTIXUGILVWVHR-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000000613 ear canal Anatomy 0.000 description 2
- 210000000883 ear external Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- ZNIFVRCDHYYMNN-QZOYHBKXSA-N (8S,10S,13S,14S,17S)-17-acetyl-4,11-dihydroxy-10,13-dimethyl-1,2,6,7,8,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound OC1=C2[C@]3(CCC(C(=C3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]2(C1)C)O)=O)C ZNIFVRCDHYYMNN-QZOYHBKXSA-N 0.000 description 1
- MATJXMUQVASJHW-ONKRVSLGSA-N (8s,10s,13s,14s,17r)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1C=C[C@]2(C)C3=CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MATJXMUQVASJHW-ONKRVSLGSA-N 0.000 description 1
- ZGMNAIODRDOMEK-UHFFFAOYSA-N 1,1,1-trimethoxypropane Chemical compound CCC(OC)(OC)OC ZGMNAIODRDOMEK-UHFFFAOYSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- IKMBWAUKPYXMMQ-UHFFFAOYSA-N 2,2-dimethylpropane-1,1,1-triol 1,1,1-triethoxybutane 1,1,1-trimethoxypentane Chemical compound CC(C)(C)C(O)(O)O.CCCCC(OC)(OC)OC.CCCC(OCC)(OCC)OCC IKMBWAUKPYXMMQ-UHFFFAOYSA-N 0.000 description 1
- GWGBNENHEGYJSN-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GWGBNENHEGYJSN-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 206010000503 Acne cystic Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010068172 Anal pruritus Diseases 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- GRJDCBFZZMNLQX-UHFFFAOYSA-N CCCCC(OC)(OC)OC.CCCC(OCC)(OCC)OCC Chemical compound CCCCC(OC)(OC)OC.CCCC(OCC)(OCC)OCC GRJDCBFZZMNLQX-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- QOLRLLFJMZLYQJ-LOBDNJQFSA-N Hecogenin Chemical compound O([C@@H]1[C@@H]([C@]2(C(=O)C[C@@H]3[C@@]4(C)CC[C@H](O)C[C@@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QOLRLLFJMZLYQJ-LOBDNJQFSA-N 0.000 description 1
- OXLGJTRVVNGJRK-UHFFFAOYSA-N Hecogenin Natural products CC1CCC2(CC3CC4C5CCC6CC(O)CCC6(C)C5CC(=O)C4(C)C3C2C)OC1 OXLGJTRVVNGJRK-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- UVLDESQWQRMYKD-UHFFFAOYSA-N Neobotogenin Natural products CC1C(C2(C(=O)CC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 UVLDESQWQRMYKD-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010030865 Ophthalmic herpes zoster Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000009544 Pruritus Ani Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- ITYMTTQVNYAJAA-OCUNRLNVSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(=O)CC)[C@@]1(C)C[C@@H]2O ITYMTTQVNYAJAA-OCUNRLNVSA-N 0.000 description 1
- HYMZEQDSGWHVKB-UHFFFAOYSA-N [ClH]1[ClH]OCC=C1 Chemical compound [ClH]1[ClH]OCC=C1 HYMZEQDSGWHVKB-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940055042 chromic sulfate Drugs 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 229910000356 chromium(III) sulfate Inorganic materials 0.000 description 1
- 239000011696 chromium(III) sulphate Substances 0.000 description 1
- 235000015217 chromium(III) sulphate Nutrition 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 230000008951 colonic inflammation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000003481 dermatitic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000002638 heterogeneous catalyst Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- VBTQNRFWXBXZQR-UHFFFAOYSA-N n-bromoacetamide Chemical compound CC(=O)NBr VBTQNRFWXBXZQR-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- JWMFYGXQPXQEEM-WZBAXQLOSA-N pregnane group Chemical group [C@@H]12CC[C@H](CC)[C@@]1(C)CC[C@H]1[C@H]2CCC2CCCC[C@]12C JWMFYGXQPXQEEM-WZBAXQLOSA-N 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
- C07J7/0055—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0015—Oxiranes at position 9(11)
Description
.DTD:
1 GB 2 070 016 A 1 im .DTD:
SPECIFICATION .DTD:
17-acyloxy-5-corticoids and 17c-acyloxy-5-corticoids Numerous patents disclose various 17-hydroxy corticoids which are useful as topical antiinflammatory agents. Various substituents and/or derivatives such as 2Cmethyl, 9ó-fluoro, 6- methyl, 4TM, 16-alkyl and 6o-fluoro have been reported to enhance pharmacological activity. 5 In general, those substituents which enhance corticoid activity such as 6C-methyl, A.4 or 9fluoro were also found to enhance resistance of the 17ó-hydroxy corticoid to metabolic transformation by the liver; that is the more potent substituted steroids were more slowly metabolized.
.DTD:
In general, 21-halo steroids have been reported as providing enhanced activity and/or favorable ratio of topical anti-inflammatory activity to systemic side effects, see U.S. patents 3,721,687 and 10 3,992,422. U.S. Patent 4,051,055 discloses 21-halo steroids but not as topcial anti-inflammatory agents but as intermediates in the synthesis of corticoids. U.S. Patent 3, 502,700 discloses various 21- halo steroids as useful for their progestational activity and does not mention topical anti-inflammatory activity. All of the above 21 -halo steroids were A4_ and A.4-9,21 - dihalo-11/3-hydroxy-16-alkylsteroids.
.DTD:
A number of these are mentioned as having an "...especially favourable topical anti-inflammatory 15 activity and/or ratio of topical anti-inflammatory activity to glucocorticoid acitivity...". In the specification of U.S. Patent 3,721,687 a number of substituents are identified as being preferred or especially preferred, these include z1.4; 9-chloro-11/3-hydroxy-16-methyl- 17-propionate; 9z-fluoro11-hydroxy-16C-methyl-17-esters with at least 3 carbon atoms and 9ofluoro-11-keto-16-methyl or - 16-methylene steroids. A particularly preferred compound appears to be "9o,21-difluoro-16- 20 methylene17-propionyloxy- 1,4-diene-3,11,20-trione".
.DTD:
Virtually all the cortical steroids disclosed for topical antiinflammatory activity are A4 or ATM steroids. U.S. Patent 3,055,922 discloses a series of 5-steroids which were alleged to retain the topical anti-inflammatory activity of the corresponding A4- or A.q- steroids while the systemic activity was for all practical purposes eliminated. The applicants have now established that the "5ó" steroids of 25 U.S. Patent 3,055,922 were actually "5/V'. This matter will be discussed fully in the Detailed Description of the Invention.
.DTD:
Therefore, both U.S. Patent 3,721,687 and 3,055,922 disclose a split between the topical anti- inflammatory activity and the systemic activity. However, U.S. Patent 3, 721,687 discloses that 1730.acyloxy-Al.4-steroids have a good activity split while U.S. Patent 3, 055,922 discloses that 17ó-hydroxy- 30 5C-steroids have a good activity split. The present invention discloses tht 17-acyloxy-5-steroids and 17ó-acyloxy-5/-steroids surprisingly and unexpectedly have an excellent activity split, and high topical anti-inflammatory topical/systemic ratio.
.DTD:
German Often 2,905,674 discloses a process of transforming a 5-pregnane to the corresponding A1.4-17o-acylate which is the opposite of the present invention. The steps in the 35 procedure include (1) protection of the 11/3-hydroxyl group as a trimetHylsilyl (TMS) derivative (Example 1), (2) esterification of the 17 -hydroxyl group to give a 5-17- acyl-11/3-TMS steroid (Example 2), (3) dehydrogenation (oxidation) of the 5z-A ring to a A1.4-A ring (Example 3) and (4) removal of the TMS protecting group (Example 4). In this process a 5ol- 17z-acyl steroid is disclosed but it does not have a free 11/3-hydroxyl group. In addition, the compound is not disclosed as having 40 any useful pharmacological activity but only as an intermediate.
.DTD:
Disclosed are 17oc-acyloxy-5/3-steroids (I) and 17o-acyloxy-5cz-steroids (IV) which have an excellent split between topical anti-inflammatory activity and systemic activity.
.DTD:
Also disclosed are 17-acyloxy-5J3-9,11.epoxy steroids (11) and 17óacyloxy-5j3-AgC}-steroids (111) which are useful intermediates in the preparation of the 17c-acyloxy-5- steroids (I) of the present 45 invention.
.DTD:
Further disclosed are 17ó-acyloxy-5-21-hydroxy steroids lIVE) which are useful intermediates in the preparation of the 17z-acyloxy-5z-steroids (IV) of the present invention.
.DTD:
Disclosed is a process for preparing 17ó-acyloxy-5-steroids (I) which comprises (1) hydrogenating the correspondingA4- or A.4-steroid (IA) in the presence of a hydrogenating catalyst 50 and (2) separating the 5/3-isomer from the 5o-isomer.
.DTD:
Also disclosed are processes for preparing the 17c-acyloxy-5/-9,11-exoxysteroid (11) and the 17-acyloxy-5t-Ag(}-steroid (111) which comprises (1) hydrogenating the corresponding 44- or A'4- steroids (IIA or IliA) respectively, in the presence of a hydrogenating catalyst and (2) separating the 5]3- isomer from the 5C-isomer. 55 Further disclosed is a process for the preparation of a 17o,21-dihydroxy- 5ó-steroid (IVD) which comprises (1) blocking the 17- and 2 l-hydroxyl groups of a A4-17,21dihydroxy steroid (IVA) by reaction with formaldehyde to give a A4-17,21-blocked steroid (IVB), (2) reducing the A4-double bond by reaction with lithium-ammonia to give the 17,21 -blocked-5ó-steroid (IVC) and (3) removing the 17,21-blocking group. 60 The 17o-acyloxy-5/3-corticoids (I) of the present invention are generally most readily prepared by hydrogenating the corresponding 64- or A,4-steroids of formula (IA) which are either well-known to those skilled in the art or can be readily prepared by well-known procedures from known compounds.
.DTD:
The 64- or A.4-steroid (IA) starting material is subjected to hydrogenation as is well-known to 2 GB 2 070 016 A 2 those skilled in the art. The A4 or &1,4-steroid (IA) is dissolved in a suitable organic solvent such as ethyl acetate, acetone, THF, toluene and alcohols such as methanol or ethanol. Preferred solvents are ethyl acetate, THF and acetone. The reaction is performed in the presence of a hydrogenation catalyst. These catalysts are well known to those skilled in the art and include, for example, heterogeneous catalysts such as palladium on carbon, platinum on carbon, platinum dioxide, palladium on barium carbonate or 5 palladium on calcium carbonate, rhodium on alumina, rhodium on carbon, palladium on barium sulfate or palladium on zinc oxide and the like. Soluble catalysts such as tris(triphenylphosphine) rhodium (I) chloride may also be employed. In addition strong acid or strong base catalysts may optionally be used.
.DTD:
Suitable strong acids include mineral acids such as hydrogen chloride or perchloric acid and organic acids such as p-toluene sulfonic acid or 2,4-dinitrobenzene sulfonic acid, suitable strong bases include 10 inorganic bases such as sodium hydroxide or potassium hydroxide and organic bases such as triethylamine or 1,4-diazabicyclo[2.2.2]octane (Dabco). The reaction is performed under hydrogen using a pressure of 1--10 atmospheres. One to two atmospheres is convenient. Higher pressure can be utilized if desired. = The reaction is performed at 20--25 until the desired uptake of hydrogen is complete. Lower or 15 higher temperatures are suitable but room temperature is most convenient.
.DTD:
When the uptake of hydrogen is complete, the mixture is filtered and the filtrate is concentrated - under reduced pressure. The concentrate contains a mixture of the 5 and 5/3 isomers. The 5 isomer is formed stereospecifically when R9 is fluorine. The 5/3 isomer predominates when the C ring functionality is 9,11-epoxy (IIA) or 69(11} (IliA). A roughly equal mixture of 5/3 and 5o isomers is formed 20 when R9 is hydrogen and Rll is hydroxyl. This ratio is dependent on the experimental conditions and the specific structure of the hydrogenation substrate.
.DTD:
The mixture of 5/3 and 5 isomers is separated by chromatography as is well-known to those skilled in the art. Adsorbents such as silica gel, Florisil and alumina may be employed. Various organic solvents such as methanol, acetone, ethyl acetate, ether, methylene chloride, hexane, Skellysolve B 25 and chloroform are used for elution either alone or in combination. Those fractions containing the steroid product with the 5/3 configuration as determined by CMR are combined and concentrated to give the desired 17-acyloxy-5/3-product (I). If desired further purification is achieved by crystallization from a suitable solvent.
.DTD:
When a 64- or a &1.4-steroid (IA--IIIA) is hydrogenated, two isomeric products, 5c and 5/{ (I--III), 0 can be and are formed. U.S. Patent 3,055,922 reported obtaining only the 5o-isomer analytically pure and in almost quantitative yield upon hydrogenation of A4- and 61.4- steroids with the appropriate noble metal catalyst. U.S. Patent 3,055,922 was filed in 1961. In 1972 J. L. Gough, J. P. Guthrie and J. P.
Stothers [J.C.S. Chem. Comm. 979 (1972)] reported a method of determining the stereochemistry of the A/B ring junction by CMR. These authors reported that when the A/B ring junction is cis(5/3), the C19 35 carbon atom is less shielded by about 11--12 ppm. Based on this evidence and their own experimentation the applicants have determined that the predominate isomer produced when a A4- or &1.4-steroid is hydrogenated under the conditions set forth in this invention is 5/3 and not 5 as reported in U.S. Patent 3,055,922. It is realized that at the time of filing of the patent application for U.S. Patent 3,055,922, CMR spectroscopy was not available. 40 Further, E. L. Shapiro et al. (J. Chem. Soc., Chem. Comm. 1976, 961) in 1976 reported that hydrogenation of A4and/k.4-3-keto-9-fluoro gave exclusively the 5/3- isomer.
.DTD:
A preferred way to produce the 5/3-steroid (I) is by hydrogenation of the corresponding 64- or Al'4-steroid (IA, where R9 is fluorine or chlorine) as disclosed in Chart A. An alternative process is to hydrogenate either the 9,11-epoxy-steroid (IIA) or the &(ll)-steroid (IliA) to the corresponding 9,11- 45 epoxy-5/3-steroid (11) or the &(l)-5/3-steroid (Ill). The 17o-acyloxy-5/3- 9,11 -epoxy steroid (11) may be converted to the desired 17o-acyloxy-5/3-steroid (I, R9 is chlorine and Rll is hydroxyl) under carefully controlled reaction conditions (see Example 129). The 17o-acyloxy-5/3- &9(11)-steroid (111) may be readily converted to the desired 17z-acyloxy-5/3-steroid (I, R9 is chlorine and Rll is chlorine) by means well known to those skilled in the art. 50 It is possible to prepare 5/3-starting materials from bile acid intermediates. For example, 11 o, 170,21-trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 21 -acetate [E. P Oliveto et al., J. Amer.
.DTD:
Chem. Soc. 80, 6687 (1958)] may readily be converted to 17,21-dihydroxy16/3-methyl-5/-pregn- 9(11)-ene-3,20-dione 21 -acetate, an intermediate for preparation of 17- acyloxy-5/3-A9cl)-steroids (111). 55 Alternatively one skilled in the art can start with a variety of A4 or 61. 4-steroids (IA) and hydrogenate to produce the corresponding 5/3- and 5C-steroids and then modify the B, C, or D ring of the steroid to obtain the desired pharmacologically active 17e;-acyloxy- 5/3-steroid (I) or 17-acyloxy5C-steroid (IV).
.DTD:
The process of hydrogenation of the A4 or 6.4-steroids (IA) has been performed with a large 60 variety of substituents, attached to the B, C and D rings of the steroid. Both 64- (Example 74) and A1.4- steroids (Examples 53, 73 and 80) are suitable starting materials for hydrogenation. For example, 9fluoro-11/3,17o,21-trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17,21propionate was prepared from both the corresponding A4-steroid (Example 74) and the corresponding 61,4-steroid (Example 75).
.DTD:
Both 11/3-hydroxyl (Examples 53, 73, 74, 76 and 78) and 11-keto (Example 80) steroids have been 65 3 GB 2 070 016 A 3 hydrogenated to give the corresponding 5/%steroid. AT C-16, 16/3-methyl (Examples 53, 73, 74 and 176), 16-methyl (Examples 104, 107, 113 and 120) and 16-hydrogen (Examples 78, 80 and 114) steroids all have been used. At C-9, 9o-chloro (Examples 115--117), 9,11- epoxy (Example 125) and A9 (Examples 38 and 44) all can be used. At C-6 both 6o-methyl (Example 80) and 6-fluoro (Example 81) have been used. AT C-21 various functionalities such as hydroxyl (Example 89), ester 5 (Examples 74, 81, 113), chlorine (Examples 53, 73 and 80), mesylate (Examples 76 and 104) and fluorine (Example 117) all can be used.
.DTD:
A given 5/{.17o-acylate (I) can be prepared by processes other than hydrogenation of the corresponding,A4 or A1.4-precursor. For example, 21 -chloro-9o-fluoro-16/- methyl-11/3,17- dihydroxy-5/-pregnane-3,20-dione 17-propionate (I) was prepared from the corresponding A.4- 10 steroid (IA) by hydrogenation, see Example 53. The same compound was also prepared by starting with the corresponding A.4-17 -hydroxy-21 -benzoate, 9-fluoro-11/3,17o,21- trihydroxy-16/3- methylpregna-1,4-diene-3,20-dione 21-benzoate and subjecting it to the following reactions:
.DTD:
hydrogenation (Preparation 2), hydrolysis of the 21-benzoate (Example 22), formation of the 17- propionate (Example 24), formation of the 21 -mesylate (Example 29) and displacement of the 21 - 15 mesylate (Example 34) by chloride.
.DTD:
Therefore, hydrogenation of the A4 or A1.4-steroid may take place early in the synthesis with other substitution and/or modification to be performed after hydrogenation or the steroid molecule can be substituted and/or modified so that the last step in the synthesis is the reduction of the unsaturation in the steroid A ring. 20 Generally, the A4 or A.4-steroids (IA) to be hydrogenated have at the 9o- position a fluorine atom and at the 11/-position a hydroxyl group. However,/k4 and A.4-steroids having at the 9 and 11 positions a double bond, A9c11, can also be hydrogenated to produce the corresponding 5/3-pregnane.
.DTD:
The Ag()-5/3-steroids are useful to prepare 9,11/3-dichloro-5/3-steroids (I), see Examples 38 43 and 44---52 (9,11/3,21-trichloro-5/3-sterolds). Likewise, A4 and A.4-steroids having at the 9 and 11 25 positions an epoxy group (9,11-epoxy) are useful to prepare 9-chloro-11/3hydroxy-5/3-steroids. The 9,11-epoxy-5/3-steroids are not useful to prepare 9-fluoro-11/3-hydroxy- 5/3-steroids because when the epoxide is reacted with hydrogen fluoride only a few percent of the desired 9-fluoro-11/3-hydroxy- 5/3-steroid are produced.
.DTD:
The 9-chloro-11/%hydroxy-5/%steroids (I) are obtained from the corresponding 9,11-epoxy-5/3- 30 steroids by reaction with hydrogen chloride, hydrogen chloride in the presence of a quaternary amine chloride (such as tetrabutylammonium chloride) or dichlorobis (benzonitrile) palladium (11) under carefully controlled conditions.
.DTD:
The 5-steroids (IV) are produced in small amounts during hydrogenation of the corresponding z4 or A1.4-steroid (IA). However, a preferred route to prepare the 5oc- steroids (IV) ls not by 35 hydrogenation of the corresponding A4 or A'4-steroid (IA) but rather by a stereoselective metal-amine reduction of a A4 or Al'4-steroid. The steroid is reduced with sodium in ammonia or lithium in ammonia or alkylamines such as methylamine, ethylamine or ethylenediamine, preferably with lithium in liquid ammonia. Before performing the lithium-ammonia reduction the pregnane side chain of the As or A1.4-steroid must be protected. The side chain is conveniently protected as a 17,20;20, 21-bisdioxy (preferably 40 bismethylenedioxy) derivative as is well-known to those skilled in the art (U.S. Patents, 2,888,456 and 2,888,457).
.DTD:
The A4 or A,4-steroid in an inert organic diluent such as THF, diethyl ether or dioxane is added to a solution of lithium in liquid ammonia at -60 to --80 . The reaction is monitored by TLC and when complete (about 1 hour), the reaction is worked up as is well-known to those skilled in the art. 45 Following the stereospecific reduction, the hydroxy protecting groups are removed, as is well-known to those skilled in the art, by acid hydrolysis. Acetic acid is a suitable acid. Alternatively, the 5C-starting materials may be obtained from a sapogenin which possesses the desired 5Cconfiguration. For example, 3/%hydroxy-5o-pregna-9(11), 16-dien-20-one 3-acetate derived from hecogenin is a versatile starting material for preparation of 5-steroids (IV) of this invention as will be apparent to one 50 skilled in the art. This intermediate has been converted to 17o,21dihydroxy-16/-methyl-5ó-pregn- 9(11)-ene-3,20-dione 21-acetate by J. Attenburrow et al., (J. Chem. Soc. 1961,4547).
.DTD:
Following reduction of the A4 or ATM double bond to produce the 5osteroid and the hydrolysis of the blocking groups to produce the 17c,21-dihydroxy-AS(l)-5-steroid (Preparation 18) the steroid is acylated at C-17. From this point, a large number of modifications at C-9, 11, and 21 can be made to 55 produce the desired 5C-steroid (IV). For example, if a 21-chloro-5- steroid (IV) is desired, the 21- hydroxyl group is transformed to the mesylate (see Example 205) and subsequently to the 21-chloro substituent (see Example 206, Step 3, and Example 251, Step 1). If a 5- steroid (IV unsubstituted at C-21 is desired, it is produced from a 21 -chloro steroid (see Example 221) If 9,11/3-dichloro-5- steroids (IV) are desired, they are produced from the corresponding A()-5- steroids as is well known 60 to those skilled in the art (see Examples 251, Step 2 and 374). Many topically active anti-inflammatory steroids have a fluorine atome at C-9. If a 5c steroid with a hydrogen atom at C-9 is desired, it can be readily prepared from the corresponding 9o-bromo-5-steroid (see Example 266 and 383). The 21 - phosphates (Examples 314--328), 21-disodium phosphate (Examples 329--- 343), 21- 4 GB 2 070 016 A 4 i hemisuccinates (Examples 344--358) and 21-sodium hemisuccinates (Examples 359m373) are produced by means well known to those skilled in the art.
.DTD:
The 17o-acyloxy-5/3-corticosteroids (I) and 17cz-acyloxy-5occorticosteroids (IV) of the present invention are therapeutically useful anti-inflammatory agents wnen applied topically or administred locally to warm-blooded animals responsive to treatment with anti- inflammatory corticosteriods. The 5 17(z-acylocy-5/3-corticosteroids (I) and 17o-acyloxy-5(z-corticosteroids (IV) are especially useful for topical and local administration because they possess the unique combination when applied locally of high potency, low systemic activity, thus producing less unwanted systemic corticoid action for a given amount of topical-local anti-inflammatory activity relative to corticoids now employed therapeutically.
.DTD:
The 17a(-acyloxy-5/}-corticosteroids (I) and 17o-acyloxy-5ocorticosteroids (IV) are administered 10 topically to the inflamed skin, eyes, external ears and mucous membranes of the mouth, nose, respiratory tract, vagina, rectum and colon. They are applied or instilled to these areas as drug suspensions or solutions in the usual dosage forms such as solutions, lotions, creams ointments, gels, -- pastes, aerosols, bandages or tape, drops, enemas, suppositories, etc. For the therapy of asthma, allergic rhinitis and other inflammatory respiratory disorders, the usual dosage forms such as aerosols 15 or powders, solutions and suspensions for inhalation are employed.
.DTD:
The 17o-acyloxy-5/-corticosteroids (I) and 17-acyloxy-5-corticosteroids (IV) are also useful -- for local intralesional therapy by intracavity (e.g., intra-articular) or soft tissue injection of solution, suspension or solution-suspension dosage forms. Also useful for the therapy of secondarily infected and inflamed conditions, particularly of the skin, eyes, external ear canals, rectum and vagina, are 20 combination dosage forms of the 17-acyloxy-5/-corticosteroids (I) or 17- acyloxy-5corticosteroids (IV) and antifungal and/or antibacterial agents such as clotrimazole, dichloroxine, miconazole, neomycin, gentamycin, clindamycin, etc.
The water-soluble esters (pharmaceutically acceptable salts) of 21hemisuccinate or 21- phosphate are useful in eye and ear drops, rectal and vaginal formulations, for inhalation and for 25 intracavity injection.
.DTD:
The concentration and dosage regimen of the dosage form used and the frequency of administration will depend upon the particular location and condition treated, the severity of the inflamed lesion, the potency of the particular 17(z-acyloxy-5/}- corticosteroids (I) and 17-acyloxy-5corticosteroids (IV), the phase and natural course of the inflamation, the age and condition of the 30 patient, and other factors known to practitioners skilled in the management of cutaneous and local inflammatory diseases.
.DTD:
The drug concentration ranges, and the dosage regimens of 17-acyloxy-5corticosteroids (I) and 17-acyloxy-5-corticosteroids (IV) administered topically (locally) on inflammatory lesions of the skin, nostrils, vagina, rectum, colon and external ears are about 0.005% to about 2.5% with one to four 35 daily applications. Generally preferred concentrations are from 0.01% to 0.2%. These same concentration ranges are used in the eyes, but with one to eight daily applications or installations, according to phase and disease severity. For the therapy of asthma or other inflammations of the respiratory tract, two to three daily inhalations or sprays, each containing from 0.001 to 2.0 mg of corticosteroid are used. From 1.0 to 100 mg doses of the 17o-acyloxy-56- corticosteroids (I) and 17oLacyloxy-5-corticosteroids (IV) are administered for intralesional inflammations of joints, tissue cavities and soft tissues. The volume and frequency of the injections are dependent primarily on lesion size, severity and response to treatment. = Some examples of inflammatory diseases wherein the 17(z-acyloxy-5/3- corticosteroids (1) and 17o-acyloxy-5-corticosteroids (IV) are useful topically and locally are (1) dermatoses such as 45 psoriasis, atopic, neuro, contact and allergic dermatitis, lichen planus, alopecia areata and immune diseases (2) pruritus ani, vulva and rectal or colonic inflammation (3) conjuctivitis, superficial punctate keratisis and herpes zoster keratitis of the eyes (4) contact, allergic and selected infective otitis of the external ear canal and (5) allergic-inflammatory nasal and respiratory conditions such as rhinitis and asthma. 50 Some examples of conditions treated with the 17-acyloxy-5/3- corticosteroids (I) and 17o- acyloxy-5-corticosteroids (IV) by injection into local lesions are (1) rheumatoid arthritis, bursitis and peritendenitis and (2) alopecia areata, cystic acne, keloids, hypertrophic scarring conditions and localized, treatment-resistant type dermatitic lesions.
.DTD:
The definitions and explanations below are for the terms as used throughout the specification. 55 .DTD:
All temperatures are in degrees Centigrade.
.DTD:
TLC refers to thin-layer chromatography.
.DTD:
THF refers to tetrahydrofuran.
.DTD:
DMF refers to dimethylformamide.
.DTD:
SSB refers to a mixture of isomeric hexanes. 60 p-TSA refers to p-toluenesulfonic acid.
.DTD:
Saline refers to an aqueous saturated sodium chloride solution.
.DTD:
IR refers to infrared spectroscopy determined on a mineral oil mull of the sample.
.DTD:
CMR refers to 13C magnetic resonance spectroscopy, in deuterochloroform, chemical shifts of C- 19 are reported in ppm (8) downfield from TMS. 65 .DTD:
G8 2 070 016 A 5 NMR refers to nuclear (Proton) magnetic resonance spectroscopy chemical shifts are reported in ppm () downfield from TMS.
.DTD:
[a]s refers to the angle of rotation of plane polarized light (specific optical rotation) of a 1% solution in dioxane at 25 .
.DTD:
When solvent pairs are used, the ratio of solvents used are volume/volume (v/v). 5 Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to a patient from a pharmacological-toxicological point-of-view and to a manufacturing pharmaceutical chemist from a physical-chemical point-of-view, regarding composition, formulation, stability, patient acceptance and bio-availability.
.DTD:
R2 and R8 are each hydrogen, fluorine, chlorine or methyl. 10 R7 and R9 are each hydrogen, fluorine or chlorine.
.DTD:
R is hydrogen or C1_4 alkyl.
.DTD:
RI is chlorine or hydroxyl in the/3-configuration or oxo.
.DTD:
R6. is hydrogen, fluorine, chlorine or methyl.
.DTD:
R1B is hydrogen or methyl, with the proviso that one of RIB and Re is hydrogen. 15 Rz is C1_6 alkyl, phenyl, p-tolyl, p-carboxyphenyl or p-carboalkoxyphenyl (in which the alkoxy group is preferably C_8, more preferably C_8 and most preferably C1_4).
.DTD:
R2 is hydrogen, fluorine, chlorine, bromine, --OR2a or --OS02CH3.
.DTD:
R2a is hydrogen, --COR2b or PO(OH)2, optionally in the form of a pharmaceutically acceptable sapt thereof. 20 R2b is C_ alkyl, phenyl, p-tolyl, p-carboxyphenyl, p-carboalkoxyphenyl (alkoxy preferably as above) or--CH2CH2COOH, optionally in the form of a pharmaceutically acceptable salt thereof.
.DTD:
indicates the attached group can be in either the a or/3 configuration.
.DTD:
- - represents a single or double bond; for RI a single bond when chlorine or hydroxyl and a double bond when oxo. 25 Any alkyl or alkoxy group may be in straight or branched chain form.
.DTD:
A hydrogenation catalyst is an additive which catalyste the hydrogenation reaction to give the corresponding 5/3-steroid (1111).
.DTD:
The following preparations and Examples illustrate the process of the invention and how the novel compounds may be prepared. 30 Preparation 1 9ó-fluoro-11/3,17ó,21 -trihydroxy-5/3-pregnane-3,20-dione 21 -acetate A mixture of 9ó-fluoro-11/3,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate (20 g)in acetone (200 ml) is hydrogenated in the presence of palladium on carbon (5%, 1 g) until the uptake of hydrogen is complete. The mixture is filtered and the filtrate is concentrated under reduced pressure. 35 The concentrate is column chromatographed on silica gel (200 g) packed in acetone-methylene chloride (10/90). Elution is performed with the same solvent system. The appropriate fractions are pooled and concentrated to give the product which upon crystallization from acetone-SSB gives 9fiuoro-11/3,17ó,21 - trihydroxy-5/3-pregnane-3,20-dione 21 -acetate, m.p. 215.5 (decomposition); []+72 ;CMR 26.66;IR (mull)3580,3380, 1745, 1730, 1680, 1260, 1235, 1190, 1105, 1050, 40 990, and 905 cm-.
.DTD:
Preparation 2 9o-fluoro- 11/3,17o,21 -trihydroxy- 16/3-methyl6/%pregnane-3,20-dione 21 -benzoate Following the general producedure of Preparation 1 and making non- critical variations but starting with 9ó-fluoro-11/3,17c,21-trihydroxy-16/3-methylpregna-l,4- diene 3,20-dione 21-benzoate 45 (betamethasone 21 -benzoate) there is obtained 9c-fluoro-11/3,17c,21 -trihydroxy-16/3-methyl-5/3pregnane-3,20- dione 21-benzoate, m.p. 205 (decomposition); CMR 26.66; IR 3600, 3340, 1740, 1720, 1695, 1605, 1585, 1490, 1275, 1255, 1125, 1115, 1160, 1045 and 710 cm- and [o]D+ 109 .
.DTD:
Preparation 3 50 17o,21 -dihydroxy- 16/3-methylpregna-1,4,9(11)triene 3,20-dione A mixture of 17ó,21-dihydroxy-16/3-methylpregna1,4,9(11)triene-3,20- dione 21-benzoate (U.S. Patent 3,725,392, 20 g) in methanol (600 ml), methylene chloride (400 ml) and methanolic sodium methoxide (25%, 13 ml) is stirred at 20--25 for one hour under an inert atmosphere. The reaction mixture is then acidified with acetic acid (4 ml), concentrated under reduced pressure to 55 about 320 ml and diluted with water (320 ml) in methanol (100 ml). The mixture is extracted with SS8, and then the aqueous methanol phase is concentrated under reduced pressure and cooled to 5 , The product is collected and dried to give the title compound, m.p. 215.5- -218.5 .
.DTD:
Preparations 4 and 5 Following the general procedure of Preparation 3 and making non-critical variations but starting with the corresponding16-methyl or 16-hydrogen (R6 is hydrogen) the following compounds are obtained.
.DTD:
6 GB 2 070 016 A 6 Preparation 4 17ó,21 -dihydroxy-16o-m ethylpregna1,4,9(11)triene-3,20-dione Preparation 5 17 ,21 -dihydroxypregna-1,4,9(11)triene-3,20-dione Preparation 6 5 17z,21-dihydroxy-16/-methylpregna-1,4,9(11)triene-3,20-dione 17propionate A mixture of 17,21 -dihydroxy-16/-methylpregna-1,4,9(11)triene-3,20-dione (Preparation 3, g)in THF (220 ml) containing triethylorthopropionate (11 ml) and p-TSA (0. 66 g) is allowed to stand at 30 for 0.5 hours. Then sulfuric acid (2N 11 ml) is addedòThe mixture is stirred for an additional 0.5 hours, made basic with potassium bicarbonate (1 N, 66 ml), diluted with water and 10 concentrated under reduced pressure. The precipitate is dissolved in methylene chloride, washed with aqueous potassium bicarbonate, dried and concentrated to give the title compound, TLC, Rf=O.40 (acetone-methylene chloride 10/90).
.DTD:
Preparations 7 and 8 Following the general procedure of Preparation 6 and making non-critical variations but starting 15 with the 17,21-dihydroxy steroids of Preparations 4 and 5, (Column A) the 17-esters of column B are obtained.
.DTD:
Preparation Column A 7 4 Column B 17o,21-dihydroxy-16a-methylpregna-1,4,9(11)- triene-3,20-dione 17-propionate 20 17ó,21 -dihydroxy-pregna-1,4,9(11)triene-3,20- dione 17-propionate 8 5 Preparation 9 17,21-dihydroxy-16/3-methylpregna-1,4,9,(11)triene-3,20-dione 17,21 dipropionate A mixture of 17,21 -dihydroxy-16/3-methylpregna- 1,4,9( 11)diene-3,20- dione 17-propionate 25 (Preparation 6, 4.1 g) in pyridine (4 ml) and propionic anhydride (8 ml) is allowed to stand for 3 hours. The reaction mixture is diluted with ice water and acetone (100 ml), allowed to stand for one hour and then concentrated under reduced pressure. The precipitate is collected, dissolved in SSB-ethyl acetate (4/1) and washed successively with aqueous potassium bisulfate, aqueous potassium bicarbonate and saline. The mixture is dried and concentrated under reduced pressure to a foam which is column 30 chromatographed on silica gel (500 g), packed in acetone-methylene chloride (5/95). Elution is performed with the same acetone-methylene chloride mixture. The appropriate fractions are pooled and concentrated to give the title compound, NMR (CDCI3) 0.73, 1.16, 1.36, 1.40, 4.57, 5.6, 6.1--6.4 and 7.1--7.35 &.
.DTD:
Preparations 10 and 11 35 Following the general procedure of Preparation 9 and making non-critical variations but starting with the 17-esters of Preparations 7 and 8 (Column C), the 17,21 - diesters of Column D are obtained.
.DTD:
Preparation Column C Column D 7 17o,21 -dihydroxy- 16ol-methylpregna1,4,9(11)- triene-3,20-dione 17,21 -dipropionate 40 11 8 17o,21-dihydroxypregna- 1,4,9(11)- " triene-3,20-dione 17,21 -dipropionate Preparation 12 17ó,21-dihydroxy-16/3-methylpregna-1,4,9(11)triene-3,20-dione 17propionate 21-mesylate A mixture of 17o,21-dihydroxy-16/-methylpregna-1,4,9(11)triene-3,20-dione 17-propionate (Preparation 6, 8.3 g) in pyridine (39 ml) is cooled to 0 and methanesulfonylchloride (9.8 ml) is added slowly. After stirring for one hour at 0% the reaction mixture is poured into a mixture of ice water containing concentrated hydrochloric acid (30 ml). The precipitate is collected, dissolved in methylene chloride and washed successively with aqueous potassium bisulfate, water and aqueous potassium bicarbonate. The mixture is dried and concentrated under reduced pressure to a foam which is column chromatographed on silica gel (1 kg), packed in acetonemethylene chloride (5/95). Elution is performed in the same acetonemethylene chloride mixture, the appropriate fractions are pooled and concentrated to give the title compound, NMR (CDCI3) 0.73, 1.16, 1.37, 1. 41,3.20, 4.7, 5.5, 6.0--6.4, and 7ò1--7.3.
.DTD:
Preparations 13 and 14 Following the general procedure of Preparation 12 and making non-critical variations but starting with and substituting the 21-hydroxy steroids of Preparations 7 and 8 (Column E), for 17ó,21 - 7 GB 2 070 016 A 7 dihydroxy-16/3-methylpregna-1,4,9(11)triene-3,20-dione 17-propionate, the 21-mesylates of Column F are obtained.
.DTD:
Preparation Column E 13 7 14 8 Column F 17o,21 -dihydroxy16o-methylpregna- 1,4,9(11)' triene-3,20-dione 17-propionate 21-mesylate 17,21-dihydro-5/3-pregna-1,4, 9(11)- triene-3,20-dione 17-propionate 21 -mesylate Preparation 15 17,21-dihydroxy-16/3-methylpregna-4,9(11)diene-3,20-dione A mixture of 17,21 -dihydroxy- 16/-methylpregna-4,9(11)diene-3,20-dione 21 -benzoate (U.S. 10 Patent 3,725,392, 32 g) in methanol (700 ml) is stirred with potassium carbonate (5.3 g) in water (50 ml) at 20--25 for about 2 hours. The mixture is cooled, acidified with acetic acid (7 ml), diluted with water (475 ml) and concentrated under reduced pressure. The precipitate is collected, washed with water and dried to give the title compound, TLC, Rf=0.70 (acetone- methylene chloride, 20/80).
.DTD:
Preparation 16 15 16j3-methyl-17 o,20:20,21 -bismethylenedioxypregna-4,9(11)dien-3-one A solution of hydrochloric acid (250 ml) and formalin (35%, 250 ml) prepared at 0 is added to a stirred suspension of 17oL,21-dihydroxy-16/3-methylpregna-4,9(11)diene- 3,20-dione (Preparation 15, 32 g) in methylene chloride (900 ml). The mixture is stirred for 16 hours at 20--25 and diluted with ice water (500 ml). The organic layer is separated, washed successively with cold aqueous 20 sodium carbonate and water and then is dried and concentrated under reduced pressure. The residue is column chromatographed on silica gel packed in methylene chloride. Elution is performed with acetone-methylene chloride mixture beginning with 0% acetone and increasing to 7%. The appropriate fractions are pooled and concentrated to give a solid which is crystallized from acetone- SSB to give the title compound, m.p. 232.5---237 ; []o --29 ; UV max=239. 5 nm (=17,250). 25 Preparation 17 16/-methyl- 17,20:20,21-bismethylenedioxy-5-pregn-9(11)en-3-one A solution of 16/3-methyl-17ó,20:20,21-bismethylenedioxypregna-4, 9(11)diene-3-one (Preparation 16, 22.8 g) in THF (290 ml) is added slowly (3/4 hour) to a solution of lithium wire (2.28 "30 g) in liquid ammonia (1.1 I) at --78 . The mixture is stirred for an additional one hour. Then ammonium 30 chloride (17.7 g) is added. The ammonia is allowed to evaporate on a steam bath and the mixture is concentrated under reduced pressure. The residue is stirred with acetone (600 ml) and water (300 ml), the pH is adjusted to 6 with hydrochloric acid and the mixture is further.diluted with water (1.1 I). The solid is collected, washed with water and dried at 60 under reduced pressure to give a solid which is recrystallized from aqueous acetone to give the title compound, m.p. 247-- -255 ; CMR 17.38 8; IR 35 (mull) 2770, 1712, 1673, 1691, 1078, 1007 and 946 cm-1.
.DTD:
Preparation 18 17,21 -dihydroxy-16/%methyl-5-pregn-9(11)ene-3,20-dione A suspension of 16/3-methyl-17ó,20:20,21 -bismethylenedioxy-5o-pregn9(11)en-3-one (Preparation 17, 12.5 g), acetic acid (375 ml) and water (125 ml) is heated under reflux for 2 hours. 40 The mixture is then diluted with ice and water to 41 and stirred for about 20 minutes. The solid is collected, washed with water and suspended in acetone (750 ml) and water (375 ml). The mixture is neutralized with sodium hydroxide (1N), diluted with ice water to 4 I, then refiltered. The product is collected and dried under reduced pressure to give the title compound TLC, Rf=0.18 (acetone- methylene chloride 10/90). 45 Example 1 .DTD:
9ó-fluoro-11/3,17,21-trihydroxy-5/3-pregnane-3,20-dione 9oL-fluoro-11/3,17ó,21 -trihydroxy-5j3-pregnane-3,20-dione 21 -acetate (Preparation 1,21.6 g) in methanol (680 ml) and aqueous potassium carbonate (10%, 75 ml) is stirred for 0.5 hours under a nitrogen atmosphere. The mixture is then acidified with acetic acid (6 ml), diluted with water and concentrated under reduced pressure. The mixture is cooled and the solid collected, dried and successively crystallized from aqueous acetone and acetone to give 9o-fluoro-11/3,17,21-trihydroxy5pregnane-3,20-dione, re.p. 220--228 (decomposition).
.DTD:
Example 2 .DTD:
9-fluoro-11/3,17,21-trihydroxy-5/-pregnane-3,20-dione 17-propionate (I} A mixture of 9oL-fluoro-11/3,17c,21-trihydroxy-5/3-pregnane-3,20-dione (Example 1, 11.2 g)in THF (230 ml) containing triethylorthopropionate (11. 6 ml) and p-TSA (0.70 g) is allowed to stand for 0.75 hours, then sulfuric acid (2N, 11.6 ml) is added, the mixture is stirred for an additional 0.3 hours, 8 GB 2 070 016 A 8 made basic with potassium bicarbonate (1 N, 70 ml), diluted with water and concentrated under reduced pressure. The precipitate is dissolved in ethyl acetate, washed with saline, dried and concentrated to give 9- fluoro-11/3,17o-21 -trihydroxy-5/3-pregnane-3,20-dione 17-propionate, as a foam, TLC, Rf=0.29 (acetone-methylene chloride, 20/80).
.DTD:
Examples 3--6 .DTD:
Following the general procedure of Example 2, and making non-critical variations but substituting the ortho esters of Column G for triethylorthopropionate, the 17-acyloxy-5/3-steroids of Column H are obtained.
.DTD:
Example .DTD:
3 Column G Trimethylorthoacetate Triethylorthobutyrate Trimethylorthovalerate Trimethylorthobenzoate Column H 9-fluoro-11/3,17oc,21 -trihydroxy- 5/3-pregnane-3,20-dione 17-acetate 9a:-fluoro- 11,17,21 -trih.ydrox.y- 5/3-pregnane-3,20-dione 17-butyrate 9 -fluoro-11/3,17,21 -trihydroxy- 5/3-pregnane-3,20-dione 17-valerate 9oc-fluoro- 11,17(,21 -trihydroxy-5/- pregnane-3,20-dione 17-benzoate Example 7 .DTD:
9oc-fluoro-11/,17ó,21-trihydroxy-5/3-pregnane-3,20-dione 17-propionate 21 -mesylate (I) A mixture of 9ó-fluoro-11/3,17c,21-trihydroxy-5/-pregnane-3,20-dione 17- propionate (Example 20 2, 11.0 g) in pyridine (49 ml) is cooled to 0 and methanesulfonyl chloride (12.2 ml) is added over a period of 0.2 hours. After stirring for 1 hour at 0 the reaction mixture is poured into a mixture of ice and water containing concentrated hydrochloric acid (37.5 ml). The precipitate is collected, dissolved in methylene chloride and washed successively with aqueous potassium bisulfate, water and aqueous potassium bicarbonate. The mixture is dried and concentrated under reduced pressure to a foam which 25 is column chromatographed on silica gel (500 g) packed in acetone- methylene chloride (5/95). Elution ' is performed with the same acetone-methylene chloride mixture. Appropriate fractions are pooled and concentrated to give 9ó-fluoro-11/3,17ó,21 -trihydroxy-5/3-pregnane-3,20- dione 17-propionate 21 - mesylate, NMR (CDCI3) 4.91,4.68---4.30, 3.18, 1.32, 1.15 and 0.95 & Examples 8--11 30 Following the general procedures of Example 7 and making non-critical variations but starting with the 21-hydroxy compounds of Examples 3--6 (Column I) the 21- mesylates of Column J are obtained.
.DTD:
Example Column I 8 3 9 4 11 6 Column J 9-fluoro- 11/;,17,21 -trihydroxy-5/3-pregnane- 3,20-dione 17-acetate 21 -mesylate 9oc-fluoro-11/3,17,21 -trihydroxy-5/3- pregna ne- 3,20-dione 17-butyrate 21 -mesylate 9(-fluoro-11/}, 17oc,21 -trihydroxy- 5/-pregnane- 3,20-dione 17-valerate 21-mesylate 9-fluoro- 11/3,17,21 -trihyd roxy-5/3- pregna ne3,20-dione 17-benzoate 21 -mesylate Example 12 .DTD:
21-chloro-9oc-fluoro-1 lj3,17o-dihydroxy-Sj3-pregnane-3,20-dione 17propionate (I) A mixture of 9-fluoro-11/3,17 oc,21 -trihydroxy-5/3-pregnane-3,20-dione 17-propionate 21 - mesylate (Example 7, 8.4 g) and lithium chloride (17.9 g) in DMF (200 ml) and acetone (330 ml) is heated under reflux for 119 hours. The mixture is cooled and the acetone is removed under reduced pressure. The mixture is then diluted with water and extracted with toluene. The organic extract is diluted with ethyl acetate, dried and concentrated under reduced pressure to give a foam which is crystallized from aqueous acetone and recrystallized from acetone-SSB to give t_he title compound; m.p. 191--19 t.5 (decomposition); [oc]s +6 ; IR (mull) 3420, 1740, 1730, 1695, 1275, 1215, 1205, 1095, 1050, 1035, and 1010 cm-1; CMR 27.10 6.
.DTD:
Examples 13--16 Following the general procedure of Example 12 and making non-critical variations but starting with the 21-mesylate compounds of Examples 8--11 (Column K) the 21-chloro steroids of Column L are obtained.
.DTD:
9 GB 2 070 016 A 9 Example Column K Column L 13 8 21 -chloro-9-fluoro11/3,17 -dihydroxy-5/3- pregnane-3,20-dione 17-acetate 14 9 21 -chloro-9o-fluoro- 11/3,17 o-dihydroxy-5/3- pregnane-3,20-dione 17-butyrate 5 21 -chloro-9-fluoro- 11/3,17 oL-dihydroxy-5/3pregnane-3,20-dione 17-valerate 16 11 21-chloro-9-fluoro-11/3,17-dihydroxy-5/- pregnane-3,20-dione 17-benzoate Example 17 10 .DTD:
21-chloro-9o-fluoro-17o-hydroxy-5/3-pregnane-3,11,20-trione 17-propionate (I) 21 -chloro-9-fluoro-11/3,17-dihydroxy-5/3-pregnane-3,20-dione 17propionate (Example 12, 2.48 g) is oxidized with Jones reagent following the general procedure of Example 64 and making non- critical variations. The reaction product is column chromatographed on silica gel (200 g) packed in acetone-methylene chloride (5/95). Elution was performed with the same acetone-methylene chloride 15 mixture. The appropriate fractions are pooled and concentrated to give a product which upon crystallization from acetone-SSB gives the title compound, m.p. 168.5-- 169; []s --110; IR (mull) 1730,1710,1270,1190,1180,1170, and1035cm-1.
.DTD:
Examples 18--21 Following the general procedure of Example 17 and making non-critical variations but starting 20 with the 11 -hydroxy steroid of Examples 13--16 (Column M) the 11 -keto compounds of Column N are obtained.
.DTD:
Example Column M 18 13 19 14 21 16 Column N 21 -chloro-9-fluoro- 17 -hydroxy-5/3-pregnane3,11,20-trione 17-acetate 21-chloro-9-fluoro17c-hydroxy-5/3-pregnane- 3,11,20-trione- 17-butyrate 21 -chloro-9 o-fluoro-17-hydroxy-5/3-pregna ne3,11,20-trione 17-valerate 21 -chloro-9cz-fluoro- 17o-hydroxy-5/3-pregnane-3,11,20-trione 17- benzoate Example 24 50 .DTD:
9<z-fluoro-11/3,17z,21-trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17propionate (I) 9ó-fluoro-11/3,17ó,21-trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione (Example 22, 1.23 g) triethylorthopropionate (1.2 ml) and p-TSA hydrate (0.072 g) in THF (24 ml) are allowed to stand at 30 for 0.5 hour under a nitrogen atmosphere. Aqueous sulfuric acid (1 N, 1.2 ml) is then added and the mixture allowed to stand an additional 0.5 hour at 30 . The mixture is cooled to 5 and potassium 55 bicarbonate (1 N, 7.2 ml) and water (48 ml) are added. The mixture is concentrated under reduced pressure, diluted with water and filtered. The filtrate is concentrated under reduced pressure to a gummy product which is column chromatographed on silica gel (150 g), packed in acetone-methylene chloride (20/80). Elution is performed with the same solvent mixture. The appropriate fractions are Example 23 .DTD:
9ó-fluoro-11/3,17oc,21 -trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17acetate (I) A mixture of 9ó-fluoro-11/3,17o, 21-trihydroxy-16/3-methyl-5/3-pregnane-3, 20-dione (Example 22, 5.5 g) in THF (110) ml) containing trimethyl orthoacetate (5.5 ml) and p-TSA (0.33 g) is stirred for 0.75 hours, then sulfuric acid (2N, 5.5 ml) is added. The mixture is allowed to stand an additional 0.5 45 hours at 30 , then is cooled, made basic with potassium bicarbonate (1 N, 33 ml), diluted with water and concentrated under reduced pressure. The precipitate is collected, dissolved in ethyl acetate, washed with saline, dried and concentrated to give the title compound, TLC, Rf=0.27 (methanol- methylene chloride, 5/95).
.DTD:
Example 22 .DTD:
9ó-fluoro- 11/3,17ce,21 -trihydroxy- 16/3-methyl-5/3-pregnene-3,20-dione 9c-fluoro- 1113,17 cz,21 -trihyd roxy- 16/3-methyl-5/3-pregnane-3,20dione 21 -benzoate (Preparation 2, 4.08 g) in methanol (110 ml) and aqueous potassium carbonate (10%, 12 ml)is stirred 35 for 1 hour under a nitrogen atmosphere. The mixture is then acidified with acetic acid (1 ml), diluted with water (120 ml) and extracted three times with SSB. The aqueous methanol phase is concentrated under reduced pressure. The mixture is cooled and the solid collected, dried and crystallized from acetone to give the title compound, m.p. 199---205 ; [o]D +78 ; IR 3520, 3460, 3420, 1705, 1080, 1060 and 1050 cm-1. 40 GB 2 070 016 A 10 pooled and concentrated. The concentrate is crystallized from acetone- hexane to give the title compound, m.p. 189 (decomposition; []o +58 ; IR 3480, 3420, 1730, 1695, 1225, 1180, 1165, 1085, 1065, 1035, 1010, 990, and 905 cm-1.
.DTD:
Examples 25--27 Following the general procedure of Examples 23 and 24, and making non- critical variations but starting with the orthoesters of Column O, the 17- acyloxy-5/-steroids of Column P are obtained.
.DTD:
Example .DTD:
26 Example 28 .DTD:
Column 0 Triethyl orthobutyrate Trimethyl orthovalerate Trimethyl orthobenzoate Column P 9-fluoro-11/3,17,21 -trihydroxy- 16/3-methyl5/3-pregnane-3,20-dione 17-butyrate 9e-fluoro- 11/3,17,21 -trihydroxy16/3-methyl-5/3- pregnane-3,20-dione 17-valerate 9-fluoro-11/3,17o,21-trihydroxy- 16/3- methyl-5/{- pregnane-3,20-dione 17-benzoate 9ó-fluoro-11/3,17o,21-trihydroxy16/3-methyl-5/3-pregnane-3,20-dione 17- acetate 21 -mesylate T5 (I) A solution of 9-fluoro-11/3,17ó,21-trihydroxy-16/-methyl-5/3-pregnane-3, 20-dione 17-acetate (Example 23, 8.06 g) in pyridine (27 ml) is cooled to 5 and methane sulfonylchloride (6.7 ml) is slowly added. After stirring for one hour at 0% the reaction mixture is poured into a mixture of ice and water containing concentrated hydrochloric acid (13.7 ml). The precipitate is collected, redissolved in 20 acetone (140 ml) and potassium bicarbonate (1 N, 25 ml) and allowed to stand one hour. The solution is concentrated under reduced pressure and extracted with methylene chloride. The extract is washed with saline, dried and concentrated to a foam which is column chromatographed on silica gel (300 g).
.DTD:
Elution is performed with acetone-methylene chloride (10/90). Appropriate fractions are pooled and concentrated under reduced pressure. The residue is crystallized from acetone-hexane to give the title 25 compound, re.p. 154154.5 ; NMR (CDCI3) 0.95, 1.30, 1.35, 2.16, 3.21,4.4 and 4.74 8.
.DTD:
Examples 29--32 Following the general procedure of Example 28 and making non-critical variations but starting with the 21 -hydroxy steroids of Examples 24--27 (Column Q) the 21 -mesylate compounds of Column R are obtained.
.DTD:
Example Column Q 29 24 31 26 32 27 Column R 9-fluoro- 11/3,17,21 -trihydroxy- 16]3- methyl-5-pregnane-3,20-dione 17- propionate 21 -mesylate 9z-fluoro- 11/3,17o,21 -trihydroxy- 16/3methyl-5/3-pregnane-3,20-dione 17- butyrate 21 -mesylate 9ó-fluoro11/3,17ó,21 -trihydroxy- 16/3- methyl-5/3-pregnane-3,20-dione 17- valerate 21 -mesylate 9-fluoro- 11/3,17ó-21 -trihydroxy- 16/3methyl-5/-pregnane-3,20-dione 17-benzoate 21 -m esylate Example 33 .DTD:
21-chloro-9ó-fluoro-11/3,17ó-dihydroxy-16/3-methyl-5/3-pregnane-3,20dione 17-acetate (I) 45 A mixture of 9-fluoro-1113,17cz,21-trihydroxy-16-methyl-5-pregnane-3,20- dione 17-acetate 21-mesylate (Example 28, 3 g) in acetone (120 ml.) and DMF (74 ml) containing lithium chloride (6.4 g) is heated under reflux for six days and then cooled and poured into ice water. The precipitate is collected and dried, then is crystallized from acetone to give the title compound, m.p. 210.8--211 o (decomposition). 50 Example 34 .DTD:
21-chloro-9ó-fluoro-11/3,17 oL-dihydroxy-16/3-methyl-5/3-pregnane-3,20dione 17-propionate (I) Following the general procedure of Example 33 and making non-critical variations but starting with 9ó-fluoro-11/3,17ó,21 -trihydroxy-16/3- methyl-5/3-pregnane-3,20-dione 17-propionate 21 mesylate (Example 29) the title compound is obtained, m.p. 190 .
.DTD:
Example 35 .DTD:
21-chloro-9-fluoro-11/3,17ó-dihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17-butyrate (I) Following the general procedure of Example 33 and making non-critical variations but starting 11 GB 2 070 016 A 11 with 9-fluoro-11/3,170,21 -trihydroxy-16/{-methyl-5/{-pregnane-3,20-dione 17-butyrate 21 -mesylate (Example 30), the title compound is obtained, m. p. 190--192 .
.DTD:
Example 36 .DTD:
21-chloro-9ó-fluoro-11/%17o-dihydroxy-16/3-methyl-5/%pregnane-3,20-dione 17-valerate (I) Following the general procedure of Example 33 and making non critical variations but starting 5 with 9-fluoro-11/3,17o,21 -trihydroxy-16/3-methyl-5/{-pregnane-3,20-dione 17-valerate 21 -mesylate (Example 31) the title compound is obtained, m.p. 173--173.8 .
.DTD:
Example 37 .DTD:
21-chloro-9ó-fluoro-1 lj3,17ó-dihydroxy-16-pregnane-3,20-dione 17benzoate (I) Following the general procedure of Example 33 and making non-critical variations but starting with 9-fluoro- 11/3,17,21-trihydroxy16t-methyl- 51-pregnane-3,20-dione 17-benzoate 21mesylate (Example 32) the title compound is obtained.
.DTD:
Example 38 .DTD:
17 o,21 -dihydroxy-16-methyl-5/-pregn-9(11)ene-3,20-dione 17,21 dipropionate A mixture of 17c,21-d[hydroxy-16/-methylpregna- 1,4,9( 11)triene-3,20- dione 17,21 - 15 dipropionate (Preparation 9, 9.5 g) in acetone (1 O0 mi) and triethylamine (16 ml)is hydrogenated under two atmospheres of pressure in the presence of palladium on carbon (5%, 0.4 g) for six hours.
.DTD:
The mixture is filtered and the filtrate is condensed under reduced pressure to a oam which is column chromatographed on silica gel (300 g) packed in acetone methylene chloride (2/98). Elution is performed with acetone-methylene chloride mixtures (2/98-,5/95). The appropriate fractions are 20 pooled and concentrated to give a product which upon crystallization from diethyl etherpentane gives the title compound, m.p. 120.5--122 ; IR (mull) 1740, 1730, 1280, 1220, 121 O, 1180, 1070, 1050 and 1005 cm-; NMR (CDCI3) 0.66, 1.14, 1.17, 1.19, 1.36, 4.6 and 5.6 8.
.DTD:
Examples 39 and 40 Following the general procedure of Example 38 and making non-critical variations but starting 25 with the ATM steroids of Preparations 10 and 11 (Column S), the 5- steroids of Column T are obtained.
.DTD:
Examples Column S 39 10 Column T 17o,21 -dihydroxy16-methyl-5/-pregn-9(11)- ene-3,20-dione 17,21-dipropionate 11 17ol,21 -dihydroxy-5/3-pregn-9(11)ene-3,20-dione 30 17,21 -dipropionate Example 41 .DTD:
9,11/3-dichloro-17,21-dihydroxy-16/;-methyl-5/3-pregnane-3,20-dione 17,21 -dipropionate (I) Following the general procedure of Example 50 and making non-critical variations but starting with 17,21 -dihydroxy-16/3-methyl-5/3-pregn-9(11)ene-3,20-dJone 17,21 - dipropionate (I), the title 35 compound is obtained.
.DTD:
Examples 423 " Following the general procedure of Example 50 and making non-critical variations but starting with the A9(1) steroids of Examples 39--40 (Column U) the 9,11 -dichloro steroids of Column V are obtained.
.DTD:
Examples Column U 42 39 43 4O Column V 9, 11/-dichloro- 17,21 -dihydroxy 16ó-methyl- 5/3-pregnane-3,20-dione 17,21-dipropionate 9o, 1 l#-dichloro17,21 - dihydroxy-5/3-pregnene- 3,20-dione 17,21 -dipropionate Example 44 .DTD:
17o,21-dihydroxy-16/3-methyl-5/3-pregn-9 (11)ene-3,20-dione 17-propionate 21-mesylate A mixture of 17e,21-dihydroxy-16J3-methylpregna-1,4,9(11)triene-3,20- dione 17-propionate 21 -mesylate (Preparation 12, 7.1 g) in acetone (1 O0 ml) and triethylamine (2 ml) is hydrogenated under two atmospheres of pressure in the presence of palladium on carbon (5%, 0.5 g). The crude product obtained from hydrogenation is column chromatographed on silica gel (350 g), packed in acetone-methylene chloride (2/98). Elution is performed with acetone-methylene chloride mixtures (2/8-,5/95). The appropriate fractions are pooled and concentrated to give the title compound, NMR (CDCI3) 0.67, 1.14, 1.19, 1.37, 3.20, 4.72 and 5.6 3.
.DTD:
Examples 45 and 46 Following the general procedure of Example 44 and making non-critical variations but starting 12 GB 2 070 016 A 12 with and substituting the A1.4-steroids of Preparations 13 and 14 (Column W) for 17,21-dihydroxy16/3-methylpregna- 1,4,9(11) triene-3,20-dione 17propionate 21 -mesylate, the 5/3-steroids of Column X are obtained.
.DTD:
Example Column W Column X 13 17,21 -dihydroxy-16-methyl-5/3-pregna-9( 11)5 ene-3,20-dione 17-propionate 21-mesylate 17 o,21 -dihydroxy-5/3-preg ha-9 ( 11) ene-3,20- dione 17-propionate 21-mesylate 46 14 Example 47 .DTD:
21-chloro-17oe-hydroxy-16/3-methyl-5/3-pregn-9(11)ene-3,20-dione 17propionate 17,21-dihydroxy- 16/3-methyl-5/3-pregn-9(11) ene-3,20-dione 17-propionate 21-mesylate (Example 44, 7.69 g) in acetone (320 ml) and DMF (200 ml) are heated under reflux with lithium chloride (17.1 g) for 90 hours. The mixture is then concentrated under reduced pressure, diluted with ice water and filtered. The filter cake is dissolved in methylene chloride, washed with saline and the 15 methylene chloride mixture is dried and concentrated under reduced pressure to a foam which is crystallized from acetone-pentane to give the title compound, m.p. 140.5-141.5 ; IR (mull) 3040, 1745, 1735, 171 O, 1645, 1355, 1205, 1195, 1175, 1040, 1015, 965 and 710 cm-1; [c]D +54 .
.DTD:
= 1"5 Examples 48 and 49 Following the general procedure of Example 47 and making non-critical variations but starting with and substituting the 5/3-steroids of Examples 45 and 46 (Column Y) for 17,21 -dihydroxy-16/320 methyl-5/3-pregn-9(11)ene-3,20-dione 17- propionate 21-mesylate, the 21 -chloro steroids of Column Z are obtained.
.DTD:
Example Column Y 48 45 Column Z 21 -chloro-17 -hydroxy-16 o-m ethyl-5/3-pregn-9(11)ene-3,20-dione 17- propionate 21-chloro-17-hydroxy-5/3-pregn-9(11)ene-3,20- dione 17-propionate 49 46 Example 50 .DTD:
9ó-11/3,21-trichloro-17ó-hydroxy-16t%methyl-5/3-pregnane-3,20-dione 17propionate (I) A mixture of 21-chloro-17ó-hydroxy-16/3-methyl-5/3-pregn-9(11)ene-3,20- dione 17-propionate 30 (Example 47, 1.3 g) in chloroform (100 ml) and pyridine (1 ml) is cooled to --10 . A chlorine solution in carbon tetrachloride (40 ml, 1.15 eq.) is added at --10 and the reaction mixture is washed successively with cold aqueous potassium bisulfate, water and cold aqueous potassium bicarbonate.
.DTD:
The layers are separated and the organic layer is concentrated under reduced pressure to a foam which is crystallized from diethyl ether-pentane and recrystallized from acetone-hexane to give the title 35 compound, m.p. 163.8--164 ; NMR (CDCI3) 1.01, 1.19, 1.38, 1.57, 3.98 and 4.7--4.8 8.
.DTD:
Examples 51 and 52 Following the general procedure of Example 50 and making non-critical variations but starting with the AgcllJ-steroids of Examples 48 and 49, (Column AA) the 21-chloro steroids of Column BB are obtained. 40 Column BB 9, 11/3,21 -trichloro-17o-hydroxy- 16-methyl-5/3pregnane-3,20-dione 17-propionate 9oe, 11/3,21 -trichloro-17-hydroxy-5/3-pregnane- 3,20-dione 17-propionate Example Column AA 51 48 52 49 Example 53 .DTD:
21-chloro-9o-fluoro-11/3,17ó-dihydroxy-16/3-methyl-5/3-pregnane-3,20dione 17-propionate (I) A mixture of 21 -chloro-9c-fluoro- 11/3,17 -dihydroxy- 16/3-methylpregna- 1,4-diene-3,20-dione 17-propionate (IA, U.S. Patent 3,721,687, Example 14, 2.0 g) in ethyl acetate is stirred with palladium on carbon (2 g) under one atmosphere of hydrogen for 2 hours and then filtered thru diatomaceous 50 earth. The filtrate is concentrated under reduced pressure. The concentrate is column chromatographed over silica gel (200 g) packed in acetone-methylene chloride (5/95). Elution is performed with the same solvent mixture. The appropriate fractions (TLC) are pooled and concentrated to a solid. Upon crystallization from acetone-SSB the title compound is obtained, m.p. 191 o; IR (mull) 3360, 1725, 1685, 1285, 1225, 1205, 1060, 1040, 1010, 990, 905 and 695 cm- 1; CMR 27.05 8 55 and []D +63 " 13 GB 2 070 016 A 13 Examples 54---63 Following the general procedure of Example 1 and making non-critical variations but starting with the A.4-steroids (U.S. Patent 3,731,687) of Column CC, the 5/3-steroids of Column DD are obtained.
.DTD:
Examp 54 59 Column CC 9cz,21 -difluoro-11/3,17otdihydroxy- 16ethylpregna-1,4-diene-3,20- dione 17-acetate 9 ,21 -difl uoro- 11/3,17 odihydroxy- 16/3-methylpregha-1,4-diene-3,20- dione 17-propionate 9-21-difluoro-11/3,17ó- dihydroxy- 16/3-methylpregna-1,4-diene-3,20-dione 17-butyrate 9,21-difluoro-11/3,17cdihydroxy-16/3-methylpregna-1,4-diene-3,20-dione 17-isobutyrate 9ó,21 -difluoro- 11/3, 17c-dihydroxy- 16/3-methylpregna- 1,4-diene-3,20- dione 17-valerate 21 -chloro-9 -fluoro- 11/3, 17ó-dihydroxy- 16/3-methylpregna1,4-diene-3, 20-dione 17-acetate 21 -chloro-9 (-flu oro11/3,17ó-dihydroxy-16/3methylpregna- 1,4-diene3,20- dione 17-butyrate 21 -chloro-9ó-fluoro- 11/3, 17 -dihydroxy- 16/3-methylpregna1,4-diene-3,20dione 17-isobutyrate 21 -chloro-9ó-fluoro- 11/3, 17c-dihydroxy-16/3-methylpregna- 1,4-diene-3, 20dione 17-valerate 21 -chloro-9o-fluoro- 11/3, 17(z-dihydroxy- 16/3-methylpregna- 1,4-diene3,20dione 17-benzoate Column DD 9cz,21 -difluoro-11/3,17c- 5 dihydroxy16/3-methyl-5/3- pregnane-3,20-dione 17-acetate 9,21 -difluoro- 11/3,17dihydroxy- 16/3-m ethyl-5/3- 10 pregnane-3,20-dione 17-propionate 9ó,21-difluoro-11/3,17(z- dihydroxy- 16/3-methyl-5/3- pregnane-3,20-dione 15 17-butyrate 9e(,21 -difluoro- 11/3,17ó- dihydroxy- 16/3-methyl-5/3pregnane-3,20-dione 17-isobutyrate 20 9m21 -difluoro-11/3,17 c-dihydroxy- 16/}-m ethyl-5/3-preg- nane-3,20-dione 17-valerate 21 -chloro-9(z-fluoro- 25 11/3,17 e(-dihydroxy- 16/3-methyl-5/3-pregnane-3,20-dione 17-acetate 21 -chloro-9 -fluoro- 11/3,17(-dihydroxy-16/330 methyl-5/3-pregnane-3,20- dione 17-butyrate 21 -chloro-9ó-fluoro- 11/3, 17 o-dihydroxy- 16/3-methyl- 5/3-pregnane-3,20-dione 35 17-isobutyrate 21 -chloro-9ó-fluoro- 11/3, 17 -dihydroxy- 16/3-m ethyl5/3-pregnane-3,20-dione 17- valerate 40 21 -chloro-9 -fluoro- 11/3, 17 e(-dihyd roxy- 16/3-methyl- 5/3-pregnane-3,20-dione 17- benzoate Example 64 45 .DTD:
21 -chloro-9-fluoro-17-hydroxy-16/3-methyl-5/3-pregnane-3,11,20-trione 17propionate (I) Jones reagent (chromium trioxide-aqueous sulfuric acid, 1.3 ml) is added to a solution of 21- chloro-9c-fluoro- 11/3,17-dihydroxy16/3-methyl-5/3-pregnane-3,20-dione 17-propionate (Example 53, 2 g) in acetone (50 ml). The mixture is stirred for 30 minutes at 20-- 25 . Isopropyl alcohol (1.3 ml) is added followed by slow addition of ice water (600 ml). The precipitate is collected, washed with 50 water and dried. The crude product is column chromatographed on silica gel eluting with acetone- methylene chloride (5/95). The appropriate fractions (TLC) are pooled, concentrated under reduced pressure and crystallized from acetone-SSB to give the title compound, m. p. 184--185.5 ; IR 1730, 1275, 1260, 1185, 1170, 1040 and 960 cm-1; CMR 24.38 ( and [o]D +42 .
.DTD:
Example 66 60 .DTD:
9-fluoro-11/3,17-dihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17propionate 21-chloro-9-fluoro- 11/3,17-dihydroxy16/3-methyl-5/3-pregnane-3,20- dione 17-propionate (I, Example 65 55 .DTD:
21 -chloro-9-fluoro-17-hydroxy-16/3-methyl5/-pregnane-3,11,20-trione 17butyrate (I) Following the general procedure of Example 64 and making non-critical variations but starting with 21 -chloro-9c-fluoro11/3,17-dihydroxy-16/3-methyl-5/3-pregnane-3, 20-dione 17-butyrate there is obtained the title compound.
*.DTD:
14 GB 2 070 O16 A 14 Example 53, 4.0 g) in acetone (1 O0 ml) containing triethylamine (2 ml) is hydrogenated in the presence of palladium on carbon (5%, 0.42 g) until the uptake of hydrogen is complete. The mixture is filtered and the filtrate is concentrated under reduced pressure. The concentrate is column chromatographed on silica gel (200 g) packed in acetone-methylene chloride (5/95) and eluted with the same mixture.
.DTD:
The appropriate fractions (TLC) are pooled and concentrated to a solid. Upon crystallization from 5 acetone-SSB the title compound is obtained, m.p. 176--178 ; []5 +430; CMR (CDCIa) 27.12 8 and IR (mull)3481, 1722, 1702, 1294, 1227, 1205, 1067, 1058, 1043, 1OO4, 988, and 953 cm-1.
.DTD:
Examples 67--72 Following the general procedure of Example 66 and making non-critical variations but starting with the 21-chloro steroid of Examples 53 and 59--63 (Column EE), the compounds of Column FF are 10 obtained.
.DTD:
Example Column EE 67 53 68 59 69 60 61 71 62 72 63 Column FF 9-fluoro-11/3,17 c-dihydroxy- 16/-methyl-5/3- pregnane-3,20-dione 17-propionate 9ó-fluoro-11/3,17 oc-dihydroxy- 16/- methyl-5/3pregnane-3,20-dione 17-acetate 9o-fluoro- 11/3,17ó-dihydroxy- 16/3-methyl5/3- pregnane-3,20-dione 17-butyrate 9ó-fluoro-11/3,17ol-dihydroxy16/-methyl- 5/- pregnane-3,20-dione 17-isobutyrate 9ó-fluoro-11/3,17 o-dihydroxy- 16/- methyl-5- pregnane-3,20-dione 17-valerate 9ó-fluoro-11/3,17ó-dihydroxy-16/3-methyl- 5/3- pregnane-3,20-dione 17-benzoate Example 73 25 .DTD:
21-chloro-9ó-fluoro-11/3,17-dihydroxy-16/-methyl-,5/3-pregnane-3,20-dione 17-benzoate (I) 21-chloro-9ó-fluoro-11/3,17-dihydroxy-16/-methylpregna-1,4-diene-3,20dione 17-benzoate (IA, 3.9 g) in ethyl acetate (375 ml) is stirred with palladium on carbon (5%, 1 g) under one atmosphere of hydrogen until the uptake of hydrogen is complete. The mixture is then filtered and the filtrate is concentrated under reduced pressure to a solid which is column chromatographed on silica gel (400 g) 30 packed in methanol-methylene chloride (2/98). Elution is performed with the same methanolmethylene chloride mixture to give the product which upon crystallization from acetone-SSB gives the title compound, m.p. 174.5--175.5 (decomposition); CMR (CDCI3) 27.18 #; IR (mull) 3440, 1735, 1715, 1695, 1600, 1580, 1490, 1275, 1260, 1105, 1025, 990, and 720 cm-.
.DTD:
Example 74 35 .DTD:
9-fluoro-11/3.17oc,21-trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17, 21-dipropionate (I) 9o-fluoro- 11/3,17ó,21 -trihydroxy16-methylpregn-4-ene-3,20-dione 17,21 -dipropionate (IA, 4.75 g) in ethyl acetate (260 ml) is stirred with palladium on carbon (5%, 2.1 g) under hydrogen (1 atmosphere) until the uptake of hydrogen is complete. The mixture is filtered and the filtrate is concentrated under reduced pressure to a solid which is column chromatographed on silica gel (400 g) 40 packed in acetone-methylene chloride (5/95). Elution is performed with the same acetone-methylene chloride mixture. The appropriate fraction (TLC) are pooled and concentrated to a solid. Upon crystallization from acetone-SSB the title compound is obtained, m.p. 143m144 ; [OJD +36 ; CMR (CDCIa) 27.0 8 and IR (mull) 3460, 1750, 1735, 1720, 1710, 1195, 1180, 1165, 1090, 1070, 1045, 1020, 990, 995 and 810 cm-1.
.DTD:
Example 75 .DTD:
9o-fluoro-11/3-17o,21-trihydroxy-16/3-methyl-5/;-preg nane-3,20-dione 17, 21-dipropionate (I) 9-fluoro- 11/3,17ó,21 -trihydroxy- 16-methylpregna1,4-diene-3,20-dione 17,21 -dipropionate (IA, betamethasone 17,21-dipropionate, 1.0 g) and p-TSA hydrate (0.1 g) in acetone (100 ml) are shaken with palladium on carbon (5%, 0.1 g) under hydrogen (2 atmospheres) until the uptake of 50 hydrogen is complete. The mixture is filtered and the filtrate is concentrated under reduced pressure.
.DTD:
The residue is dissolved in methylene chloride, washed with aqueous sodium bicarbonate and dried.
.DTD:
The mixture is concentrated and the residue is column chromatographed over silica gel (100 g) packed in acetone-methylene chloride (10--90). Elution is performed with the same solvent mixture. The appropriate fractions are pooled and concentrated. Upon crystallization from acetone-hexane the title 55 compound is obtained, m.p. 142--143.5 .
.DTD:
Example 76 .DTD:
9ó-fluoro-11/3,17-21 -trihydroxy-16/-methyl-5-pregnane-3,20-dione 17propionate 21 mesylate (I) 9ó-fluoro11/3,17,21-trihydroxy-16/-methylpregna- 1,4-diene-3,20-dione 17-propionate 21- GB 2 070 016 A 15 mesylate (IA, U.S. Patent 3,721,687, Example 1,5.0 g) in acetone (1 O0 ml) is hydrogenated in the presence of palladium on carbon (5%, 0.5 g) and p-TSA (0.10 g) until the uptake of hydrogen is complete. The mixture is filtered and the filtrate is concentrated under reduced pressure. The concentrate is chromatographed on silica gel (250 g) packed in acetone- methylene chloride (595).
.DTD:
Elution is performed on the same mixture. The appropriate fractions (TLC) are pooled and concentrated 5 to give a solid. An acetone solution of the foam is slowly added to water to give an amorphous precipitate which is collected and dried to give the title compound, m.p. 109--I 15 ; [c]s +44 ; CMR (CDCI3) 27.07 & and IR (mull) 3544, 3464, 1736, 1706, 1356, 1177, 1041, 1013, 987,952,926 and 812 cm-.
.DTD:
Example 77 10 .DTD:
21-bromo-9c-fluoro-11/],17oc-dihydroxy-16/]-methyl-5/]-pregnane-3,20dione 17-propionate (I) A mixture of 9o-fluoro-11/],17,21-trihydroxy-16/]-methyl-5/]-pregnane-3, 20-dione 17propionate 21-mesylate (Example 76, 2.0 g), lithium bromide (4 g), acetone (80 ml) and DMF (50 ml) is heated under reflux for 70 hours. The reaction mixture is concentrated under reduced pressure and the concentrate is poured into ice water. A precipitate is collected, dried and then column 15 chromatographed on silica gel (300 g) and eluted with acetone-methylene chloride (5/95). The appropriate fractions (TLC) are pooled and concentrated to a solid. Upon crystallization from acetone- SSB the title compound is obtained, m.p. 184.5 (decomposition); [ó]s + 640; CMR (CDCI3) 27.14 and IR (mull)3353, 1725, 1689, 1284, 1244, 1206, 1088, 1062, 1014, 1012, 990 and 905 cm-.
.DTD:
Example 78 20 .DTD:
21-chloro-9-fluoro-11/3,17o-dihydroxy-6ó-methyl-5/]- pregnane-3,20-dione 17-valerate (I) 21 -chloro-9-fluoro-11/],17ó-dihydroxy-6ó-methyl-pregna-1,4-diene-3,20- dione 17-valerate (IA, 0.6 g) in acetone (100 ml) is hydrogenated in the presence of palladium on carbon (5%, 0.1 g) until the uptake of hydrogen is complete. The mixture is filtered and the filtrate concentrated under reduced pressure. The concentrate is column chromatographed on silica gel (50 g) packed in methylene 25 chloride. Elution is performed with acetone-methylene chloride mixtures. The appropriate fractions are pooled and concentrated to give a solid which upon crystallization from acetone-SSB gives the title compound, m.p. 168--169 ; []o=s -11 o; CMR (CDCI3) 27.48 3; IR (mull) 3540, 3400, 1735, 1725, 1720, 1695, 1265, 1240, 1185, and 980 cm-.
.DTD:
Example 79 30 .DTD:
9-fluoro-11/], 17cz-dihydroxy-6z-methyl-5/-pregnane-3,20-dione 17-acetate (I) Following the general procedure of Example 78 and making non-critical variations but starting with 9o-fluoro-11/3,17-dihydroxy-6ó-methylpregna-1,4-diene-3,20-dione 17acetate the title compound is obtained.
.DTD:
Example 80 35 .DTD:
21-ohloro-9-fluoro-17o-hydroxy-6-methyl-5/]-pregnane-3,11,20-trione 17valerate (I) 21 -chloro-9-fluoro-17-hydroxy6ó-methylpregna-1,4-diene-3,11,20-trione 17-valerate (IA, 1.15 g) is hydrogenated following the general procedure of Example 78 and making non-critical variations, the title compound is obtained as an amorphous solid, m.p. 67- -72 ; []s _270; CMR 24.71 &;IR (mull) 1725, 1270, 1235, 1160, 1110, 1095, and 1030 cm-. 40 Example 81 .DTD:
6ó,9c-difluoro-11/],17ó,21-trihydroxy-16-methyl-6/]-kpregnane-3,20-dione 17,21 -diacetate (I) Following the general procedure of Example 78 and making non-critical variations but starting with 6z,9ó-difluoro11/3,17,21 -trihydroxy-16/]-methylpregna- 1,4-diene- 3,20-dione 17,21 -diacetate (IA, U.S. Patent 3,980,778, 7.82 g) the title compound is obtained upon crystallization from acetone- 45 SSB and recrystallization from acetone, m.p. 225 (decomposition); []6 + 280; CMR 27.24 3; IR (mull) 3540, 1745, 1735, 1710, 1245, 1210, 1025, 1010, 1000 and 960 cm-.
.DTD:
Examples 82m84 Following the general procedure of Example 81 and making non-critical variations but starting with the 1.4-steroids of Column DD (U.S. Patent 3, 780,177) the corresponding 5-steroids (I) of Column EE are obtained.
.DTD:
Examp Column DD 6,9ó-difluoro- 11/],17ol,21 - trihyd roxypreg na1,4-diene3,20-dione 17-butyrate 21 -acetate 6m9-difluoro-11/],17,21trihydroxypregna- 1,4-diene3,20-dione 17-butyrate 21-propionate Column EE 6c,9ó-difluoro- 11/3,17,21 trihydroxy-5/]-pregnane3,20-dione 17-butyrate 21-acetate 6,9-difluoro-11/],17,21 trihydroxy-5/]-pregnane3,20-dione 17-butyrate 21 - propionate 16 GB 2 070 016 A 16 Example Column DD Column EE 84 6o,9-difluoro- 11/3,17,21 - 6o,9 -difluoro-11/3, 70,21 trihydroxypregna- 1,4-diene- trihydroxy-5/3-p regna ne- 3,20-dione 17,21 -dibuty- 3,20-dione 17,21 -dibuty- rate rate Example 85 .DTD:
6o,9c-difluoro-17o,21-dihydroxy-16/3-methyl-5/3-pregnane-3,11,20-trione 17,21 -diacetate (I) Following the general procedure of Example 64 and making non-critical variations and starting with 6ó,9 oc-difluoro11/3,17,21 -trihydroxy- 16/3-methyl-5/3-pregnane-3,20-dione 17,21 -diacetate (Example 81, 5 g) the title compound is obtained, upon crystallization from acetone-SSB, m. p. 251.5 ; [o]s + 1 o; CMR (CDCI3) 24.68; IR (mull) 1755, 1735, 1715, 1240, 1205, 1070, 1045, and 1015 cm-1.
.DTD:
Examples 86--88 Following the general procedure of Example 85 and making non-critical variations but starting with the steroids of Examples 82--84, (Column GG) the 11-keto steroids of Column HH are obtained.
.DTD:
Example Column GG 86 82 87 83 88 84 Column HH 6c,9-difluoro- 17o,21 -dihydroxy-5/3-pregna ne- 3,11,20-trione 17-butyrate 21 -acetate 6,9 o-difluoro- 17ó,21 -dihydroxy- 5/3-pregnane- 3,11,20-trione 17-butyrate 21-propionate 60,9 c-difluoro- 17o,21 - dihydroxy-5/3-pregnane3,11,20-trione 17,21 -dibutyrate 92 Column II 9o-fluo ro- 11/3,17 o,21 -tri- hydroxy-16/3-methylpregna1,4-diene-3,20-dione 17acetate 9 o-fl uoro-11/3,17,21 -trihydroxy-16/3-methylpregna1,4-diene-3,20-dione 17-propionate 9-fluoro-11/3,17o,21-trihydroxy-16/3-methylpregna1,4-diene-3,20-dione 17- butyrate 9ó-fluoro-11/3,17ó,21 -tri- hydroxy-16/3-methylpregna1,4-diene-3,20-dione 17-benzoate 9o-fluoro- 11/3,17c,21 -trihydroxy16o-methylpregna1,4-diene-3,20-dione- 17 acetate 9-fluoro-11/3,17,21 -tri hydroxy-16o-methylpregna1,4-diene-3,20-dione 17propionate Column JJ 9ó-fluoro- 11/3,17,21 -tri- hydroxy-16/3-methyl-5/-preg- nane-3,20-dione 17-ace- o tate 40 9c-fluoro- 11/3,17o,21 -tri- hydroxy- 16/3-m ethyl-5/3pregnane-3,20-dione 17- propionate 9ó-fluoro-11./J, 17o,21 -trihydroxy-16/3-methyl-5/3- pregnane-3,20-dione 17- butyrate 9 -fluoro11/3,170,21 -tri- hydroxy-16/3-methyl-5/3- 50 pregnane-3,20-dione 17benzoate 9ó-fluoro-1 1/3,170,21 -tri- hydroxy-16-methyl-5/3pregnane-3,20-dione 17- 55 acetate 9 -fluoro-11/3,17ó,21 -tri- hydroxy16ó-methyl-5/3- pregnane-3,20-dione 17- propionate 60 Examp Example 89 .DTD:
9ó-fluoro-11/3,17ó,21-trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17valerate (I) 9ó-fluoro-11/3,17cz,21 -trihydroxy-16/3-methylpregna-1,4-diene-3,20-dione 17-valerate (IA, 25 betamethasone 17-valerate, 3.0 g) and triethylamine (1.5 ml) in acetone (1 O0 ml) are shaken with palladium on carbon (5%, 0.3 g) under hydrogen (2 atmospheres) until the uptake of hydrogen is complete. The mixture is filtered and the filtrated concentrated under reduced pressure. The residue is column chromatographed on silica gel (300 g) packed in acetone-methylene chloride (10--90). Elution is performed with the same solvent mixture. The appropriate fractions are pooled and concentrated. 30 Upon crystallizing the residue from ether-pentane the title compound is obained, m.p. 135--136 ; IR 3480, 3440, 1725, 1710, 1295, 1260, 1180, 1090, 1065, 1040, 1015, 985 and 950 cm-.
.DTD:
Examples 9Oral 03 Following the general procedure of Example 89 and making non-critical variations but starting with the &1.4-steroids of Column II, the 5/3-steroids of Column JJ are obtained. 35 17 GB 2 070 016 A 17 Example .DTD:
Column II Column JJ 9ó-fluoro- 11,17o,21-tri- 9ó-fluoro- 11/3,17,21-trihydroxy- 16cz-methylpregna- hydroxy- 16-methyl-5/- 1,4-diene-3,20-dione 17- pregnane-3,20-dione 17- butyrate butyrate 9-fluoro- 11/3,17ó,21 -tri9z-fluoro- 11/3,17ol,21 -tri- hydroxy- 16ó-methylpregan- hydroxy16-methyl-5- 1,4-diene-3,20-dione 17- pregnane-3,20-dione 17- valerate valerate 98 9(z-fluoro- 11/3,17oe,21 -tri- 9ó-fluoro- 11/% 17oL,21 -tri10 hydroxy- 16ó-methylpregna- hydroxy- 16c-methyl-5/- 1,4-diene-3,20-dione 17- pregnane-3,20-dione 17- benzoate benzoate 9 -fl u oro- 11/3,17 ,21 -tri- 9 -fluoro- 11, 17 ,21 -tri- hydroxypregna- 1,4-dienehydroxy-5-pregnane-3,20- 15 3,20-dione 17-acetate dione 17-acetate 9-fluoro-11/3,17z,21-tri- 9ó-fluoro-11/3,17ó,21-tri- hydroxypregna1,4-diene- hydroxy-5/3-pregnane-3,20- 3,20-dione 17-propionate dione 17-propionate 9-fluoro- 11/3,17ó,21 -tri- 9ó-fluoro-11/%17ó,21 -trihydroxypregna-1,4-diene- hydroxy-5-pregnane-3,20- 3,20-dione 17-butyrate dione 17-butyrate 9-fluoro-11/3,17,21 -tri- 9-fluoro- 11/3,17,21 -trihydroxypregna-1,4-diene- hydroxy-5/3-pregnane-3,20- 3,20-dione 17-valerate dione 17-valerate 9ó-fluoro- 11/3,17ó,21 -tri- 9ó-fluoro- 11/3,17ó,21 -tri- hydroxypregna-1,4-diene- hydroxy-5/3-pregnane,3,20- 3,20-dione 17-benzoate dione 17-benzoate 101 20 102 103 Example 104 .DTD:
30.9ó-fluoro-11/3,17oe,21-trihydroxy-16ó-methyl-5-pregnane-3,20-dione 17propionate 21- 30 mesylate (I} A mixture of 9ó-fluoro-11, 17,21-trihydroxy- 16c-methylpregna-1,4-diene-3, 20-dione 17- propionate 21-mesylate (IA, dexamethasone 17-propionate 21-mesylate, U.S. Patent 3,721,687, Example 5, 3.6 g), triethylamine (1.5 ml) and acetone (100 ml) are shaken with palladium on carbon (5%, 0.3 g) under hydrogen (2 atmospheres) until the uptake of hydrogen is complete. The mixture is 35 filtered and the filtrate concentrated under reduced pressure. The residue is column chromatographed on silica gel (200 g), packed in methanol-methylene chloride (2/98). Elution is performed in the same solvent mixture. The appropriate fractions are pooled and concentrated to give the title compound; NMR (CDCI) 0.90, 1.0, 1.16, 1.29, 3.2, 4.4, 4.84 (.
.DTD:
Example 105 40 21-bromo-9ó-fluoro-11/3,17ó-dihydroxy-16ó-methyl-5/3-pregnane-3,20-dione 17-propionate (I) A mixture of 9cz-fluoro- 11/3,17,21-trihydroxy16ó-methyl-5/3-pregnane-3, 20-dione 17- propionate 21-mesylate (Example 104, 3.6 g) and lithium bromide (fused, 7. 2 g) in acetone (144 ml) and DMF (90 ml) are heated under reflux for 10 days. The mixture is then concentrated under reduced pressure, diluted with water and filtered to obtain the precipitate. The solid is chromatographed on 45 silica gel (360 g) packed in acetone-methylene chloride (5/95) and eluted with the same solvent mixture. The appropriate fractions are pooled and concentrated. The concentrate is rechromatographed on silica gel using acetone-methylene chloride (2/98) as the eluant. The appropriate fractions are pooled and concentrated. Upon crystallization from acetone the title compound is obtained, m.p.
178--178.5 (decomposition); []n +22 , 50 Example 106 .DTD:
9-fluoro-11/3,17ó-dihydroxy-16-methyl-5/-pregnane-3,20-dione 17propionate (I) 21 -bromo-9ó-fluoro-11/3,17-dihydroxy-16-methyl-5t-pregnane-3,20-dione 17propionate (I, Example 105, 1.6 g) in acetone (100 m I) containing triethylamine (1 ml)is hydrogenated in the presence of palladium on carbon (5%, O. 1 g) and worked up in the usual manner. Crystallization of the chromatographed product from acetone gives the title compound, m.p. 144.5m147.5 (decomposition); [c]o + 12 o.
Example 107 .DTD:
21-chloro-9ó-fluoro-11/3,17z-dihydroxy-16-methyl-5-pregnane-3,20-dione 17propionete (I) 21-chloro-9cz-fluoro- 11/3,17-dihydroxy16-methylpregna-1,4-diene-3,20- dione 17propionate (IA, U.S. Patent 3,721,687, Example 20, 1.67 g) in acetone (1 O0 ml) is hydrogenated in the 18 GB 2 070 016 A 18 presence of p-TSA hydrate (0.18 g) and palladium on carbon (5%, O. 18 g) until the uptake of hydrogen is complete. The mixture is filtered and the filtrate is concentrated under reduced pressure. The crude product is dissolved in acetone and precipitated by the addition of water to give a solid which is obtained by filtration. Crystallization of the solid from acetone gives the title compound, m.p. 198 (decomposition); CMR 27.1 8; []o +14; IR 3360, 1715, 1680, 1290, 1240, 1200, 1085, 1045, 1020, 1010 and 905 cm-1.
.DTD:
Examples 108--111 Following the general procedure of Example 107 and making non-critical variations but starting with the AI.4-steroids of Column KK, the 5/3- steroids of Column LL are obtained.
.DTD:
Example .DTD:
108 109 111 Column KK 21 -ch Ioro-9-fluoro11/3,17ó-dihydroxy-16ocmethylpregna-1,4-diene3,20- dione 17-acetate 21 -chloro-9oc-fluoro11/%17oc-dihydroxy16ocmethylpregna-1,4-diene3,20- dione 17-butyrate 21 -ch Ioro-9 oL-fluoro11/3,17-dihydroxy-16ómethylpregna- 1,4-diene3,20- dione 17-valerate 21 -chlo ro-9ó-fluoro11/,17ó-dihydroxy-16ocmethylpregna-1,4-diene3,20- dione 17-benzoate Column LL 21 -chloro-9 oc-fluoro11/3,17ó-dihydroxy-16ómethyl-5-pregna ne-3,20dione 17-acetate 21-chloro-9c-fluoro- 11/3,17oc-dihydroxy16a:methyl-5/3-pregnane-3,20dione 17-butyrate 21 -chloro-9 -fluoro11/3,17 oc-dihydroxy-16ómethyl-5/3-pregnane-3,20dione 17-valerate 21 -chloro-9 oc-fluoro11/3,17ol-dihydroxy-16ómethyl-5/3-pregnane-3, 20dione 17-benzoate Example 112 .DTD:
9-fluoro-11/3,17ó-dihydroxy-16-methyl- 5/3-pregnane-3,20-dione 17,21dipropionate (I) Following the general procedure of Example 106 and making non-critical variations but starting with 21-chloro-9-fluoro-11/3,17-dihydroxy-16ó- methyi-5/3-pregnane-3,20-dione 17-propionate (Example 107) the title compound is obtained.
.DTD:
Example 113 .DTD:
9ó-fluoro-11/3,17oc,21-trihydroxy-16ó-methyl-5/3pregnane3,20-dione 17,21dipropnate (I) 9ó-fluoro- 11/3,170c,21-trihydroxy- 16z-methylpregna1,4-diene-3,20- dione 17,21 -dipropionate (IA, 2.66 g) in acetone (100 ml) is hydrogenated in the presence of p-TSA hydrate (0.1 g) and 35 palladium on carbon (5%, 0.1 g) until the uptake of hydrogen is complete. The mixture is filtered and the filtrate concentrated under reduced pressure. The crude product is column chromatographed on silica gel (100 g) and eluted with acetone-methylene chloride (5/95). The appropriate fractions are pooled and concentrated to a solid. Crystallization of the solid from acetone-hexane gives the title compound, m.p. 176 ; CMR 27.01 8; IR 3540, 1750, 1730, 1710, 1275, 1220, 1185, 1170, 1090, 40 1055, 1040, 1025, 1005 and 990 cm-1.
.DTD:
Example 114 .DTD:
9ó-fluoro-11/3,17ó,21-trihydroxy-5/3-pregnane-3,20-dione 17,21dipropionate (I) 9-fluoro- 11/3,17ó,21 -trihydroxypregna1,4-diene-3,20-dione 17,21 - dipropionate in acetone (100 ml) containing triethylamine (2 ml) is hydrogenated in the presence of palladium on carbon (5%, 45 0.1 g) until the uptake of hydrogen is complete. The mixture is filtered and the filtrate is concentrated under reduced pressure. The residue is column chromatographed on silica gel (125 g) packed in acetone-methylene chloride (5:95) and eluted with the same mixture. The appropriate fractions (TLC) are pooled and concentrated to a solid which is crystallized from acetone- pentane. The crystalline product is pulverized and dried at 80 under high vacuum to afford the title compound, m.p. 153.2-- 50 154 ; [oc]o +4 ; CMR 27.0 8; IR 3540, 1750, 1735, 1705, 1285, 1230, 1205, 1185, 1160, 1095, 1075, 1010 and 905 cm-L Example 115 .DTD:
9ó-chloro-11/3,17,21-trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17,21 -dipropionate (I) A mixture of beclomethasone dipropionate (9o-chloro-11/3,17ó,21 - trihydroxy-16/3methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, 3.0 g) in ethyl acetate (200 ml) is hydrogenated in the presence of palladium on carbon (5%, 0.3 g) and p-TSA (0.1 g) for 2.5 hours and is then filtered. The filtrate is washed with cold aqueous potassium bicarbonate and saline and dried and evaporated under reduced pressure. The residue is column chromatographed on silica gel (300 g) 19 GB 2 070 016 A 19 packed in acetone-methylene chloride (5/95). Elution is performed with the same solvent mixture.
.DTD:
Appropriate fractions are pooled and concentrated to give the title compound.
.DTD:
Example 118 .DTD:
9,21-dichloro- 11/% 17c-dihydroxy- 16/-methyl-5/-pregnane-3,20-dione 17propionate (I) A mixture of 9c,21 -dichloro-11/3,17ó-dihydroxy-16/3-methylpregna-1,4- diene-3,20-dione 17- 5 propionate (U.S. Patent 3,721,687, 1.5 g) in acetone (100 ml) is hydrogenated in the presence of palladium on carbon (5%, 0.2 g) for about 1 hour. The crude product is column chromatographed on silica gel (150 g) packed in acetone-methylene chloride (5/95). Elution with acetone-methylene chloride mixture and crystallization of appropriate fractions from acetone-pentane gives the title compounds, m.p. 148.5--149 ; [a]o +55 . 10 Example 117 .DTD:
9o-chloro-21-fluoro-11/,17o-dihydroxy-5/-pregnane-3,20-dione 17propionate (I) Following the general procedure of Example 118 by making non-critical variations but starting with 9-chloro-21 -fluoro-11/3,17a-dihydroxypregna-1,4-diene-3,20-dione 17- propionate (German Often 2,742,982), the title compound is obtained. 15 Examples 118 and 119 Following the general procedure of Example 116 and making non-critical variations but starting with the A4-steroids of Column MM, the 5/3- steroids of Column NN are obtained.
.DTD:
Examp 118 119 Column MM 9,21-dichloro- 11/3,17odihydroxypregn-4-e ne3,20-dione 17-propionate 9-chloro-21 -fluoro- 11/3,17 o-di hydroxypregna4-ene-3,20-dione 17propionate Column NN 9c,21 -Dichloro11/3,17 a-di- 20 hydroxy-5t-pregnane-3,20-dione 17-propionate 9-Chloro-21 -fluoro-11/3,17e- dihydroxy-5/3-pregnane-3,20- dione 17-propionate 25 Example 120 .DTD:
11/3,17,21-trihydroxy-16ó-methyl-5/3-pregnane-3,20-dione 17,21dipropionate (I) A mixture of 11/3,17ol,21-trihydroxy-16c-methylpregna-1,4-diene- 3,20- dione 17,21dipropionate (IA, 2.0 g) in acetone (200 ml) and triethylamine (2 ml) is hydrogenated in the presence of 30 palladium on carbon (5%, 0.1 g) until the uptake of hydrogen is complete. The mixture is filtered and the filtrate concentrated under reduced presssure to a foam which is chromatographed on silica gel (150 g), packed in acetone-methylene chloride (5/95). Elution is performed with the same acetonemethylenechloride mixture. The appropriate fractions are pooled and concentrated to give the title compound which is crystallized from diethylether-pentane, m.p. 142m142.9 ; NMR (CDCI) 4.82, 4.4, 35 1.25, 1.16, 1.06, and 0.95 8.
.DTD:
Example 124 .DTD:
21-chloro-11/3,17ó-dihydroxy-5/3-pregnane-3,20-dione 17-butyrate (I) Following the general procedure of Example 53 and making non-critical variations but starting with 21-chloro-1113,17ó-dihydroxypregna-4-ene-3,20-dione 17-butyrate (Japan, Kokai 77 83,446), 55 the title compound is obtained.
.DTD:
Example 123 .DTD:
21-chloro-11/3,17-dihydroxy-5/-pregnane-3,20-dione 17-propionate (I) Following the general procedure of Example 53 and making non-critical variations but starting with 21-chloro-11/3,17ó-dihydroxypregn-4-ene-3,20-dione (Japan, Kokai 77 83,446), the title 50 compound is obtained.
.DTD:
Example 122 .DTD:
7,-chloro- 11/3,17ó,21-trihydroxy- 16z-methyl-5/-pregnane-3,20-dione 17, 21 -dipropionate Following the general procedure of Example 53 and making non-critical variations but starting with 7ó-chloro-11/3,17o,21-trihydroxy-16ó-methylpregna-l,4-diene-3,20- dione 17,21-dipropionate 45 (U.S. Patent 4,124,707) the title compound is obtained.
.DTD:
Example 121 .DTD:
11/3,17ó,21 -trihydroxy-16/%methyl-5-pregnane-3,20-dione 17,21 dipropionate (I) Following the general procedure of Example 120 and making non-critical variations but starting with 11/3,17c,21 -trihydroxy-'l 6/3-methylpregna-1,4-diene-3,20-dione 17, 21 -dipropionate, the title 40 compound is obtained.
.DTD:
GB 2 070 016 A 20 Example 125 .DTD:
21-chloro-9,11-epoxy-17ó-hydroxy-5/3-pregnane-3,20-dione 17-propionate (II) Following the general procedure of Example 53 and making non-critical variations but starting with 21-chloro-9,11-epoxy-17z-hydroxypregn-4-ene-3,20-dione 17-propionate, the title compound is obtained. 5 Examples 126---128 Foll0wing the general procedure of Example 125 and making non-critical variations but starting with the A4-steroids of Column OO, the 5/3- steroids of Column PP are obtained.
.DTD:
Example .DTD: 126 127 128 Column O0 21 -chloro-9,11 -epoxy17ó-hydroxy-
16/3-methylpregn-4-ene-3,20-dione 17- propionate 21 -chloro-9,11 -epoxy17o-hydroxy- 16-methylpregn-4-ene-3,20-dione 17- propionate 9,11 -epoxy- 17ó,21-dihydroxy-16/3-methylpregn-4-ene3,20-dione 17,21dipropionate Column PP 21-chloro-9,11 -epoxy- 17ochydroxy-16/3-methyl-5/3-pregnane3,20-dione 17-propionate 21-chloro-9,11-epoxyo 17ó- hydroxy- 16z-m ethyl-5/3-pregnane3,20-dione 17-propionate 9,11 -epoxy-17,21 -dihydroxy16/3-methyl-5/3-pregnane-3,20dione 17,21- dipropionate Example 129 .DTD:
9,21-dichloro-11/3,17ó-dihydroxy-5/3-pregnana-3,20-dione 17-propionate (I) To a solution of 21-chloro-9,11-epoxy-17ó-hydroxy-5/3-pregnane-3,20-dione 17-propionate (Example 125, 4.9 g) in alcohol-free chloroform (250 ml) containing tetrabutylammonium chloride (10 25 g containing 15% n-butyl alcohol) is added slowly a chloroform solution of acetyl chloride (1.1 equivalents). The mixture is allowed to stand for 1 hr at 20--25 and is then concentrated under reduced pressure. The residue is column chromatographed on silica gel (500 g) packed in acetone- methylene chloride. Elution with an acetone-methylene chloride mixture and pooling of the appropriate fractions gives the title compound. 3() Example 130 .DTD:
9=-fluoro-11/3,17,21 -trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17valerste 21 dihydrogen Phosphate (I) A solution of 9oc-fluoro11/3,17oc,21-trihydroxy-16/3-methyl-5/3- pregnane-3,20-dione 17valerate (Example 89, 1 g) in THF (50 ml) is added to a stirred solution of pyrophosphoryl chloride (0.65 ml) in THF (10 ml) at -50 . The temperature is allowed to rise slowly to -10 where it is held for five hours and then is allowed to stand at --4 for 18 hours. The mixture is diluted with water and concentrated under reduced pressure. The precipitate is collected and dissolved in ethyl acetate. The solution is washed with saline, dried and concentrated to give the title compound.
.DTD:
Example 131 .DTD:
9-fluoro-11/3,17ó,21 -trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17benzoate 21 dihydrogen Phosphate (I) Phosphorus oxychloride (8 g) is added to a solution of 9-fluoro-11/3,17, 21-trihydroxy-16/3methyl-5/3-pregnane-3,20-dione 17-benzoate (Example 93, 4 g) in THF. The solution is cooled to --10 , pyridine (0.65 ml) is added slowly, and the mixture is allowed to warm slowly to 20--25 and stand for about 6 hours. The mixture is then diluted with ice water and concentrated under reduced pressure. The precipitate is collected, washed with water and suspended in aqueous methanol and sodium hydroxide (0.1 N) is added until the pH is 9.0. The aqueous solution is extracted with ethyl acetate, then acidified with dilute hydrochloric acid. The precipitate is collected, washed with water and dissolved in ethyl acetate. The ethyl acetate solution is washed with saline, dried and concentrated to give the title compound.
.DTD:
= Examples 132--144 Following the general procedure of Examples 130 and 131, and making non- critical variations but starting with the 21-hydroxy steroids of Examples 90--103 (Column QQ), the 21 -dihydrogen phosphate esters of Column RR are obtained.
.DTD:
21 GB 2 070 016 A 21, Example Column QQ 132 90 133 9,1 134 92 94 136 95 137 96 138 97 139 98 99 141 100 142 101 143 102 144 103 Column RR 9ó-fluoro- 11/3,17o,21 -trihydroxy- 16/3-methyl5/3-pregnane-3,20-dione 17acetate 21 -dihydrogen phosphate 9z-fluoro- 11,17,21 -trihydroxy-16/3-methyl-5pregnane-3,20-dione 17- propionate 21 -dihydrogen phosphate 9 -fluoro- 11/3,17 ,21 -trihyd roxy16/3-methyl5/3-pregnane-3,20-dione 17-butyrate 21 -dihydrogen phosphate 9ó-fluoro- 11/3,17ó,21 -trihydroxy- 16-methyl-5/3pregnane-3,20-dione 17acetate 21-dihydrogen phosphate 9e-fluoro- 11/3,17ó,21 -trihydroxy16z-methyl-5/3pregnane-3,20-dione 17- propionate 21 -dihydrogen phosphate 9ó-fluoro- 11/3,17ó,21 -trihydroxy- 16ó-methyl-5/3pregnane-3,20-dione 17butyrate 21-dihydrogen phosphate 9oL-fluoro-11/3,17ó,21 -trihydroxy-16o-methyl-5/3pregnane-3,20-dione 17- valerate 21 -dihydrogen phosphate 9ó-fluoro- 11/3,17ó,21 -trihydroxy- 16-m ethyl-5/3pregnane-3,20-dione 17- benzoate 21 -dihydrogen phosphate 9 o-fluoro- 11/3,17,21 -trihydroxy-5/3-preg nane- 3,20-dione 17-acetate 21-dihydrogen phosphate 9 -fluoro- 11/3,17 cz,21 - trihyd roxy-5/3-pregnane- 3,20-dione 17-propionate 21-dihydrogen phosphate 9-fluoro- 11/3,17,21 - trihydroxy-5/3-pregnane- 3,20-dione 17-butyrate 21-dihydrogen phosphate 9ó-fluoro-11/3,17m21- trihydroxy-5/3-pregnane3,20-dione 17-valerate 21-dihydrogen phosphate 9z-fluoro-11/3,17m21 trihydroxy-5/3-pregnane- 3,20-dione 17-benzoate 21-dihydrogen phosphate Example 145 .DTD:
9-fluoro-11/3,17,21 -trihydroxy-16/3-methyl-5/3-preg nane-3,20-dione 17propionate 21 disodium Phosphate (I) A finely ground sample of 9o-fluoro11/3,17cz,21 -trihydroxy-16/3-methy- 5/3-pregnane-3,20 dione 17-propionate 21-dihydrogen phosphate (Example 133, 5 g) is suspended in water (50 ml) and stirred while sodium hydroxide (1 N) is added until the pH is 9. The solution is filtered and freeze dried to give the title compound.
.DTD:
25" Examples 146--159 Following the general procedure of Example 145, and making non-critical variations but starting with the 21-dihydrogen phosphate esters of Examples 130--144 (Column SS), there are obtained the 45 corresponding 21- disodium phosphate ester salts of Column 3-1".
.DTD:
Example Column SS 146 132 147 134 Column TT 9-fluoro- 11/3,17m21 -trihydroxy- 16/3-methyl-5/3- pregnane-3,20-dione 17-acetate 21-disodium phosphate 9-fluoro- 11/3,170,21 -trihydroxy- 16/3-methyl-5/3pregnane-3,20-dione 17-butyrate 21 -disodium phosphate 148 130 9z-Fluoro11/3,17cz,21 -trihydroxy- 16/3-methyl-5/3- pregnane-3,20-dione 17-valerate 21-disodium 55 phosphate 9c-fluoro-11/3,17ó,21-trihydroxy-16/3-methyl-5/3pregnane-3,20-dione 17-benzoate 21 -disodium phosphate 9ó-fluoro11/3,17,21 -trihydroxy-16 -methyl-5/3- pregnane-3,20-dione 17-acetate 21 -disodium - phosphate 149 131 135 22 GB 2 070 016 A 22 Example Column SS 151 136 152 137 153 138 154 139 156 141 157 142 158 143 159 144 Column TT 9ó-fluoro-11/3,17ó,21 -trihydroxy- 16o-methyl-5/3- pregnane-3,20-dione 17-propionate 21-disodium phosphate 9-fluoro-11/3,17m21-trihydroxy-16cz-methyl-5/3pregnane-3,20-dione 17butyrate 21-disodium phosphate 9ó-fluoro- 11/3,17ó,21 -trihydroxy16ó-methyl-5/3pregnane-3,20-dione 17- valerate 21-disodium phosphate 9ó-fluoro- 11/3,17m21 -trihydroxy- 16ó-methyl-5/3pregnane-3,20-dione 17benzoate 21-disodium phosphate 9ó-fluoro-11/3,17o,21-trihydroxy-5/3-pregnane- 3,20-dione 17-acetate 21-disodium phosphate 9z-fluoro- 11/3,17cz,21 - trihydroxy-5/3-pregnane3,20-dione 17-propionate 21-disodium phosphate 9-fluoro-11/3,17,21trihydroxy-5/3-pregnane- 3,20-dione 17-butyrate 21-disodium phosphate 9-fluoro- 11/3,17,21 - trihydroxy-5/3-pregnane- 3,20-dione 17-valerate 21 -disodium phosphate 9-fluoro-11/3,17ó,21-trihydroxy-5t3-pregnane3,20-dione -17-benzoate 21-disodium phosphate Example 160 .DTD:
9ó-fluoro-11/3,17,21 -trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17propionate 21 hemisuccinate (I) A mixture of 9-fluoro-11/3,17ó,21-trihydroxy-16/3-methyl-5/3-pregnane-3, 20-dione 17propionate (Example 91,5.4 g) and succinic anhydride (5.6 g) in pyridine (46 ml) is stirred overnight at 20---25 . The reaction mixture is then poured slowly into a stirred mixture of ice water (1 I) containing hydrochloric acid, (46 ml). The precipitate is collected, washed thoroughly with water and dried to give the title compound. Examples 161--174 Following the general procedure of Example 160, and making non-critical variations but starting with the 21 -hydroxy steroids of Examples 89--103 (Column UU), the 21 -hemisuccinate esters of Column W are obtained.
.DTD:
Examp Column UU 161 90 162 92 4O 163 89 164 93 94 166 95 167 96 168 97 169 98 99 171 100 172 101 173 102 174 103 Column VV 9ó-fluoro-11/3,17m21 -trihydroxy- 16/3-methyl-5/3- pregnane-3,20-dione 17-acetate 21-hemisuccinate 9ó-fluoro- 11/3,17ó,21 - trihydroxy-16/3-methyl-5/3pregnane-3,20-dione 17-butyrate 21-hemisuccinate 9o-fluoro- 11/3,17o,21 trihydroxy- 16/3-methyl-5/3- pregnane-3,20-dione 17-valerate 21 -hemisuccinate 9ó-fluoro-11/3,17,21 - trihydroxy- 16/3-methyl-5/3pregnane-3,20-dione 17-benzoate 21 -hemisuccinate 9ó-fluoro-11/3,17m21trihydroxy- 16o-methyl-5/3- pregnane-3,20-dione 17-acetate 21 -hemisuccinate 9ó-fluoro- 11/3,17m21 - trihydroxy- 16ó-methyl-5/3pregnane-3,20-dione 17-propionate 21-hemisuccinate 9ó-fluoro-11/3,17m21 trihydroxy- 16ó-methyl-5/3- pregnane-3,20-dione 17-butyrate 21-hemisuccinate 9ó-Fluoro- 11/3,17m21 - trihydroxy- 16-methyl-5/3pregnane-3,20-dione 17-valerate 21-hemisuccinate 9ó-fluoro-11/3,17m21 trihydroxy-16o-methyl-5/3- pregnane-3,20-dione 17-benzoate 21-hemisuccinate 9-fluoro- 11/3,17m21 - trihydroxy-5/3-pregnane3,20-dione 17-acetate 21 -hemisuccinate 9o-fluoro- 11/3,17ó,21 -trihydroxy-5/3-pregnane- 3,20-dione 17-propionate 21-hemisuccinate 9ec-fluoro- 11/3,17 o,21 - trihyd roxy-5/3-pregna ne- 3,20-dione 17-butyrate 21 -hemisuccinate 9 o-fluoro- 11/3,17 m21 -trihydroxy-5/3-p reg nane- 3,20-dione 17-valerate 21 -hemisuccinate 9o-fluoro-11/3,17m21-trihydroxy- 5/3-pregnane- 3,20-dione 17-benzoate 21 -hemisuccinate 23 GB 2 070 016 A 23 Example 175 .DTD:
9ó-fluoro-11/3,17o/,21-trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17propionate 21disodiumhemisuccinate (I) A solution of 9ó-fluoro-11/3,17o/,21-trihydroxy- 16/3-methyl-5/3-pregnane- 3,20-dione 17propionate 21-hemisuccinate (Example 160, 1.63 g) in acetone (10 ml) is diluted with water (10 ml) and a solution of sodium bicarbonate (0.248 g, 1.0 equivalent) in water (13.5 ml) is added. The mixture is concentrated under reduced pressure and freeze-dried to give the title compound.
.DTD:
Examples 176--189 Following the general procedure of Example 175 and making non-critical variations but starting with the 21-hemisuccinate esters of Examples 161-- 174 (Column WW), the 21-sodium hemisuccinate ester salts of Column XX are obtained.
.DTD:
Example Column WW 176 161 177 162 Column XX 9ó-fluoro- 11/3,17z,21 -trihydroxy- 16/3methyl-5/3-pregnane-3,20-dione 17- acetate 21 -sodium hemisuccinate 9z-fluoro- 11/3,17,21 -trihydroxy16/3methyl-5/3-pregnane-3,20-dione 17- butyrate 21 -sodium hemisuccinate 9-fluoro- 11/3,17,21 -trihydroxy- 16/3methyl-5/3-pregnane-3,20-dione 17valerate 21-sodium hemisuccinate 9(z-fluom- 11/3},17,21-trihydroxy16/3methyl-5/3-pregnane-3,20-dione 17- benzoate 21-sodium hemisuccinate 9-fluoro- 11/3,17ó,21 -trihydroxy- 16o/methyl-5/3-pregnane-3,20-dione 17acetate 21-sodium hemisuccinate 9ó-fluoro- 11/3,17,21 -trihydroxy16(zmethyl-5/3-pregnane-3,20-dione 17- propion- ate 21-sodium hemisuccinate 9ó-fluoro-11/3,17ol,21-trfhydroxy- 16o/methyl-5/3-pregnane-3,20-dione 17-butyrate 21-sodium hemisuccinate 178 163 179 164 165 25 181 166 182 167 183 168 184 169 186 171 187 172 Example 190 55 17,21-dihydroxy-16/3-methyl-5cz-pregn-9(11)ene-3,20-dione 17-propionate (IVE) A mixture of 17ó,21-dihydroxy-16/3-methyl-5-pregn-9(11)ena-3,20-dione (Preparation 18, 2.2 g) in THF (45 ml) containing triethylorthopropionate (2.2 ml) and p-TSA (0.14 g) is stirred for 0.5 hrs, then sulfuric acid (2N, 2.2 ml) is added. The mixture is allowed to stand an additional half hour at 30 , then is cooled, made basic with potassium bicarbonate (1 N, 15 ml), diluted with water and 60 concentrated under reduced pressure. The precipitate is collected, dissolved in ethyl acetate, washed with saline, dried and concentrated to give the title compound.
.DTD:
189 174 188 173 9ó-fluoro-11/3,17 ol,21-trihydroxy- 16olmethyl-5/3-pregnane-3,20-dione 17-valerate 35 21-sodfum hemfsuccinate 9(z-fluoro- 11/3,17(z,21 -trihydroxy-16(z- methyl-5/3-pregnane-3,20-dione 17-benzoate 21-sodium hemisuccinate 170 9-fluoro-11/3,17 ol,21 -trihydroxy-5/3-preg- 40 nane-3,20-dione 17-acetate 21-sodium hemisuccinate 9-fluoro- 11/3,17,2"1 -trihydroxy-5/3-preg- nane-3,20-dione 17-propionate 21-sodium hemisuccinate 45 9 -fluoro- 11/3,17ol,21 -trihydroxy-5/3-preg- nane-3,20-dione 17-butyrate 21-sodium hemisuccinate 9ó-fluoro-11/3,17oi,21 -trihydroxy-5/3-preg- nane-3,20-dione 17-valerate 21-sodium 50 hemisuccinate 9ó-fluoro- 11/3,17ol,21-trihydroxy-5/3-pregnane-3,20-dione 17-benzoate 21-sodium hemi- succinate 24 GB 2 070 016 A 24 Examples 191--204 Following the general procedure of Preparations 15--18 and Example 190, but starting with 17e,21-dihydroxy16/-methylpregna-4,9(11)-diene-3,20- dione 21 -acetate (U.S. Patent 3,072,685), 17,21-dihydroxy- 16 o- methylpregna-4,9(11)diene-3,20-dione 21 -acetate and 17 o,21 dihydroxypregna-4,9(11)diene-3,20-dione 21-acetate and using for the esterifying agents trimethylorthoacetate, triethylorthopropionate, triethylorthobutyrate, trimethylorthovalerate, and trimethylorthobenzoate, according to the procedure of Example 190 the.5o-steroids of Column YY are obtained.
.DTD:
Examp 191 192 193 194 196 197 198 199 201 202 203 204 Column YY 17ó,21-dihydroxy- 16/3-methyl-5o-pregn-9( 11)ene-3,20-dione 17-acetate 17z,21 -dihydroxy- 16/-methyl-5ó-pregn-9(11)ene-3,20-dione 17-butyrate 17ó,21-dihydroxy- 16/-methyl-5ó-pregn-9(11)ene-3,20-dione 17-valerate 17m21-dihydroxy-16/3-methyl-5o-pregn-9(11)ene-3,20-dione 17-benzoate 17, 21-dihydroxy- 16o-methyl-5 -pregn-9(11)ene-3,20-dione 17-acetate 17,21dihydroxy-16-methyl-5z-pregn-9(11)ene-3,20-dione 17-propionate 17,21dihydroxy- 16ó-methyl-5ó-pregn-9(11)ene-3,20-dione 17-butyrate 17,21dihydroxy- 16ó-methyl-5ó-pregn-9(11)ene-3,20-dione 17-valerate 17o,21dihydroxy- 16o-methyl-5o-pregn-9(11)ene-3,20-dione 17-benzoate 17m21dihydroxy-5ó-pregn-9(11)ene-3,20-dione 17-acetate 17ó,21-dihydroxy-5ocpregn-9(11)ene-3,20-dione 17-propionate 17,21-dihydroxy-5o-pregn-9(11)ene3,20-dione 17-butyrate 17,21 -dihydroxy-5-pregn-9(11)ene-3,20-dione 17valerate 17,21-dihydroxy-5o-pre.qn-9(11)ene-3,20-dione 17-benzoate Step 2 9,11 -epoxy-17ó,21 -dihydroxy-16/3-methyl-5o-preg nane-3,20-dione 17propionate 21 -mesylate A solution of 9-bromo-11/3,17,21 -trihydroxy-16/3-methyl-5c-pregnane-3,20- dione 17- propionate 21-mesylate (Step 1,2.9 g) in THF (200 ml) is cooled to 5 and 1,8diazabicyclo[5.4.0]undec-7-ene (DBU, 1 ml) is added. The mixture was allowed to warm to 20--25 and stand for several hours at 20---25 . The reaction mixture is then diluted with water (380 ml) and concentrated under reduced pressure to give a precipitate which is dissolved in methylene chloride.
.DTD:
The solution is washed with aqueous potassium bisulfate, water and aqueous potassium bicarbonate and dried and concentrated to give a solid which is chromatographed on silica gel. Elution is performed 55 with acetone-methylene chloride mixtures and the appropriate fractions are pooled and concentrated under reduced pressure. The product is crystallized from acetone-ether to give 9,11-epoxy-17,21dihydroxy16/3-methyl-5ol-pregnane-3,20-dione 17- propionate 21 -mesylate, m.p. 140--142 o; NMR (CDCI3) 0.89, 1.18, 1.20, 1. 34, 3.17, 3.45 and 4.68 8.
.DTD:
Step 1 9ó-bromool 1/3,17,21-trihydroxy-16-methyl-5ó-pregnane-3,20-dione 17- propionate 21mesylate A mixture of 17oc,21-dihydroxy16/-methyl-5ó-pregn-9(11)ene-3,20-dione 17-propionate 21 - mesylate (Example 205, 12.9 g) in t-butyl alcohol (5 ml) and methylene chloride (40 ml) is mixed with z0 a solution of perchloric acid (70%, 36 ml) in water (490 ml) and then a solution of N-bromoacetamide (5.6 g) in t-butyl alcohol (70 ml) is added at 20--25 . The mixture is stirred for 03 hours at 20--25 , then is diluted with a solution of sodium sulfate (6. 6 g) in water (70 ml), concentrated under reduced pressure to remove the methylene chloride, then further diluted with water (1 I) and concentrated. The precipitate is collected and dried to give 9o-bromo-1113,17<z,21trihydroxy-16/-methyl-5ó-pregnane- 45 3,20-dione 17-propionate 21-mesylate.
.DTD:
Example 206 .DTD:
21-chloro-9ó-fluoro-11/3,17ó-dihydroxy-16/3-methyl-5ó-pregnane-3,20-dione 17-propionate (IV) 35 Example 205 .DTD:
17o,21-dihydroxy-16/3-methyl-5ó-pregn-9(11)ene-3,20-dione 17-propionate 21-mesylate 25 A mixture of 17ó,21-dihydroxy-16/3-methyl-5ó-pregn-9(11)ene-3,20-dione 17- propionate (Example 190, 4.1 g) in pyridine (20 ml) is cooled to 0 and methanesulfonylchloride (5 ml) is added slowly. After stirring for 1 hour at 0% the reaction mixture is poured into a mixture of ice and water containing hydrochloric acid (15 ml). The precipitate is collected, dissolved in methylene chloride and washed successively with aqueous potassium bisulfate, water and aqueous potassium bicarbonate. 30 The extract is concentrated to a foam which is chromatographed on silica gel (500 g) and eluted with acetone-methylene chloride mixtures. Appropriate fractions are pooled and concentrated to give the title compound.
.DTD:
GB 2 070 016 A 25 Step 3 21-chloro-9,11-epoxy-17-hydroxy-16/3-methyl-5ó-pregnane-3,20-dione 17propionate A mixture of 9,11-epoxy-17ó,21-dihydroxy-16/3-methyl-5ó-pregnane-3,20- dione 17-propionate 21-mesylate (Step 2, 4 g) and lithium chloride (8 g) in DMF (100 ml) and acetone (100 ml) is heated under reflux for about 100 hours. The reaction mixture is concentrated under reduced pressure and diluted with water. The precipitate is collected, dried and chromatographed on silica gel (200 g). The column is eluted with acetone- methylene chloride; the appropriate fractions are pooled and concentrated to give 21-chloro-9,11-epoxy-17o-hydroxy-16/3-methyl-5-pregnane-3,20- dione 17propionate.
.DTD:
Step4 21-chloro-9o-fluoro-11/3,17z-dihydroxy-16/3-methyl-5o-pregnane-3,20-dione 17-propionate (IV) Following the general procedure of (Example 290--298, Step 3) and making non-critical variations but starting with 21-chloro-9,11-epoxy-17ó- hydroxy-16/3-methyl-5oL-pregnane-3,20-dione 17-propionate (Step 3), the title compound is obtained, m.p. 195 ; NMR (CDCI3) 0.95, 1.18, 1.35, 4.0, 15 4.25 #; IR (mull) 3500, 1720, 1295, 1245, 1020, 1005, 995 and 895 cm-1.
.DTD:
Examples 207--220 Following the general procedure of Example 205 and 206 and making non- critical variations but starting with the A9(11-21-hydroxy-steroids of Example 191 m204 (Column ZZ) the 21 -chloro steroids of Column AAA are obtained.
.DTD:
Examp ColumnZZ 207 191 208 192 209 193 210 194 211 195 212 196 213 197 214 198 215 199 216 200 217 201 218 202 219 203 220 204 Column AAA 21 -chloro-9 -fluoro- 11/3,17 -dihyd roxy- 16/3methyl-5-pregnane-3,20- dione 17-acetate 21-chloro-9ó-fluoro-11/3,17ó-dihydroxy-16/3methyl-5ó-pregnane-3,20-dione 17-butyrate 21 -chloro-9c-fluoro- 11/3,17 -dihydroxy- 16/3methyl-5c-pregnane,3,20- dione 17-valerate 21 -chloro-9ó-fluoro- 11/3,17-dihydroxy- 16/3methyl-5-pregnane-3,20-dione 17-benzoate 21-chloro-9ol-fluoro- 11/3,17-dihydroxy- 16ómethyl-5-pregnane-3,20-dione 17-acetate 21-chloro-9cz-fluoro-11/3,17odihydroxy- 16c- methyl-5z-pregnane-3,20-dione 17-propionate 21-chloro-9o-fluoro- 11/3,17- dihydroxy- 16ómethyl-5ó-pregnane-3,20-dione 17-butyrate 21 -chloro-9-fluoro-11/3,17 oL-dih' rdroxy- 16oLmethyl-5-pregnane-3,20- dione 17-valerate 21 -chloro-9 o-fluoro- 11/3,17z-dih, rdroxy- 16ó- methyl-5c-pregnane-3,20-dione 17-benzoate 21 -chloro-9ó-fluoro- 11/3,17ó-dih rdroxy-5ópregnane-3,20-dione 17- acetate 21 -chloro-9ó-fluoro-11/3,17-dih fdroxy-5 pregnane-3,20-dione 17- propionate 21 -chloro-9z-fl uoro- 11/3,17 -dih idroxy-5 pregnane-3,20-dione 17- butyrate 21 -chloro-9ó-fluoro11/3,17 o-dih Idroxy-5 pregnane-3,20-dione 17- valerate 21-chloro-9z-fluoro-11/3,17ó-dih/droxy-5 - pregnane-3,20-dione 17-benzoate Example 221 .DTD:
9-fluoro-11/3,17-dihydroxy-16/3-methyl-5-pregnane-3,20-dione 17propionate (IV) 50 A sample of 21-chloro-9ó-fluoro-11/3,17-dihydroxy-16/3-methyl-5o-pregnane- 3,20-dione 17- propionate (Example 206, 8 g) in acetone (200 ml) containing triethylamine (4 ml) is hydrogenated at 2 atmospheres in the presence of palladium on carbon (5%, 0.8 g) until the uptake of hydrogen is complete. The mixture is filtered and the filtrate is concentrated under reduced pressure. The residue is chromatographed on silica gel (400 g) and eluted with acetone-methylene chloride mixtures. The 55 appropriate fractions are pooled and concentrated under reduced pressure to give the title compound.
.DTD:
Examples 222--235 Following the general procedure of Example 221 and making non-critical variations but starting with the 17-acetate, 17-butyrate, 17-valerate or 17-benzoate esters of 21 -chloro-9o-fluoro-11/3,17ódihydroxy-16/3-methyl- 5ó-pregnane-3,20-dione (Examples 207--210), there are obtained the 26 GB 2 070 016 A 26 corresponding 21 -unsubstituted esters, namely the 17-acetate, 17butyrate, 17-valerate, or 17- benzoate esters of 9(-fluoro-11, 17-dihydroxy-16/3-methyl-5o-pregnane-3, 20-dione are obtained.
.DTD:
Following the procedure of Example 221 and making non-critical variations but starting with the 17-acetate, 17-propionate, 17-butyrate, 17-valerate or 17-benzoate esters of 21-chloro-9-fluoro11/3,17ó-dihydroxy-16-methyl-5ó-pregnane-3,20-dione and 21-chloro-9ófluoro-11/3,17(- 5 dihydroxy-5-pregnane-3,20-dione (Examples 211--220), the corresponding 21- unsubstituted esters, namely the 17-acetate, 17-propionate, 17-butyrate, 17-valerate or 17-benzoate esters of 9ofluoro-11/3,17-dihydroxy-16-methyl-5o-pregnane-3,20-dione and 9ó-fluoro11/3,17o-dihydroxy- 5-pregnane-3,20-dione are obtained.
.DTD:
Example 236 10 21 -Chloro-9ó-fluoro-17o-hydroxy-16/3-methyl-5o-pregnane-3,11,20-trione 17-propionate (IV) Jones reagent (chromium trioxide-aqueous sulfuric acid, 2.6 ml) is added to a solution of 21 chloro-9-fluoro-11/3,17-dihydroxy-16/3-methyl-5o-pregnane-3,20-dione 17propionate (Example, 206, 4 g) in acetone (100 ml). The mixture is stirred for one-half hour at 20--25% Isopropyl alcohol is added followed by slow addition of ice water (600 ml). The mixture is concentrated under reduced 15 pressure and filtered. The crude product is dried and chromatographed on silica gel (400 g), eluting, with an acetone-methylene chloride mixture. The appropriate fractions are pooled and concentrated under reduced pressure to give the title compound.
.DTD:
Examples 237--250 Following the procedure of Example 236 and making non-critical variations but starting with the 20 17-acetate, 17-butyrate, 17-valerate or 17-benzoate esters (Examples 207-- -210) of 21 -chloro-9fluoro-11/3,17 e-dihydroxy-16/-methyl-5o-pregnane-3,20-dione the corresponding trione esters, namely the 17-acetate, 17-butyrate, 17-valerate and 17-benzoate esters, of 21 -chloro-9-fluoro-17óhydroxy-16-methyl-5-pregnane-3,11,20-trione are obtained.
.DTD:
Following the general procedure of Example 236 and making non-critical variations but starting 25 with the 17-acetate, 17-propionate, 17-butyrate, 17-valerate or 17- benzoate esters of 21-chloro-9zfluoro-11/3,17 -dihydroxy-16o-methyl-5-pregnane-3,20-dione and 21-chloro9-fluoro- 11/3,17-dihydroxy-5-pregnane-3,20-dione (Examples 211---220), the corresponding trione esters, namely the 17-acetate, 17-propionate, 17-butyrate, 17-valerate or 17- benzoate esters of 21 -chloro9o-fluoro-17-hydroxy-16-methyl-5ó-pregnane-3,11,20-trione and 21-chloro9ó-fluoro-17- 30 hydroxy-5-pregnane-3,11,20-trione are obtained.
.DTD:
Example 251 .DTD:
9ó,11/3,21-trichloro-17 -hydroxy-16/3-methyl-5ó-pregnane-3,20-dione 17propionate (IV) Step 1 21-óhloro-17ó-hydroxy-16/3-methyl-5ó-pregn-9(11)ene-3,20-dione 17propionate 35 Following the general procedure of Example 206, Step 3, and making non- critical variations but starting with 17ó,21-dihydroxy-16/3-methyl-5o-pregn-9(11)ene-3,20-dione 17-propionate 21- mesylate, (Example 205) 21 -chloro-17ó-hydroxy-16/3-methyl-5ó-pregn9(11)ene-3,20-dione 17- propionate is obtained.
.DTD:
Step 2 40 9ó,11/3,21-trichloro-17ó-hydroxy-16/3-methyl-5-pregnane-3,20-dione 17propionate A mixture of 21-chloro-17-hydroxy-16/3-methyl-5ó-pregn-9(11)ene-3,20- dione 17-propionate (Step 1, 1.3 g) in chloroform (100 ml) and and pyridine (1 ml) is cooled to --10 .The chlorine solution in carbon tetrachloride (40 ml, 1.15 equivalents) is added at --10 and the reaction mixture is washed successively with cold aqueous potassium bisulfate, water and cold aqueous potassium bicarbonate. 45 The organic extract is dried and concentrated and the residue is chromatographed on silica gel. The column is eluted with an acetone-methylene chloride mixture. The appropriate fractions are pooled and concentrated under reduced pressure to give the title compound.
.DTD:
Examples 252--265 Following the general procedure of Examples 205 and 251, and making non- critical variations 50 but starting with the 17-acetate, 17-butyrate, 17-valerate and 17- benzoate esters of 17ó,21dihydroxy-16-methylpregn-9(11)ene-3,20-dione (Examples 191--194), the corresponding trichlorinated steroids, namely the 17-acetate, 17-butyrate, 17-valerate and 17- benzoate of 9ó,11/3,21-trichloro-17o-hydroxy16/3-methyl-5o-pregnane-3, 20-dione are obtained.
.DTD:
Following the general procedure of Examples 205 and 251 and making noncritical variations but 55 starting with the 17-acetate, 17-propionate, 17-butyrate, 17-valerate and 17-benzoate esters of 17ó,21 -dihydroxy16ó-methyl-5o-pregn-9(11)ene-3,20-dione and 17,21 - dihydroxy-5ó-pregn9(11)ene-3,20-dione (Examples 195--204) the corresponding trichlorinated steroids, namely the 17- acetate, 17-propionate, 17-butyrate, 17-valerate and 17-benzoate esters of 9o,11/3,21 -trichloro-17hydroxy-16o-methyl-5z-pregna-3,20-dione and 9ó,11/3,21-trichloro-17hydroxy-5z-pregna-3,20- 60 dione are obtained.
.DTD:
27 GB 2 070 016 A 27 illl Examples 266m280 Following the general procedure of Example 383 and making non-critical variations but starting with the 17-acetate 21-mesylate, 17-propionate 21-mesylate, 17-butyrate 21-mesylate, 17-valerate 21-mesylate or 17-benzoate 21-mesylate diesters of 9ó-bromo-11/3,17z,21 - trihydroxy-16/3-methyl- 5ó-pregnane-3,20-dione, 9ó-bromo-11/3,17c,21-tdhydroxy-16-methyl-5ó- pregnane-3,20-dione 5 and 9-bromo-11/% 17z,21 -trihydroxy-5ó-pregnane-3,20-dione, (Examples 206-220, Step 1) the corresponding 9-unsubstituted diesters, namely the 17-acetate 21 - mesylate, 17-propionate 21 - mesylate, 17-butyrate 21-mesylate, 17-valerate 21-mesylate or 17-benzoate 21 -mesylate diesters of 11/3,17ó,21 -trihydroxy- 16/3-methyl-5ó-pregnane-3,20-dione, 1 lJ, 17,21 - trihydroxy- 16C-methyl- 5z-pregnane-3,20-dione and 11/3,17z,21 -trihydroxy-5z-pregnane-3,20-dione are obtained. 10 Example 281 .DTD:
17c,21-dihydroxy-16/-methyl-5ó-preg n-9(11)ene-3,20-dione 17,21 dipropionate A solution of 17ó,21-dihydroxy16/3-methyl-5ó-pregn-9(11)ene-3,20-dione 17-propionate (Example 190, 2 g) in pyridine (8 ml) and propionic anhydride (4 ml) was allowed to stand overnight at 20--25 . The mixture is then diluted with ice and water to give a precipitate which was collected and 15 dried. The crude produce is chromatographed on silica gel (200 g) and eluted with acetone-methylene chloride mixtures. The appropriate fractions are pooled and concentrated to give the title compound.
.DTD:
Example 282 .DTD:
Following the general procedure of Example 281 and making non-critical variations but using acetic anhydride in place of propionic anhydride the corresponding 21 - ester, namely 17ó,21dihydroxy-16/3-methyl-5ó-pregn-9(11)ene-3,20-dione 17-propionate 21acetate is obtained.
.DTD:
Examples 283 and 284 Following the general procedure of Examples 281 and 282 and making non- critical variations but starting with 17z,21-dihydroxy-16z-methyl-5z-pregn-9(11)ene-3,20-dione 17- propionate (Example 196), the corresponding 17,21-diesters, namely 17c,21-dihydroxy-16z- methyl-5-pregn-9(11)ene- 25 3,20-dione 17-propionate 21 -acetate and 17,21 -dihydroxy-16ó-methyl-5c- pregn-9(11)ene-3,20- dione 17,21 -dipropionate are obtained.
.DTD:
Examples 285 and 286 Following the general procedure of Examples 281 and 282 and making non- critical variations but starting with 17c,21-dihydroxy-5c-pregn-9(11)ene-3,20-dione 17-propionate (Example 201), the 30 corresponding 21 -esters, namely the 17ó,21 -dihydroxy-5z-pregn-9(11)ene- 3,20-dione 17- propionate 21-acetate and 17ó,21-dihydroxy-5z-pregn-9(11)ene-3,20-dione 17,21-dipropionate are obtained.
.DTD: Examples 287--289 Following the general procedure of Example 282 and
making non-critical variations but starting 35 with the 17-butyrate esters of 17ó,21 -dihydroxy-16j-methyl-5ó-pregn- 9(11)ene-3,20-dione, 17ó,21 -dihydroxy- 16-methyl-5cz-pregn-9(11)ene-3,20-dione or 17ó,21 dihydroxy-5ol-pregn- 9(11)ene-3,20-dione (Examples 192, 197 and 202) the corresponding 17,21- diesters, namely the 17- butyrate 2 l-acetate diesters of 17,21-dihydroxy- 16/3-methyl-5-pregn- 9(11)ene-3,20-dione, 17ó,21-dihydroxy- 16ó-methyl-5ó-pregn-9(11)ene-3,20-dione, or 17ó,21dihydroxy-5ó-pregn- 40 9(11)ene-3,20-dione are obtained.
.DTD:
Examples 290--298 Step 1 Following the general procedure of Example 206, Step 1, and making non- critical variations but starting with the 17-propionate 21-acetate, 17,21-dipropionate, or 17- butyrate 21-acetate diesters of 45 17,21 -dihydroxy-16/3-methyl-5z-pregn9(11)erie-3,20-dione, 17,21 -dihydroxy- 16-methyl5ó-pregn-9(11)ene-3,20dione and 17c,21 -dihydroxy-5ó-pregn-9(11)ene-3,20- dione (Examples 281--289) the corresponding bromohydrins, namely the 17-propionate 21 -acetate, 17,21 dipropionate, or 17-butyrate 21-acetate diesters of 9o-bromo-11/3, 17ó,21-trihydroxy-16/3-methyl- 5ó-pregnane-3,20-dione, 9-bromo11/3,17ó,21-trihydroxy-16c-methyl-5ó- pregnane-3,20-dione 50 and 9-bromo11/3,17c,21-trihydroxy-5-pregnane-3,20-dione are obtained, Step 2 Following the general procedure of Example 206, Step 2, and making noncritical variations but starting with the 17-propionate 21 -acetate, 17,21 -dipropionate, or 17- butyrate 21 -acetate diesters of 9z-bromo-11/3,17ó,21-trihydroxy-16/3-methyl-5o-pregnane-3,20-dione, 9óbromo-1 I/3,17ó,21- 55 trihydroxy- 16ó-methyl-5z-pregnane-3,20-dione and 9ó-bromo- 11/3,17ó,21- trihydroxy-5ó- pregnane-3,20-dione (Step 1), the corresponding 9,11-epoxides, namely the 17-propionate 21 - acetate, 17,21-dipropionate or 17-butyrate 21-acetate diesters of 9,11 epoxy-17e,21-dihydroxy-16J- 28 GB 2 070 016 A 2,R methyl-5ó-pregnane-3,20-dione, 9,11-epoxy-I 7ó,21-dihydroxy-16ó-methyl-5pregnane-3,20dione and 9,11 epoxy-17ó,21- dihydroxy-5ó-pregnane-3,20dione are obtained.
.DTD:
Step 3 9-fluoro-11/3,17 oc,21 -trihydroxy-16/3-methyl-5ó-pregnane-3,20-dione 17, 21 -dipropionate (IV) A sample of 9,11-epoxy-17ó,21-dihydroxy-16/-methyl-5ó-pregnane-3,20-dione 17,21- 5 dipropionate (Step 2) is added to a stirred mixture of hydrogen fluoride (9.2 g), methylene chloride (6.6 ml) and water (3.57 ml) at--70 . The mixture is stirred for one hour at -70 and then one hour at --30 , then cooled to --70 and diluted with cold THF (14 ml). The reaction mixture is then poured into a cold stirred mixture of potassium carbonate, water and THF. The aqueous phase is separated, diluted with water and extracted with methylene chloride. The organic extracts are combined, washed with 10 water, dried and concentrated under reduced pressure. The residue is chromatographed on silica gel (200 g), eluted with an acetone-methylene chloride mixture. The appropriate fractions are pooled and concentrated under reduced pressure. Crystallization of the residue from hexane-ether gives the title compound, m.p. 147.5--147.6 o; NMR (CDCI3) 0.94, 1.16, 1.18, 1.36, 4.28, 4.57; CMR 14.51 8; I R (mull) 3360,1750,1735,1700,1360,1345,1070, lO20,1185,1175, 975, 940 and 880 cm-1. 15 Following the general procedure of Step 3 above and making non-critical variations but starting with the 17-propionate 21-acetater 17 butyrate 21-acetate diesters of 9, 11-epoxy-17ó,21 -dihydroxy16/3-methyl-5ó-pregnane-3,20-dione (Step 2), the corresponding fluorohydrins, namely the 17- propionate 21 -acetate and 17-butyrate 21 -acetate diesters of 9ó-fluoro- 11,17ó,21 -trihydroxy-16methyl-5ó-pregnane-3,20-dione are obtained. 20 Following the procedure of Step 3 above and making non-critical variations but starting with the 17-propionate 21-acetate, 17,21 -dipropionate or 17-butyrate 21 -acetate diesters of 9,11 -epoxy- 17ó,21 -dihydroxy16ó-methyl-5ó-pregnane-3,20-dione and 9,11 -epoxy- 17ó, 21 -dihydroxy-5ópregnane-3,20-dione (Step 2) the corresponding fluorohydrins, namely the 17-propionate 21-acetate, 17,21-dipropionate, or 17-butyrate 21-acetate diesters of 9oc-fluoro-11/3, 17ó,21-trihydroxy-16ómethyl-5-pregnane-3,20-dione and 9oc-fluoro- 118,17ó,21-trihydroxy-5ópregnane-3,20-dione are obtained.
.DTD:
Example 299 .DTD:
9oc-fluoro-11/3,17,21-trihydroxy-16/3-methyl-5oL-pregnane-3,20-dione 17propionate (IV) Step 1 30 9-fluoro-11/3,17o,21 -trihydroxy-16/3-methyl5-pregnane-3,20-dione A mixture of 9o-fluoro-11/3,17,21 -trihydroxy-16/3-methyl-5-pregnane-3,20- dione 17,21 - dipropionate (Example 290, 2.1 g) in methanol (70 ml) and aqueous potassium carbonate (10%, 15 ml) is stirred for about 1 hour under a nitrogen atmosphere. The mixture is then acidified with acetic acid, diluted with water and concentrated under reduced pressure. The mixture is cooled and the solid 35 is collected, washed with water and dried to give 9ó-fluoro-11/3,17ó,21- trihydroxy-16/3-methyl-5ó- pregnane-3,20-dione.
.DTD:
Step 2 9-fluoro-11/3,17,21-trihydroxy-16/3-methyl-5oc-pregna ne-3,20-dione 17- propionate A mixture of 9o-fluoro-11/3,17,21 -trihydroxy-I 6/3-methyl-5ó-pregnane-3, 20-dione (Step 1, 40 1.1 g) in THF (25 ml) containing triethylorthopropionate (1.2 ml) and p- TSA (1.07 g) is allowed to stand at 30 for about 1 hour and then sulfuric acid (2N, 1.2 ml) is added. The mixture is stirred for an additional half hour, then made basic with potassium carbonate (1 N, 7 ml) diluted with water and concentrated under reduced pressure. The precipitate is collected, dissolved in ethyl acetate, washed with saline, dried and concentrated to give the title compound. 45 Examples 300--313 Step 1 Following the general procedure of Example 299, Step 1, and making non- critical variations but starting with the 17,21 -dipropionate, 17-propionate 21 -acetate, and 17- butyrate 21 -acetate diesters of 9-fluoro-11/3,17oc,21-trihydroxy-16/3-methyl-5oc-pregnane-3,20-dione, 9ó-fluoro-11/3,17oc,21- 50 trihydroxy-16oc-methyl-5oc-pregnane-3,20-dione and 9-fluoro-11/3,17ó,21- trihydroxy-5ó-pregnane- 3,20-dione (Examples 290---298), the corresponding triols, namely 9ófluoro-11/3,17ó,21-trihydroxy- 16/3-methyl-5ó-pregnane-3,20-dione, 9oc-fluoro- 11/3,17ó,21-trihydroxy-5ó- pregnane-3,20-dione and 9ó-fluoro11/3,17,21-trihydroxy-5-pregnane-3,20-dione are obtained.
.DTD:
Step 2 55 Following the general procedure of Example 299, Step 2, and making non- critical variations but substituting trimethylorthoacetate, triethylorthobutyrate, trimethylorthovalerate, or trimethylorthobenzoate for trimethylorthopropionate, the corresponding 17- esters, namely the 17acetate, 17-butyrate, 17-valerate and 17-benzoate esters of 9ó-fluoro11/3,17oc,21-trihydroxy-16/3- methyl-5oc-pregnane-3,20-dione are obtained. 60 29 GB 2 070 O16 A 29 Following the general procedure of Example 299, Step 2, and making non- critical variations but starting with 9z-fluoro-11/3,17ó,21-trihydroxy- 16ó-methyl-5-pregnane-3,20-dione and 9z-fluoro11/3,17c,21-trihydroxy-5z- pregnane-3,20-dione, the corresponding 17C-esters, namely the 17acetate, 17-propionate, 17-butyrate, 17-valerate or 17-benzoate estes of 9ó-fluoro11/3,17ó,21trihydroxy-16z-methyl-5o-pregnane-3,20-dione and 9-fluoro-11/3, 17ó,21 -trihydroxy-5-pregnane3,20-dione are obtained.
.DTD:
Example 314 .DTD:
9ó-fluoro-11/3,17,21-trihydroxy-16/3-methyl-5ó-pregnane-3,20-dione 17valerate 21- dihydrogen Phosphate (IV) A solution of 9z-fluoro11/3,17ó,21-trihydroxy- 16/3-methyl-5/3-pregnane- 3,20-dione 17valerate (Example 302, 1 g) in TFIF (50 ml) is added to a stirred solution of pyrophosphoryl chloride (0.65 ml) in THF (10 ml) at --50 . The temperature is allowed to rise slowly to --10 where it is held for five hours and then is allowed to stand at-4 for 18 hours. The mixture is diluted with water and concentrated under reduced pressure. The precipitate is collected and dissolved in ethyl acetate. The solution is washed with saline, dried and concentrated to give the title compound. 15 Example 315 .DTD:
9ó-fluoro-11/,17ó,21-trihydroxy-16/3-methyl-5oL-pregnane-3,20-dione 17benzoate 21- dihydrogen Phosphate (IV} Phosphorus oxychlorJde (8 g) is added to a solution of 9ó-fluoro-11/3,17o, 21-trihydroxy-16/3methyl-5/3-pregnane-3,20-dione 17-benzoate (Example 303, 4 g) in THF. The solution is cooled to 20 -10% pyridine (0.65 ml) is added slowly, and the mixture is allowed to warm slowly to 20--25 and stand for about 6 hours. The mixture is then diluted with ice water and concentrated under reduced pressure. The precipitate is collected, washed with water and suspended in aqueous methanol and sodium hydroxide (0.1 N) is added until the pH is 9.0. The aqueous solution is extracted with ethyl acetate, then acidified with dilute hydrochloric acid. The precipitate is collected, washed with water and dissolved in ethyl acetate. The ethyl acetate solution is washed with saline, dried and concentrated to give the title compound.
.DTD:
"3O Examples 316--328 Following the general procedure of Examples 314 and 315, and making non- critical variations but starting with the 21-hydroxy steroids of Examples 299--313 (Column BBB), the 21-dihydrogen phosphate esters of Column CCC are obtained.
.DTD:
Example Column BBB 316 300 317 299 318 301 319 304 320 305 321 306 322 307 323 308 324 309 325 310 Column CCC 9-fluoro-11/3,17cz,21-trihydroxy-16/3-methyl- 5ó-pregnane-3,20-dione 17-acetate 21 -dihydrogen phosphate 9-fluoro- 11/3,17,21 -trihydroxy16/-methyl-5pregnane-3,20-dione 17- propionate 21 -dihydrogen phosphate 9o-fluoro-11/3,17o,21-trihydroxy- 16/3-methyl5-pregnane-3,20-dione 17butyrate 21-dihydrogen phosphate 9-fluoro- 11/3,17,21 -trihydroxy16-methyl-5pregnane-3,20-dione 17- acetate 21-dihydrogen phosphate 9z-fluoro- 11/3,17 c,21 -trihydroxy- 16ó-methyl-5czpregnane-3,20-dione 17propionate 21-dihydrogen phosphate 9ó-fluoro-11/3,17oL,21 -trihydroxy16ó-methyl-5ópregnane-3,20-dione 17- butyrate 21 -dihydrogen phosphate 9c-fluoro- 11/3,17c,21 -trihydroxy- 16ó-methyl-5ópregnane-3,20-dione 17valerate 21 -dihydrogen phosphate 9ó-fluoro-11/3,17,21 -trihydroxy16-methyl-5ópregnane-3,20-dione 17- benzoate 21-dihydrogen phosphate 9 oL-fluoro- 11/3,17z,21 -trihydroxy-5 -pregnane- 3,20-dione 17-acetate 21-dihydrogen phosphate 9ó-fluoro-11/3,17,21 - trihydroxy-5-pregnane3,20-dione 17-propionate 21 -dihydrogen phosphate GB 2 070 016 A 30 Example Column BBB Column CCC 326 311 9o-fluoro-11/3,17ó,21 -trihydroxy-5o-pregnane- 3,20-dione 17-butyrate 21-dihydrogen phosphate 327 312 9ó-fluoro-11/3,17 ,21 -trihydroxy-5ó-pregnane- 3,20-dione 17-valerate 21-dihydrogen phosphate 5 328 313 9o-fluoro- 11/3,17,21 -trihydroxy-5c-pregna ne- Example 329 3,20-dione 17-benzoate 21-dihvdro.qen phosphate 9ó-fluoro-11/3,17o,21-trihydroxy-16/3-methyl-5o-preg nane-3,20-dione 17propionate 21- disodium Phosphate (IV) A finely ground sample of 9-fluoro-11/3,17c,21-trihydroxy-16/3-methyl-5ó- pregnane-3,20- 10 dione 17-propionate 21-dihydrogen phosphate (Example 316, 5 g) is suspended in water (50 ml) and stirred while sodium hydroxide (1 N) is added until the pH is 9. The solution is filtered and freeze dried to give the title compound. " Examples 330331 Following the general procedure of Example 329, and making non-critical variations but starting with the 21-dihydrogen phosphate esters of Examples 314--326 (Column DDD), there are obtained the corresponding 21- disodium phosphate ester salts of Column EEE, Example Column DDD 330 317 331 318 332 314 333 315 334 319 335 320 336 321 337 322 338 323 339 324 340 325 341 326 342 327 343 328 Column EEE 9ó-fluoro- 11/3,17ó,21-trihydroxy- 16/3-methyl-5ópregnane-3,20-dione 17- acetate 21-disodium phosphate 9o-fluoro- 11/3,17z,21 -trihydroxy16/3-methyl-5ópregnane-3,20-dione 17- butyrate 21-disodium phosphate 9 -fluoro- 11/3,17 ,21 -trihydroxy- 16/3-methyl-5 pregnane-3,20-dione 17valerate 21-disodium phosphate 9o-fluoro- 11/3,17o,21 -trihyd roxy16/3-methyl-5opregnane-3,20-dione 17- benzoate 21 -disodium phosphate 9o-fluoro- 11/3,17,21-trihydroxy- 16c-methyl-5cpregnane-3,20-dione 17acetate 21-disodium phosphate 9-fluoro-11/3,17,21 -trihydroxy16c-methyl-5pregnane-3,20-dione 17- propionate 21-disodium phosphate 9-fluoro-11/3,17c,21 -trihydroxy- 16-methyl-5ópregnane-3,20-dione 17butyrate 21-disodium phosphate 9ó-fluoro-11/3,17ó,21 -trihydroxy-16ó-methyl-5pregnane-3,20-dione 17- valerate 21-disodium phosphate 9ó-fluoro- 11/3,17ó,21 -trihydroxy- 16 -methyl-5pregnane-3,20-dione 17- benzoate 21 -disodium phosphate 9c-fluoro-11/3,17o,21 -trihydroxy-5cz-pregnane- 3,20-dione 17-acetate 21-disodium phosphate 9c-fluoro-11/3,17c,21 - trihydroxy-5-pregnane3,20-dione 17-propionate 21-disodium phosphate 9o-fluoro-11/3,17ó,21 trihydroxy-5ó-pregnane- 3,20-dione 17-butyrate 21-disodium phosphate 9ó-fluoro-11/3,17ó,21- trihydroxy-5ó-pregnane- 3,20-dione 17-valerate 21-disodium phosphate 9-fluoro-11/3,17ó,21 - trihydroxy-5z-pregnane3,20-dione 17-benzoate 21-disodium phosphate Example 344 .DTD:
9-fluoro-11/3,17ó,21 -trihydroxy-16/3-methyl-5-pregnane-3,20-dione 17propionate 21 hemisuccinate (IV) A mixture of 9ó-fluoro-11/3,17ó,21-trihydroxy-16/3-methyl-5c-pregnane-3, 20-dione 17propionate (Example 299, 5.4 g) and succinic anhydride (5.6 g) in pyridine (46 ml) is stirred overnight at 20--25% The reaction mixture is then poured slowly into a stirred mixture of ice water (1 I) 31 GB 2 070 016 A 31 containing hydrochloric acid (46 ml). The precipitate is collected, washed throughly with water and dried to give the title compound.
.DTD:
Examples 345--358 Following the general procedure of Example 344, and making non-critical variations but starting with the 21 -hydroxy steroids of Examples 2991313 (Column FFF), the 21 -hemisuccinate esters of Column GGG are obtained.
.DTD:
Examp Column FFF 345 300 346 301 347 302 348 303 349 304 350 305 351 306 352 307 353 308 354 309 355 310 356 311 357 312 358 313 Column GGG 9-fluoro-11/3,17o,21 -trihydroxy- 16/3-methyl-5 o- pregnane-3,20-dione 17-acetate 21-hemisuccinate 9o-fluoro- 11/3,17,21 - trihydroxy16/3-methyl-5- pregnane-3,20-dione 17-butyrate 21-hemisuccinate 9-fluoro11/3,17,21 - trihydroxy- 16/3-methyl-5 - pregnane-3,20-dione 17-valerate 21-hemisuccinate 9o-fluoro- 11/3,17,21 - trihydroxy- 16/3-methyl-Sapregnane-3,20-dione 17-benzoate 21-hemisuccinate 9-fluoro-11/3,17c,21 trihydroxy- 16oc-methyl-5 o- pregnane-3,20-dione 17-acetate 21-hemisuccinate 9-fluoro- 11/3,17,21- trihydroxy- 16-methyl-5pregnane-3,20-dione 17-propionate 21-hemisuccinate 9 o-fluoro- 1 lj%17,21 -trihydroxy- 16o-methyl-5 - pregnane-3,20-dione 17-butyrate 21-hemisuccinate 9z-fluoro- 11/3,17,21- trihydroxy- 16-methyl-5 apregnane-3,20-dione 17-valerate 21 -hemisuccinate 9c-fluoro11/3,17,21-trihydroxy- 16-methyl-5opregnane-3,20-dione 17- benzoate 17-benzoate 21-hemisuccinate 9-fluoro-11/3,17,21 -trihydroxy-5-pregnane3,20-dione 17-acetate 21-hemisuccinate 9-fluoro- 11/3,17,21 -trihydroxy-Sa-pregnane- 3,20-dlone 17-propionate 21 -hemisuccinate 9oL-fluoro- 11/3,17,21 - trihydroxy-5-pregnane- 3,20-dione 17-butyrate 21-hemisuccinate 9cz-fluoro- 11/3,17m21 -trihyd roxy-5 o-p regna ne3,20-dione 17-valerate 21 -hemisuccinate 9cz-fluoro11/3,17,21-tdhydroxy-5-pregnane- 3,20-dione 17-benzoate 21 -hemisuccinate Example 359 .DTD:
9-fluoro- 1 I/3,17,21-trihydroxy- 16/3-methyl-5-pregnane-3,20-dione 17propionate 2 lsodium Hemisuccinate (IV) A solution of 9-fluoro-11/3,17,21-trihydroxy-16/3-methyl-5-pregnane-3,20- dione 17propionate 21-hemisuccinate (Example 344, 1.63 g) in acetone (10 ml) is diluted with water (10 ml) and a solution of sodium bicarbonate (0. 248 g, 1.O equivalent) in water (13.5 ml) is added. The mixture is concentrated under reduced pressure and freeze-dried to give the title compound.
.DTD:
Examples 360--373 Following the general procedure of Example 359 and making non-critical variations but starting with the 21-hemisuccinate esters of Examples 345-- 358 (Column HHH), the 21-sodium hemisuccinate ester salts of Column 111 are obtained.
.DTD:
Examp ColumnHHH 360 345 361 346 362 347 363 348 364 349 365 350 Column III 9ó-fluoro- 1113,17ó,21 -trihydroxy- 16/3-methyl-5- pregnane-3,20-dione 17-acetate 21-sodium hemisuccinate 50 9-fluoro-11/3, 17c,21 -trihydroxy16/3-methyl-5ó- pregnane-3,20-dione 17-butyrate 21-sodium hemisuccinate 9-fluoro-11/3,17, 21 -trihydroxy- 16/3-methyl-5- pregnane-3,20-dione 17-valerate 21-sodium hemisuccinate 9o-fluoro- 11/3,17ó,21-trihydroxy16/3-methyl-5c- 55 pregnane-3,20-dione 17-benzoate 21-sodium hemisuccinate 9cz-fluoro- 11/3,17z,21 -trihydoxy- 16ó-methyl-5ó- pregnane-3,20-dione 17-acetate 21-sodium hemisuccinate 9o-fluoro- 11/3,17c,21 -trihydroxy16e-methyl-5ó- pregnane-3,20-dione 17-propionate 21-sodium hemisuccinate 60 32 GB 2 070 016 A 32 Example Column HHH 366 361 367 352 368 353 369 354 370 355 371 356 372 357 373 358 Column III 9oc-fluoro11/3,17,21-trihydroxy- 16o-methyl-5- pregnane-3,20-dione 17-butyrate 21-sodium hemisuccinate 9-fluoro-11/3,17ó, 21-trihydroxy- 16oc-methyl-5pregnane-3,20-dione 17-valerate 21-sodium hemisuccinate 9oc-fluoro- 11/3, 17,21 -trihydroxy- 16-methyl-5- pregnane-3,20-dione 17-benzoate 21-sodium hemisuccinate 9-fluoro-11/,17, 21-trihydroxy-5-pregnane- 3,20-dione 17-acetate 21-hemisuccinate 9-fluoro- 11/3,17,21 -trihydroxy-5-pregnane 3,20-dione 17-propionate 21-sodium hemisuccinate 9oc-fluoro-I 1/3,17,21 trihydroxy-5-pregnane- 3,20-dione 17-butyrate 21-sodium hemisuccinate 9-fluoro-11/3,17,21 - trihydroxy-5-pregnane- 3,20-dione 17-valerate 21-sodium hemisuccinate 9-fluoro- 11/3,17,21 - trihydroxy-5-pregnane3,20-dione 17-benzoate 21-sodium hemisuccinate Examples 384 and 385 Following the general procedure of Example 383 and making non-critical variations but starting with the 17-propionate 21-acetate or 17-butyrate 21-acetate diesters of 9- bromo-11/3,17,21trihydroxy-16/-methyl-5-pregnane-3,20-dione (Examples 290 and 292, Step 2),the corresponding 40 9-unsubstituted diesters, namely the 17-propionate 21-acetate or 17- butyrate 21-acetate diesters of 11/3,17,21 -trihydroxy-16/3-methyl-5-pregnane-3,20-dione are obtained.
.DTD:
Examples 386--391 Following the general procedure of Example 383 and making non-critical variations but starting with the 17-pmpionate 21-acetate, 17,21-dipropionate or 17-butyrate 21- acetate diesters of 9ó45 bromo- 11/3,17eó,21-trihydroxy-16oc-methyl-6oc-pregnane-3,20-dione and 9oc-bromo- 11/},17ó,21- trihydroxy-5oc-pregnane-3,20-dione (Examples 293--298, Step 1) the corresponding 9-unsubstituted diesters, namely the 17-propionate 21 -acetate, 17,21-dipropionate or 17- butyrate 21 -acetate diesters of 11/3,17,21-trihydroxy- 16-methyl-5-pregnane-3,20-dione and 11/3,17ó,21- trihydroxy-5z- pregnane-3.20-dione are obtained. 50 KKK are obtained.
.DTD:
Example Column JJJ 392 266 393 267 Examples 392---406 Following the general procedure of Example 206, Step 3 and making non- critical variations but starting with the 21-mesylate of Examples 266-- 280 (Column J J J) the 21 -chloro steroids of Column Column KKK 21 -chloro11/3,17ó-dihydroxy- 16/3-methyl-5ópregnane-3,20-dione 17- propionate 21-chloro-11/3,17z-dihydroxy-16/3-methyl-5ó- pregnane-3,20-dione 17-acetate Example 383 .DTD:
11/3,17,21-trihydroxy-16/3-methyl-5oc-pregna ne-3,20-dione 17,21 dipropionate (IV) A solution of 9-bromo-11/3,17c,21-trihydroxy-16/3-methyl-5c-pregnane-3,20- dione 17,21dipropionate (Example 291, Step 1, 15.6 g) in DMF (90 ml) containing mercaptoacetic acid (12 ml) is 30 stirred at 20--25 during the addition of aqueous chromous sulfate (35 ml). The chromous sulfate is - prepared from chromic sulfate hydrate (26.9 g) and zinc (70 g, 30 mesh), stirred in water (66 ml) for 16 hours under nitrogen. The steroid reaction mixture is stirred for several hours and then is diluted with water (400 ml) and filtered. The crude product is dried and chromatographed on silica gel (670 g), eluting with an acetone-methylene chloride mixture. The appropriate fractions are pooled and 35 concentrated under reduced pressure to give the title compound.
.DTD:
Examples 374--382 Following the general procedure of Example 251, Step 2, and making non- critical variations but starting with the 17-propionate 21-acetate, 17,21-dipropionate, or 17- butyrate 21-acetate diesters of 20 17ó,21-dihydroxy-16/3-methyl-5-pregn- 9(11)ene-3,20-dione, 17,21-dihydroxy- 16ó-methyl-5ópregn-9(11)ene-3,20- dione and 17,21 -dihydroxy-5o-pregn-9(11)ene-3,20-dione (Examples 281- 289), the corresponding 9,11-dichloro diesters, namely the 17-propionate 21-acetate, 17,21dipropionate or 17-butyrate 21-acetate diesters of 9ó, 11/3-dichloro-17ó,21-dihydroxy- 16/3-methyl- 5-pregnane-3,20-dione, 9ó,11/3-dichloro-17ó,21-dihydroxy-16-methyl-5ó- pregnane-3,20-dione 25 and 9z,11/3-dichloro-17ó,21-dihydroxy-5ó-pregnane-3,20-dione are obtained.
.DTD:
33 GB 2 070 016 A 33 Examp ColumnJJJ 394 268 395 269 396 270 397 271 398 272 399 273 400 274 401 275 402 276 403 277 404 278 405 279 406 280 Column KKK 21 -chloro- 11/3,17 -dihydroxy- 16/3-methyl-5epregnane-3,20-dione 17butyrate 21 -chloro- 11/3,17-dihydroxy- 16/3-methyl-5 pregnane-3,20-dione 17- valerate 21-chloro- 11/3,17-dihydroxy- 16/3-methyl-5pregnane-3,20-dione 17-benzoate 21 -chloro- 11/3,17-dihydroxy16-methyl-5pregnane-3,20-dione 17-acetate 21 -chloro- 11/3,17 -dihydroxy16-methyl-5pregnane-3,20-dione 17- propionate 21 -chloro-11/3,17 -dihydroxy- 16-methyl-5pregnane-3,20-dione 17-butyrate 21-chloro-11/3,17a-dih fdroxy- 16ó-methyl-5ó- pregnane-3,20-dione 17-valerate 21 -chloro- 11/3,17 a-dih' id roxy- 16 c-m ethyl-5 pregnane-3,20-dione 17- benzoate 21 -chloro- 11/3,17 -dih' rd roxy-5c-pregna ne3,20-dione 17-acetate 21 -chloro- 11/3,17o-dih, rdroxy-5ó-pregnane3,20-dione 17-propionate 21 -chloro- 11/3,17 <z-dih pdroxy-5-pregnane3,20-dione 17-butyrate 21 -chloro- 11/3,17ó-dih, rdroxy-5 -p regnane3,20-dione 17-valerate 21 -chloro- 11/3,17z-dih, rdroxy-5-pregnane-3,20-dione 17-benzoate Example 407 .DTD:
21 -chloro-6,9-difluoro-11/3,17-dihydroxy-16/3-methyl-5/3-pregnane-3,20dione 17- 30.propionate (I) 30 Step 1 6ó,9ó-difluoro-1!/3,17,21-trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione A solution of 6ó,9-difluoro-11/3,17ó,21 -trihydroxy-16/3-methyl-5/3pregnane-3,20-dione 17,21-diacetate (I, Example 81, 14.2 g) in methanol (530 m I) is boiled to remove oxygen, cooled to 25 under nitrogen and then mixed with potassium carbonate (10%, 76 ml) previously purged with 35 nitrogen. The mixture is stirred at 20--25 for 1 hr, then neutralized with acetic acid (4.8 ml), diluted with water and concentrated under reduced pressure. The product is collected and dried to give 6,9ódifluoro-11/3,17ó,21 -trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione, NMR (CDCI) 1.08, 1.25, 1.30, 4.3---4.5 and 5.0 3.
.DTD:
Step 2 40 6,9-difluoro-11/3,17,21-trihydroxy-16/3-methyl-5-pregnane-3,20-dione 17propionate 6,9ó-difluoro-11/3,17ó,21 -trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione (Step 1, 10.2 g) is converted by the orthoester procedure of Example 2 to the corresponding 17-propionate, TLC Rf=0.46 (10% acetone-methylene chloride).
.DTD:
Step 3 45 6ó,9-difluoro-11/3,17ó,21-trihydroxy-16/3-methyl-5/3-pregnane-3,20-dione 17-propionate 21 - mesylate Following the general procedure of Example 28 and making non-critical variations but starting with the 21-hydroxy steroid of Step 2, 6o,9ó-difluoro- 11/3,17oL,21 trihydroxy-16/3-methyl-5/3- pregnane-3,20-dione 17-propionate 21-mesylate is obtained.
.DTD:
Step 4 21 -chloro-6ó,9ó-difluoro-11/3,17 o-dihydroxy16/3-methyl-5/3-pregnane-3, 20-dione 17- propionate Following the general procedure of Example 33 and making non-critical 'variations but starting with the 21-mesylate of Step 3 the title compound is obtained, m.p. 212. 8 ; NMR (CDCI) 0.95, 1.18, 55 1.30, 1.39, 4.45 and 5.0 8.
.DTD:
Example 408 .DTD:
* 6,9-difluoro- 11/3,17ó,21 -trihydroxy-16/3-methyl-5/3-preg nane-3,20dione 17,21 -dipropionata (I) Following the general procedure of Preparation 9 and Example 281, but starting with 6,9difluoro-11/3,17o,21-trihydroxy-16/3-methyl-5/3-pregnane- 3,20-dione 17-propionate (I, Example 407, 34 GB 2 070 016 A 34 Step 2, 3.67 g) a crude product is obtained. The product is chromatographed on silica gel (400 g) packed in acetone-methylene chloride (5/95). Elution is performed with acetone-methylene chloride (5/95, 5 I) followed by (10/90, 1 I) collecting 200 ml fractions. The appropriate fractions are pooled and concentrated. Crystallization from acetone-hexane gives the title compound, m.p. 209.5--210 ; NMR (CDCI)0.93, 1.16, 1.19, 1.30, 1.35, 4.45, 4.28 and 4.81 &.
.DTD:
CHART A "" R21 R - II 11<. A I 0--C--R17 R6 GB 2 070 016 A 35 CHART B 0 R21 A I.,,"-0C0-RI"7 R2 " H =,,7 (II) R6 36 GB 2 070 016 A 36 CHART C H2 0R21 I.., -O-o--CO--RIv,F/ y "-R16cL R2. II I I -RI, R6 37 GB 2 070 016 A 37 (IVA) (IVB) (IVC) (IVD) 38 GB 2 070 016 A 38 CHART D-2 IVD) -I Jo-OCO--R17 u - _,,7 (IVE) H = R6 .DTD:
Claims (1)
- Claims .CLME:1. A compound of the formula I I I - R,, R=_ %0 '(1) H - R6 wherein R2, R6 and Rle= are independently selected from hydrogen, fluorine, chlorine and methyl; R7 and R9 are independently selected from hydrogen, fluorine and chlorine; R. is/3-Cl,/3-OH or oxo; R18 is hydrogen or methyl; R17 is C_6 alkyl, phenyl, p-tolyl, p-carboxyphenyl or p-carboalkoxyphenyl; R=I is hydrogen, fluorine, chlorine, bromine, OH, OPO(OH)=, OSO=CH3 or 0COR21b in which R21b is C1_8 alkyl, phenyl, p-tolyl, p-carboxyphenyl, pcarboalkoxyphenyl or CH2CH2COOH; and -, indicates either (z or configuration; 39 GB 2 070 016 A 39 provided that at least one of R16, and R16 is hydrogen; or a pharmaceutically acceptable salt of any acid form thereof..CLME:2. A compound according to Claim 1 wherein R2 is hydrogen or methyl..CLME:3. A compound according to Claim 2 wherein R2 is hydrogen..CLME:4. A compound according to any preceding claim wherein R8 is hydrogen, fluorine or methyl. 5 5. A compound according to Claim 4 wherein R8 is hydrogen..CLME:6. A compound according to any preceding claim wherein R is hydrogen or chlorine..CLME:7. A compound according to Claim 6 wherein R7 is hydrogen..CLME:8. A compound according to any preceding claim wherein R9 is fluorine or chlorine..CLME:9. A compound according to any preceding claim wherein R is chlorine or hydroxyl. 10 10. A compound according to Claim 9 wherein R is hydroxyl..CLME:11. A compound according to Claim 10 wherein R9 is fluorine..CLME:12. A compound according to any of Claims 1 to 7 wherein R9 and RI are each chlorine..CLME:13. A compound according to any preceding claim wherein R16 is hydrogen..CLME:14. A compound according to any of Claims 1 to 12 wherein R6= is methylò15 15. A compound according to Claim 13 wherein R18 is methyl..CLME:16. A compound accordng to any preceding claim wherein R17 is C1_4 alkyl, phenyl or p-tolyl..CLME:17. A compound according to Claim 17 wherein R is C1_4 alkyl or phenyl..CLME:18. A compound according to any preceding claim wherein R21 is not bromine..CLME:19. A compound according to Claim 18 wherein R21 is hydrogen, chlorine or OCOR21b wherein 20 R2b is as defined in Claim 1..CLME:20. A compound according to Claim 18 wherein R2 is hydrogen, fluorine, chlorine, OPO(OH)2 or OCOCH2CH2COOH..CLME:21. A compound according to any preceding claim which is a 5/]-pregnane derivative..CLME:22. A compound according to Claim 1 which is 9ó-fluoro-11/],17o,21trihydroxy-5/]-pregnane- 25 3,20-dione 17-propionate..CLME:23. A compound according to Claim 1 which is 9o-fluoro-11/],17,21trihydroxy-5/]-pregnane- 3,20-dione 17-acetate..CLME:24. A compound according to Claim 1 which is 9ó-fluoro-11/3,17ó,21trihydroxy-5/3-pregnane- 3,20-dione 17-butyrate. 30 25. A compound according to Claim 1 which is 9ó-fluoro-11/3,17cz,21trihydroxy-5/]-pregnane- 3,20-dione 17-valerate..CLME:26. A compound according to Claim 1 which is 9a-fluoro-11/3,17a,21 trihydroxy-5/3-pregnane- 3,20-dione 17-benzoate..CLME:27. A compound according to Claim 1 which is 9a-fluoro-11/3,17z,21trihydroxy-5/3-pregnane- 35 3,20-dione 17-propionate 21 -mesylate..CLME:28. A compound according to Claim 1 which is 9a-fluoro-11/3,17.z,21trihydroxy-5/]-pregnane- 3,20-dione 17-acetate 21 -mesylate..CLME:29. A compound according to Claim 1 which is 9z-fluoro-11/3,17ó,21trihydroxy-5/3-pregnane- 3,20-dione 17-butyrate 21-mesylate. 40 30. A compound according to Claim 1 which is 9ó-fluoro-11/3,17oL,21trihydroxy-5/]-pregnane- 3,20-dione 17-valerate 21 -mesylate..CLME:31. A compound according to Claim 1 which is 9ó-fluoro-11/],17c,21trihydroxy-5/]-pregnane- 3,20-dione 17-benzoate 21 -mesylate..CLME:32. A compound according to Claim 1 which is 21-chloro-9ó-fluoro-11/],17ódihydroxy-5/]- 45 pregnane-3,20-dione 17-propionate..CLME:33. A compound according to Claim 1 which is 21 -chloro-9ó-fluoro-11/], 17o-dihydroxy-5/]- pregnane-3,20-dione 17-acetate..CLME:34. A compound according to Claim 1 which is 21-chloro-9c-fluoro-11/],17dihydroxy-5/]- pregnane-3,20-dione 17-butyrate. 50 35. A compound according to Claim 1 which is 21-chloro-9ó-fluoro-11/],17o- dihydroxy-5/pregnane-3,20-dione 17-valerate..CLME:36. A compound according to Claim 1 which is 21-chloro-9ó-fluoro-11/],17ódihydroxy-5/3- pregnane-3,20-dione 17-benzoate..CLME:37. A compound according to Claim 1 which is 21-chloro-9ó-fluoro-17ahydroxy-5/]-pregnane- 55 3,11,20-trione 17-propionate..CLME:38. A compound according to Claim 1 which is 21 -chloro-9ó-fluoro-17czhydroxy-5/3-pregnane- 3,11,20-trione 17-acetate..CLME:39. A compound according to Claim 1 which is 21 -chloro-9c-fluoro-17óhydroxy-5/]-pregnane- 3,11,20-trione 17-butyrate. 60 40. A compound according to Claim 1 which is 21-chloro-9z-fluoro-17hydroxy-5/3-pregnane- 3,11,20-trione 17-valerate..CLME:41. A compound according to Claim 1 which is 21-chloro-9ó-fluoro-I 7chydroxy-5/-pregnane- 3,11,20-trione 17-benzoate..CLME:GB 2 070 016 A 40 42. A compound according to Claim 1 which is 9ó-fluoro-11/3,17ó,21- trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-acetate..CLME:43. A compound according to Claim 1 which is 9ó-fluoro-11/3,17ó,21trihydroxy-16/3-methyl- 5]3-pregnane-3,20-dione 17-propionate..CLME:44. A compound according to Ciaim 1 which is 9ó-fluoro-11/3,17ó,21 trihydroxy-16/3-methyl- 5 5/3-pregnane-3,20-dione 17-butyrate..CLME:45. A compaund according to Claim 1 which is 9ó-fluoro-11/3,17o,21trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-valerate..CLME:46. A compound according to Claim 1 which is 9-fluoro-11/3,17ó,21trihydroxy-16/3-methyl- 5/3-pregnene-3,20-dione 17-benzoate. 10 47./k compound according to Claim 1 which is 9ó-fluoro-11/3,17ó,21trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-acetate 21-mesylate..CLME:48. A compound according to Claim 1 which is 9-fluoro-11/3,17ó,21 trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-propionate 21 -mesylate. " 49. A compound according to Claim 1 which is 9-fluoro-11/3,17ó,21- trihydroxy-16/3-methyl- 15 5/3-pregnane-3,20-dion 17-butyrate 21 -mesylate..CLME:50. A compound according to Claim 1 which is 9-fluoro-11/3,17,21 trihydroxy-16/3-methyF " 5/-prejcnane-3,20-dione 17-valerate 21-mesylate..CLME:51. A compound according to Claim 1 which is 9oc-fluoro- 11/3,17ó,21trihydroxy-16/3-methyl- 5/3-pragnane-3,20-dione 17-benzoate 21-mesylate. 20 52. A compound according to Claim 1 which is 21-chloro-9-fluoro-11/3,17ó- dihydroxy-16/3methyI-5/3-pregnane-3,20-dione 17-acetate..CLME:53. A compound according to Claim 1 which is 21-chloro-9ó-fluoro-11/3,17dihydroxy-16/3- methyl-5]3-pregnane-3,20-dione 17-butyrate..CLME:54. A compound according to Claim 1 which is 21 -chloro-9z-fluoro-11/3,17dihydroxy-16/3- 25 methyl-5/3-pregnane-3,20-dione 17-valerate..CLME:55. A compound according to Claim 1 which is 21-chloro-9ó-fluoro-11/3,17ódihydroxy-16/3- pregnane-3,20-dione 17-benzoate..CLME:56. A compound according to Claim 1 which is 9,11/3-dichloro-17o,21 dihydroxy-16/3-methyl- 5/}-pregnane-3,20-dione 17,21-dipropionate. 30 57. A compound according to Claim 1 which is 9ó,11/3-dichloro-17ó,21dihydroxy-16ó-methyl- 5/3-pregnane-3,20-dione 17,21 -dipropionate..CLME:58. A compound according to Claim 1 which is 9,11/3-dichloro-17ó,21dihydroxy-5/3- pregnane-3,20-dione 17,21-dipropionate..CLME:59. A compound according to Claim 1 which is 9,1113,21 -trichloro-17hydroxy-16/3-methyl- 35 5/3-pregnane-3,20-dione 17-propionate..CLME:60. A compound according to Claim 1 which is 9ó,11/3,21-trichloro-17óhydroxy-16ó-methyl- 5/}-pregnane-3,20-dione 17-propionate..CLME:61. A compound according to Claim 1 which is 9ó,11/3,21-trichloro-17óhydroxy-5/3-pregnane- 3,20-dione 17-propionate. 40 62. A compound according to Claim t which is 21-chloro-9ó-fluoro-11/3,17odihydroxy-16/3- methyl-5/3-pregnane-3,20-dione 17-propionate..CLME:63. A compound according to Claim 1 which is 9,21-difluoro-11/3,17ocdihydroxy-16/3-methyl-..CLME:5/3-pregnane-3,20-dione 17-acetate..CLME:64. A compound according to Claim 1 which is 9,21-difluoro-11/3,17dihydroxy-16/3-methyl- 45 5-pregnane-3,20-dione 17-propionate..CLME:65. A compound according to Claim 1 which is 9,21-difluoro-11/3,17dihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-butyrate..CLME:66. A compound according to Claim 1 which is 9,21-difluoro-11/3,17dihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-isobutyrate. 50 67. A compound according to Claim 1 which is 9ó,21 -difluoro- 11/3,17 odihydroxy- 16/3-methyl- 5/3-pregnane-3,20-dione 17-valerate..CLME:68. A compound according to Claim 1 which is 21-chloro-9ó-fluoro-11/3,17dihydroxy-16/3- methyl-5/3-pregnane-3,20-dione 17-isobutyrate..CLME:69. A compound according to Claim 1 which is 21-chloro-9-fluoro-17hydroxy-16/3-methyl- 55 5/3-pregnane-3,11,20-trione 17-propionate..CLME:70. A compound according to Claim 1 which is 21-chloro-9ó-fluoro-17hydroxy-16/3-methyl- 5/3-pregnane-3,11,20-trione 17-butyrate..CLME:71. A compound according to Claim 1 which is 9-fluoro-11/3,17ó-dihydoxy16/3-methyl-5/3- pregnane-3,20-dione 17-propionate. 60 72. A compound according to Claim 1 which is 9o-fluoro-11/3,17-dihydroxy16/3-methyl-5/3- pregnane-3,20-dione 17oacetate..CLME:73. A compound according to Claim 1 which is 9ó-fluoro-11/3,17ó-dihydroxy16/3-methyl-5/3- pregnane-3,20-dione 17-butyrate..CLME:41 GB 2 070 016 A 41 74. A compound according to Claim 1 which is 9-fluoro-11/],17a-dihydroxy- 16/]-methyl-5/]- pregnane-3,20-dione 17-isobutyrate..CLME:75. A compound according to Claim 1 which is 9-fluoro-11/],17a-dihydroxy16/]-methyl-5/]- pregnane-3,20-dione 17-valerate..CLME:76. A compound according to Claim 1 which is 9-fluoro-1113,17a-dihydroxy16/]-methyl-5/]- 5 pregnane-3,20-dione 17-benzoate..CLME:77. A compound according to Claim 1 which is 9c-fluoro-11/],17a,21trihydroxy-16/]-methyl- 5/]-pregnane-3,20-dione 17,21 -dipropionate..CLME:78. A compound according to Claim 1 which is 21-bromo-9z-fluoro-11/],17ódihydroxy-16/]- methyl-5/]-pregnane-3,20-dione 17-propionate. 10 79. A compound according to Claim 1 which is 21-chloro-9-fluoro-11/],17dihydroxy-6ó- methyl-5/]-pregnane-3,20-dione 17-valerate..CLME:80. A compound according to Claim 1 which is 9c-fluoro-11/3,17ó-dihydroxy6o-methyl-5/]- pregnane-3,20-dione 17-acetate..CLME:81. A compound according to Claim 1 which is 21-chloro-9-fluoro-17hydroxy-6o-methyl-5/]- 15 pregnane-3,11,20-trione 17-valerate..CLME:82. A compound according to Claim 1 which methyl-5/]-pregnane-3,20-dione 17,21-diacetate..CLME:83. A compound according to Claim 1 which pregnane-3,20-dione 17-butyrate 21-acetate. 20 84. A compound according to Claim 1 which pregnane-3,20-dione 17-butyrate 21-propionate..CLME:85. A compound according to Claim 1 which pregnane-3,20-dione 17,21 -dibutyrate..CLME:86. A compound according to Claim I which 25 5/]-pregnane-3,11,20-trione 17,21 -diacetate..CLME:87. A compound according to Claim 1 which 3,11,20-trione 17-butyrate 21-acetate..CLME:88. A compound according to Claim 1 which "30 3,11,20-trione 17-butyrate 21-propionate. 30 89. A compound according to Claim 1 which 3,11,20-trione 17,21 -dibutyrate..CLME:90. A compound according to Claim 1 which 5/]-pregnane-3,20-dione 17-benzoate..CLME:91. A compound according to Claim 1 which 35 5/]-pregnane-3,20-dione 17-acetate..CLME:92. A compound according to Claim 1 which 5/]-pregnane-3,20-dione 17-propionate..CLME:93. A compound according to Claim 1 which 5/]-pregnane 1,20-dione 17-butyrate. 40 94. A compound according to Claim 1 which 5/]-pregnane-3,20-dione 17-valerate..CLME:95. A compound according to Claim 1 which is 9a-fluoro-11/],17ó,21trihydroxy-16ó-methyl- 5/]-pregnane-3,20-dione 17-benzoate..CLME:96. A compound according to Claim 1 which is 9-fluoro-11./],17,21trihydroxy-16-methyl- 45 5/]-pregnane-3,20-dione 17-propionate 21 -mesylate..CLME:97. A compound according to Claim 1 which is 21-bromo-9-fluoro-11/3,17ódihydroxy-16(z- methyl-5/]-pregnane-3,20-dione 17-propionate..CLME:98. A compound according to Claim 1 which is 9ó-fluoro-11/],17-dihydroxy16-methyl-5/]- pregnane-3,20-dione 17-propionate. 50 99. A compound according to Claim 1 which is 21-chloro-9- fluoro-1!/3,17ó- dihydroxy-16methyl-5/3-pregnane-3,20-dione 17-propionate..CLME:100. A compound according to Claim 1 which is 21-chloro-9ó-fluoro-11/], 17ol-dihydroxy-16ol- methyl-5/]-pregnane-3,20-dione 17-acetate..CLME:101. A compound according to Claim 1 which is 21 -chloro-9-fluoro-11/], 17ó-dihydroxy-16(z- 55 methyl-5/]-pregnane-3,20-dione 17-butyrate..CLME:102, A compound according to Claim 1 which is 21-chloro-9ó-fluoro-11/], 17e-dihydroxy-16z- methyl-5/]-pregnane-3,20-dione 17-valerate..CLME:103. A compound according to Claim 1 which is 21-chloro-9ó-fluoro-11/], 17ó-dihydroxy-16ó- methyl-5/]-pregnane-3,20-dione 17-benzoate. 60 104. A compound according to Claim 1 which is 9-fluoro-11/],17ó,21trihydroxy-16-methyl- 5/]-pregnane-3,20-dione 17,21 -dipropionate..CLME:105. A compound according to Claim 1 which is 9c-fluoro-11/],17o,21trihydroxy-5/]-pregnane- 3,20-dione 17,21-dipropionate..CLME:is 6ó,9-difluoro-1113, 17ó,21 -trihydroxy-16/3- is 6ó,9o-difluoro- 1113, 17ó,21 -trihydroxy-5- is 6z,9z-difluoro-11/3,17z,21-trihydroxy-5/]- is 6,9ó-difluoro-11/],17,2 l-trihydroxy-5/]- is 6(z,9-.difiuoro-17ó,21-dihydroxy-16/]-methylis 6,9o-difluoro- 17,21 dihydroxy-5/]-pregnaneis 6o:,9z-difluoro- 17,21 -dihydroxy-5/]-pregnaneis 6ó,9o-difluoro-17ó,21 -dihydroxy-5/;-pregnaneis 9z-fluoro-11/, 17z,21trihydroxy- 16/-methylis 9ó-fluoro- 11/],17ó,21-trihydroxy-16c-methylis 9ó-fluoro-11/],17z,21-trihydroxy- 16cz-methylis 9ó-fluoro-11/],17,21trihydroxy-16c-methylis 9z- fluoro-11/],17,21 -trihydroxy-16o-methyi- 42 GB 2 070 016 A 42 106. A compound according to Claim 1 which 5/3-pregnane-3,20-dione 17,21-dipropionate..CLME:107. A compound according to Claim 1 which 5/3-pregnane-3,20-dione 17-propionate..CLME:108. A compound according to Claim 1 which pregnane-3,20-dione 17-propionate..CLME:109. A compound according to Claim 1 which pregnane-3,20-dione 17-propionate..CLME:110. A compound according to Claim 1 which pregnane-3,20-dione 17-propionate..CLME:111. A compound according to Claim 1 which pregnane-3,20-dione 17,21-dipropionate..CLME:112. A compound according to Claim 1 which pregnane-3,20-dione 17,21 -dipropionate..CLME:113. A compound according to Claim 1 which 5/3-pregnane-3,20-dione 17,21-dipropionate..CLME:114. A compound according to Claim 1 which 3,20-dione 17-propionate..CLME:115. A compound according to Claim 1 which 3,20-dione 17-butyrate..CLME:is 9<z-chloro- 11/3,17,21-trihydroxy-16/3-methylis 9ó,21-chloro-11/3,17ódihydroxy-16/3-methylis 9 -chloro-21 -fluoro-11/3,17ó-dihyd roxy-5/3is 9, 21 -dichloro- 11/3,17-dihydroxy-5/3is 9-chloro-21-fluoro- 11/3,17dihydroxy-5/3is 11/3,17z,21 -trihydroxy-16-methyl-5/3is 11/3,17oi,21 trihydroxy- 16/3-methyl-5/3is 7 -chloro- 11/3,17,21 -trihydroxy- 16methylis 21 -chloro- 11/3,17ó-dihydroxy-5/3-pregnaneis 21 -chloro- 11/3, 17 -dihydroxy-5/3-pregnane- 116. A compound according to Claim 21 which is 9(-fluoro-11/3,17<z,21- trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-valerate 21 -dihydrogen phosphate..CLME:117. A compound according to Claim 21 which is 9ó-fluoro-11/3,17<z,21trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-benzoate 21-dihydrogen phosphate..CLME:118. A compound according to Claim 21 which is 9oi-fluoro-11/3,17ó,21trihydroxy-16/3-methyl- 25 5/3-pregnane-3,20-dione 17-acetate 21 -dihydrogen phosphate..CLME:119. A compound according to Claim 21 which is 9ó-fluoro-11/3,170,21trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-propionate 21-dihydrogen phosphate..CLME:120. A compound according to Claim 21 which is 9-fiuoro-11/3,17ó,21trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-butyrate 21-dihydrogen phosphate. 30 121. A compound according to Claim 21 which is 9-fluoro-11/3,17<z,21- trihydroxy-16ó- methyl-5/3-pregnane-3,20-dione 17-acetate 21-dihydrogen phosphate..CLME:122. A compound according to Claim 21 which is 9ó-fluoro-11/3,17ó,21trihydroxy-16- methyl-5/3-pregnane-3,20-dione 17-propionate 21-dihydrogen phosphate..CLME:123. A compound according to Claim 21 which is 9-fluoro-11/3,17,21 trihydroxy-16ó- 35 methyl-5/3-pregnane-3,20-dione 17-butyrate 21-dihydrogen phosphate..CLME:124. A compound according to Claim 21 which is 9-fluoro-11/3,17c,21 trihydroxy-16ó- methyl-5J3-pregnane-3,20-dione 17-valerate 21-dihydrogen phosphate..CLME:125. A compound according to Claim 21 which is 9ó-fluoro-11/3,17,21trihydroxy-16- methyl-5/3-pregnane3,20-dione 17-benzoate 21-dihydrogen phosphate. 40 126. A compound according to Claim 21 which is 9cz-fluoro-11/3,17,21- trihydroxy-5/3- pregnane-3,20-dione 17-acetate 21-dihydrogen phosphate..CLME:127. A compound according to Claim 21 which is 9-fluoro-11/3,17c,21 trihydroxy-5/3- pregnane-3,20-dione 17-propionate 21-dihydrogen phosphate..CLME:128. A compound according to Claim 21 which is 9oi-fluoro-11/3,17oe,21trihydroxy-5/3- 45 pregnane-3,20-dione 17-butyrate 21-dihydrogen phosphate..CLME:129. A compound according to Claim 21 which is 9ó-fluoro-11/3,17ó,21trihydroxy-5/3- pregnane-3,20-dione 17-valerate 21 -dihydrogen phosphate..CLME:130. A compound according to Claim 21 which is 9ó-fluoro-11/3,170,21trihydroxy-5/3- pregnane-3,20-dione 17-benzoate 21-dihydrogen phosphate. 50 13 i. A compound according to Claim 21 which is 9ó-fluoro-11/3,17ó,21 trihydroxy-16/3- methyl-5/3-pregnane-3,20-dione 17-propionate 21 -disodium phosphate..CLME:132. A compound according to Claim 21 which is 9-fiuoro-11/3,17,21trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-acetate 21 -disodium phosphate..CLME:133. A compound according to Claim 21 which is 9ó-fluoro-11/3,17,21trihydroxy- 55 16/3-methyl-5/3-pregnane-3,20-dione 17-butyrate 21 -disodium phosphate..CLME:134. A compound according to Claim 21 which is 9cz-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-valerate 21-disodium phosphate..CLME:135. A compound according to Claim 21 which is 9ó-fluoro-11/3,17ó,21trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-benzoate 21-disodium phosphate. 60 136. A compound according to Claim 21 which is 9-fluoro-11/3,170,21 - trihydroxy-16ó- methyl-5/3-pregnane-3,20-dione 17-acetate 21-disodium phosphate..CLME:137. A compound according to Claim 21 which is 9z-fluoro-11/3,17,21trihydroxy-16ol- methyl-5/3-pregnane-3,20-dione 17-propionate 21-disodium phosphate..CLME:= 43 GB 2 070 016 A 43 ill 138. A compound according to Claim 21 which is 9-fluoro-11/3,17ol,21- trihydroxy-16ol- methyl-5/3-pregnane-3,20-dione 17-butyrate 21-disodium phosphate..CLME:139. A compound according to Claim 21 which is 9ó-fluoro-11/3,17,21 trihydroxyl 6ó-methyl- 5/3-pregnane-3,20-dione 17-valerate 21 -disodium phosphate..CLME:140. A compound according to Claim 21 which is 9ó-fluoro-11/3,17ol,21trihydroxy-16o/- 5 methyl-5/3-pregnane-3,20-dione 17-benzoate 21-disodium phosphate..CLME:141. A compound according to Claim 21 which is 9ó-fluoro-11/3,17ol,21trihydroxy-5/3- pregnane-3,20-dione 17-acetate 21-disodium phosphate..CLME:142. A compound according to Claim 21 which is 9-fluoro-11/3,17ó,21trihydroxy-5/3- pregnane-3,20-dione 17-propionate 21-disodium phosphate. 10 143. A compound according to Claim 21 which is 9ó-fluoro-11/3,17c,21trihydroxy-5/3- pregnane-3,20-dione 17-butyrate 21 -disodium phosphate..CLME:144. A compound according to Claim 21 which is 9ó-fluoro-11/3,17,21trihydroxy-5/3- pregnane-3,20-dione 17-valerate 21-disodium phosphate..CLME:145. A compound according to Claim 21 which is 9-fluoro-11/3,17,21 trihydroxy-5/3- 15 pregnane-3,20-dione 17-benzoate 21 -disodium phosphate..CLME:146. A compound according to Claim 21 which is 9ó-fluoro-.11/3,17z,21trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-propionate 21-hemisuccinate..CLME:147. A compound according to Claim 21 which is 9o-fluoro-11/3,17,21 trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-acetate 21-hemisuccinate. 20 148. A compound according to Claim 21 which is 9ol-fluoro-11/3,17ó,21- trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-butyrate 21-hemisuccinate.*.CLME:149. A compound according to Claim 21 which is 9ol-fluoro-11/3,17ó,21trihydroxy- 16/5-methyl- 5/3-pregnane-3,20-dione 17-valerate 21-hemisuccinate..CLME:150. A compound according to Claim 21 which is 9ol-fluoro-11/3,17,21trihydroxy-16/3-methyl- 25 5/-pregnane-3,20-dione 17-benzoate 21 -hemisuccinate..CLME:151. A compound according to Claim 21 which is 9ó-fluoro-11/,17ó,21trihydroxy-16- methyl-5/3-pregnane-3,20-dione 17-acetate 21-hemisuccinate..CLME:152. A compound according to Claim 21 which is 9-fluoro-'l 1/3,17ol,21trihydroxy-16- methyl-5/3-pregnane-3,20-dione 17-propionate 21-hemisuccinate. 30 153. A compound according to Claim 21 which is 9ó-fluoro-11/3,17ó,21- trihydroxy-16- methyl-5/3-pregnane-3,20-dione 17-butyrate 21-hemisuccinate..CLME:154. A compound according to Claim 21 which is a 9-fluoro- 11/3,17,21trihydroxy-16- methyl-5/3-pregnane-3,20-dione 17-valerate 21 -hemisuccinate..CLME:155. A compound according to Claim 21 which is 9-fluoro-11/3,17,21trihydroxy-16ó- 35 methyl-5/3-pregnane-3,20-dione 17-benzoate 21-hemisuccinate..CLME:156. A compound according to Claim 21 which is 9z-fluoro-11/3;17,21trihydroxy-5/3- pregnane-3,20-dione 17-acetate 21-hemisuccinate..CLME:157. A compound according to Claim 21 which is 9-fluoro-11/3,17z,21trihydroxy-5/3- pregnane-3,20-dione 17-propionate 21-hemisuccinate. 40 158. A compound according to Claim 21 which is 9-fluoro-11/3,17,21trihydroxy-5/3- pregnane-3,20-dione 17-butyrate 21-hemisuccinate..CLME:159. A compound according to Claim 21 which is 9z-fluoro-11/3,17, 21trihydroxy-5/3- pregnane-3,20-dione 17-valerate 21 -hemisuccinate..CLME:160. A compound according to Claim 21 which is 9-fluoro-11/3,17c,21trihydroxy-5/3- 45 pregnane-3,20-dione 17-benzoate 21-hemisuccinate..CLME:161. A compound according to Claim 21 which is 9ó-fluoro-11/3,17c,21trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-propionate 21-disodiumhemisuccinate..CLME:162. A compound according to Claim 21 which is 9-fluoro-11/3,17c,21trihyoxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-acetate 21-sodium hemisuccinate. 50 163. A compound according to Claim 21 which is 9c-fluoro-11/3,17c,21- trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-butyrate 21-sodium hemisuccinate..CLME:164. A compound according to Claim 21 which is 9ó-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5/3-pregnane-3,20-dione 17-valerate 21 -sodium hemisuccinate..CLME:165. A compound according to Claim 21 which is 9ol-fluoro-11/3,17ó,21trihydroxy-16/3-methyl- 55 5/3-pregnane-3,20-dione 17-benzoate 21 -sodium hemisuccinate..CLME:166. A compound according to Claim 21 which is 9-fluoro-11/3,17,21trihydroxy-16- methyl-5/3-pregnane-3,20-dione 17-acetate 21-sodium hemisuccinate..CLME:167. A compound according to Claim 21 which is 9fluoro-11/3,17,21trihydroxy-16z- methyl-5/3-pregnane-3,20-dione 17-propionate 21-sodium hemisuccinate. 60 168. A compound according to Claim 21 which is 9-fluoro11/3,17ó,21- trihydroxy-16ó- methyl-5/3-pregnane-3,20-dione 17-butyrate 21-sodium hemisuccinate..CLME:169. A compound according to Claim 21 which is 9o-fluoro- 11/3,17,21 trihydroxy- 16ol- methyl-5/3-pregnane-3,20-dione 17-valerate 21 -sodium hemisuccinate..CLME:44 GB 2 070 016 A 44 170. A compound according to Claim 21 which is 9c-fluoro-11/3,17,21- trihydroxy-16methyl-5#-pregnane-3,20-dione 17-benzoate 21-sodium hemisuccinate..CLME:171. A compound according to Claim 21 which is 9oc-fluoro-11/3,17,21 trihydroxy-5/3pregnane-3,20-dione 17-ecetate 21-sodium hemisuccinate..CLME:172. A compound according to Claim 21 which is 9-fluoro-11/3,17oc,21trihydroxy-5#pregnane-3,20-dione 17-propionate 21-sodium hemisuccinate..CLME:173. A compound according to Claim 21 which is 9-fluoro-11/3,17,21 trihydroxy-5/3pregnane-3,20-dione 17-butyrate 21-sodium hemisuccinate..CLME:174. A compound according to Claim 21 which is 9-fluoro-11/3,17,21 trihydroxy-5/3pregnane-3,20-dione 17-valerate 21-sodium hemisuccinate..CLME:175.A compound according to Claim 21 which is 9(z-fluoro-11/3,17,21trihydroxy-5/3pregnane-3,20-dione 17-benzoate 21-sodium hemisuccinate..CLME:178. A compound according to any of Claims 1 to 20 which is a 5(zpregnane derivative..CLME:177. A compound according to Claim 1 which is 21-chloro-9e(-fluoro-11/3, 17-dihydroxy-16/3methyl-5c-pregnane-3,20-dione 17-propionate..CLME:178. A compound according to Claim 1 which is 21-chloro-9(z-fluoro-11/}, 17o-dihydroxy-16/3methyl-Sc-pregnane-3,20-dione 17-acetate..CLME:17. A compound according to Claim 1 which is 21-chloro-9-fluoro-11/3,17e(dihydroxy-16/3methyl-5(z-pregnane-3,20-dione 17-butyrate..CLME:t 80. A compound according to Claim 1 which is 21-chloro-9-fluoro-11/3, 17a(-dihydroxy-16/3methyl-5oc-pregnane-3,20-dione 17-valerate..CLME:181. A compound according to Claim 1 which is 21-chloro-9-fluoro-11/3, 17oc-dihydroxy-16/3methyl-5oc-pregnane-3,20-dione 17-benzoate..CLME:182. A compound according to Claim 1 which is 21-chloro-9-fluoro-11#, 17dihydroxy-16methyl-5o-pregnane-3,20-dione 17-acetate..CLME:183. A compound according to Claim 1 which is 21- chloro-9o-fluoro-11/3, 17-dihydroxy-16methyl-5-pregnane-3,20-dione 17-propionate..CLME:184. A compound according to Claim 1 which is 21-chloro-9-fluoro-11/3,17dihydroxy-16methyi-5-pregnane-3,20-dione 17-butyrate..CLME:185. A compound according to Claim 1 which is 21 -chloro-9-fluoro-11/3, 17o-dihydroxy-16methyl-5z-pregnane-3,20-dione 17-valerate..CLME:186. A compound according to Claim 1 which is 21-chloro-9(z-fluoro-11/3, 17o-dihydroxy-16ocmethyl-5(-pregnane-3,20-dione 17-benzoate..CLME:187. A compound according to Claim 1 which is 21-chloro-9-fluoro-11/3,17dihydoxy-5ocpregnane-3,20-dione 17-acetate..CLME:188. A compound according to Claim 1 which is 21-chloro-9a-fluoro-11 S, 17a-dihydroxy-5(pregnane-3,20-dione 17-propionate..CLME:189. A compound according to Claim 1 which is 21-chloro-9oc-fluoro-11 S, 17-dihydroxy-5(zpregnane-3,20-dione 17-butyrate..CLME:190. A compound according to Claim 1 which is 21-chloro-9-fluoro-11/3, 17oc-dihydroxy-5ocpregnane-3,20-dione 17-valerate..CLME:191. A compound according to Claim 1 which is 21-chloro-9-fluoro-11/3,17dihydroxy-5pregnane-3,20-dione 17-benzoate..CLME:1 2. A compound according to Claim 1 which is 9-fluoro-11/3,17z-dihydoxy16/3-methyl-5pregnane-3,20-dione 17-propionate..CLME: 193. A compound according to Claim 1 which is 9z-fluoro-11/3,17-dihydroxy-16/3-methyl-5(zpregnane-3,20-dione 17-acetate..CLME:194. A compound according to Claim 1 which is 9(-fluoro-11/3,17(zdihydroxy-16/3-methyl-5ocpregnane-3,20-dione 17-butyrate..CLME:195. A compound according to Claim 1 which is 9-fluoro-11/3,17-dihydroxy16#-methyl-5pregnane-3,20-dione 17-valerate..CLME:198. A compound according to Claim 1 which is 9-fluoro-11/3,17-dihydroxy16/-methyl-5ocpregnane-3,20-dione! 7-benzoate..CLME:197. A compound according to Claim 1 which is 9-fluoro-11/3,17-dihydroxy16-methyl-5pregna ne-3,20-dione 17-acetate..CLME:198. A compound according to Claim 1 which is 9-fluoro-11/3,17-dihydroxy16oc-methyl-5pregnane-3,20-dione 17-propionate..CLME:199. A compound according to Claim! which is 9oc-fluoro-11/3,17-dihydroxy16-methyl-5pregnane-3,20-dione 17-butyrate..CLME:200. A compound according to Claim 1 which is 9-fluoro-11/3,17(zdihydroxy-16-methyl-5ocpregnane-3,20-dione 17-valerate..CLME:201. A compound according to Claim 1 which is 9(-fluoro-11/3,17-dihydroxy16oc-methyl-5apregnane-3,20-dione 17-benzoate..CLME:= GB 2 070 016 A 45 202. A corn ound according to Claim 3,20-dione! 7-acetate..CLME:203. A compound according to Claim 3,20-dione 17-propionate..CLME:204. A compound according to Claim 3,20-dione 17-butyrate..CLME:205. A compound according to Claim 3,20-dione 17-valerate..CLME:206. A compound according to Claim 3,20-dione 17-benzoate..CLME:1 which is 9o-fluoro-11/3,17o-dihydroxy-5-pregnane1 which is 9-fluoro11/3,17-dihydroxy-5-pregnane1 which is 9c-fluoro-11/3,17ol-dihydroxy-5opregnane1 which is 9o-fluoro-11/3,17-dihydroxy-5-pregnane1 which is 9cfluoro-11/3},17-dihydroxy-5-pregnane- 207. A compound according to Claim 1 which is 21-chloro-9(-fluoro-17ahydroxy-16/3-methyl5-pregnane-3,11,20-trione 17-propionate..CLME:208. A compound according to Claim 1 which is 21-chloro-9-fluoro-17(hydroxy-16/3-methyl5c-pregnane-3,11,20-trione 17-acetate..CLME:209. A com3ound according to Claim 1 which is 21-.chloro-9-fluoro-17ehydroxy-16/3-methyl- 15 5-pregnane-3,11,20-trione 17-butyrate..CLME:210. A compound according to Claim 1 which is 21-chloro-9-fluoro-17ohydroxy-16/3methyl-5-pregnane-3,11,20-trione 17-valerate..CLME:211. A compound according to Claim 1 which is 21-chloro-9oL-fluoro-17ahydroxy-16/}-methyl- 5-pregnane-3,11,20-trione 17-benzoate. 20 212. A compound according to Claim 1 which is 21 -chloro- 9-fluoro-17hydroxy-16-methyl- 5o-pregnane-3,11,20-trione 17-acetate..CLME:213. A compound according to Claim 1 which is 21 -chloro-9o-fluoro-17ahydroxy-16-methyl- 5(-pregnane-3,11,20-trione 17-propionate..CLME:214. A compound according to Claim 1 which is 21-chloro-9o-fluoro-17ahydroxy-16o-methyl- 25 5-pregnane-3,11,20-trione 17-butrate..CLME:215. A compound according to Claim 1 which is 21-chloro-9-fluoro-17e(hydroxy-16-methyl5o-pregnane-3,11,20-trione 17-valerate..CLME:216. A compound according to Claim 1 which is 21-chloro-9-fluoro-17(hydroxy-16-methyl- 5c-pregnane-3,11,20-trione 17-benzoate. 30 217. A compound according to Claim 1 which is 21-chloro-9(-fluoro-17(- hydroxy-5pregnane-3,11,20-trione 17-acetate..CLME:218. A compound according to Claim 1 which is 21 -chloro-9-fluoro-17chydroxy-5c- pregnane-3,11,20-trione 17-propionate..CLME:219. A compound according to Claim 1 which is 21-chloro-9-fluoro-17ohydroxy-5- 35 pregnane-3,11,20-trione 17-butyrate..CLME:220. A compound according to Claim 1 which is 21-chloro-9-fltoro-17ahydroxy-5(- pregnane-3,11,20-trione 17-valerate..CLME:221. A compound according to Claim 1 which is 21-chloro-9a(-fluoro-17hydroxy-5- pregnane-3,11,20-trione 17-benzoate. 40 222. A compound according to Claim 1 which is 9a,11/3,21-trichloro-17- hydoxy-16/3-methyl5-pregnane-3,20-dione 17-propionate..CLME:223. A compound according to Claim 1 which is 9(,11/3,21-trichloro-17ahydroxy-16/-methyl- 5a-pregnane-3,20-dione 17-acetate..CLME:224. A compound according to Claim 1 which is 9,11/3,21-trichloro-17hydroxy-16/3-methyl- 45 5o-pregnane-3,20-dione 17-butyrate..CLME:225. A compound according to Claim 1 which is 9,11/3,21-trichloro-17hydroxy-16/-methyl- 5-pregnane-3,20-dione 17-valerate..CLME:226. A compound according to Claim 1 which is 9, 11/},21 -trichloro-17hydroxy-16/-methyl- 5(-pregnane-3,20-dione 17-benzoate. 50 227. A compound according to Claim 1 which is 9e(,11/3,21-trichloro-17chydroxy-16-methyl- 5o-pregna-3,20-dione 17-acetate..CLME:228. A compound according to Claim 1 which is 9m 11/3,21-trichloro-17ahydroxy-16o-methyl- 5(-pregna-3,20-dione 17-propionate..CLME:229. A compound according to Claim 1 which is 9o,11/3,21-trichloro-17(hydroxy-16-methyl- 55 5(-pregna-3,20-dione 17-butyrate..CLME:230: A compound according to Claim 1 which is 9,11/3,21-trichloro-17ahydroxy-16-methyl5(-pregna-3,20-dione 17-valerate..CLME:231. A compound according to Claim 1 which is 9,I 1/3,21-trichloro-17ahydroxy-16-methyl- 5c-pregna-3,20-dione 17-benzoate. 60 232. A compound according to Claim 1 which is 9,11/3,21-trichloro-17(- hydroxy-5a-pregna3,20-dione 17-acetate..CLME:233. A compound according to Claim 1 which is 9o,11),21-trichloro-17ahydroxy-5a-pregna- 3,20-dione 17-propionate..CLME:46 GB 2 070 016 A 46 234. A compound according to Claim 1 which is 9oi,11/3,21-trichloro-17ó- hydroxy-5ec-pregna- 3,20-dione 17-butyrate..CLME:235. A compound according to Claim 1 which is 9,11/3,21-trichloro-17hydroxy-5-pregna- 3,20-dione 17-valerate..CLME:236. A compound according to Claim 1 which is 9cz,11/3,21-trichloro-17óhydroxy-5ó-pregna- 5 3,20-dione 17-benzoate..CLME:237. A compound according to Claim 1 which is 11/3,17z,21-trihydroxy-16/3methyl-5- pregnane-3,20-dione 17-propionate..CLME:238. A compound according to Claim 1 which is 11/3,17ol,21-trihydroxy-16/methyl-5(- pregnane-3,20-dione 17-acetate. 10 239. A compound according to Claim 1 which is 11/3,17ó,21-trihydroxy-16/3- methyl-5pregnane-3,20-dione 17-butyrate..CLME:240. A compound according to Claim 1 which is 11/3,17oc,21-trihydroxy16/3-methyl-5ó- pregnane-3,20-dione 17-valerate. 241. A compound according to Claim 1 which is 11/},17,21-trihydroxy-16/3- methyl-5e(pregnane-3,20-dione 17-benzoate..CLME:242. A compound according to Claim 1 which is 11/},17o/,21-trihydroxy-16methyl-5- pregnane-3,20-dione 17-acetate..CLME:243. A compound according to Claim 1 which is 11/3,17,21 -trihydroxy-16methyl-5(- pregnane-3,20-dione 17-propionate. 20 244. A compound according to Claim 1 which is 11/},17,21-trihydroxy-16(z- methyl-5(pregnane-3,20-dione 17-butyrate..CLME:245. A compound according to Claim 1 which is 11/3,17(z,21-trihydroxy16ec-methyl-5z- pregnane-3,20-dione 17-valerate..CLME:246. A compound according to Claim 1 which is 11/3,17o,21-trihydroxy-16ómethyl-5(- 25 pregnane-3,20-dione 17-benzoate..CLME:247. A compound according to Claim 1 which is 11/3,17ó,21-trihydroxy-5olpregnane-3,20- dione 17-acetate..CLME:248. A compound according to Claim 1 which is 11/3,17ó, 21-trihydroxy-5ecpregnane-3,20- dione 17-propionate. 30 249. A compound according to Claim 1 which is 11/3,17z,21-trihydroxy-5ó- pregnane-3,20- dione 17-butyrate..CLME:250. A compound according to Claim 1 which is 11/3,17,21-trihydroxy-5opregnane-3,20- dione 17-valerate..CLME:251. A compound according to Claim 1 which is 11/3,17,21-trihydroxy-5ópregnane-3,20- 35 dione 17-benzoate..CLME:252. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5ó-pregnane-3,20-dione 17-propionate 21-acetate..CLME:253. A compound according to Claim 1 which is 9(z-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5-pregnane-3,20-d!one 17,21-dipropionate. 40 254. A compound according to Claim 1 which is 9oc-fluoro-11/3,17,21 trihydroxy-16/3-methyl- 5ó-pregnane-3,20-dione 17-butyrate 21 -acetate..CLME:255. A compound according to Claim 1 which is 9ó-'fluoro-11/3,17cz,21trihydroxy-16-methvl- 5-pregnane-3,20-dione 17-propionate 21 -acetate. = 256. A compound according to Claim 1 which is 9(z-fluoro-11/3,17ó,21trihydroxy-16C-methyl- 45 5-pregnane-3,20-dione 17,21 -dipropionate..CLME:257. A compound according to Claim 1 which is 9(z-fluoro-11/3,17ó,21 trihydroxy-16ó-methyl- 5oi-pregnane-3,20-dione 17-butyrate 21 -acetate..CLME:258. A compound according to Claim 1 which is 9(z-fluoro-11/3,17(,21trihydroxy-5ó-pregnane- 3,20-dione 17-propionate 21-acetate. 50 259. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-5ó-pregnane- 3,20-dione 17,21-dipropionate..CLME:260. A compound according to Claim 1 which is 9ó-fluoro-11/3,17ol,21trihydroxy-5(-pregnane- 3,20-dione 17-butyrate 21 -acetate..CLME:261. A compound according to Claim 1 which is 9ó-fluoro-11/},17,21trihydroxy-16/3-methyl- 55 5oi-pregnane-3,20-dione 17-propionate..CLME:262. A compound according to Claim 1 which is 9-fluoro-11/3,17z,21trihydroxy-16/3-methyl- 5-pregnane-3,20-dione 17-acetate..CLME:263. A compound according to Claim 1 which is 9(-fluoro-11/3,17ó,21trihydroxy-16/3-methyl- 5ó-pregnane-3,20-dione 17-butyrate. 60 264. A compound according to Claim 1 which is 9ó-fluoro-11/3,17ó,21trihydroxy-16/3-methyl- 5ó-pregnane-3,20-dione 17-valerate..CLME:265. A compound according to Claim 1 which is 9(z-fluoro-11/3,17(,21trihydroxy-16/3-methyl- 5ec-pregnane-3,20-dione 17-benzoate..CLME:47 GB 2 070 016 A 47 u 266. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21- trihydroxy-16o:-methyl- 5o:-pregnane-3,20-dione 17-acetate..CLME:267. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21trihydroxy-16o:-methyl- 5o:-pregnane-3,20-dione 17-propionate..CLME:268. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21trihydroxy-16o:-methyl- 5 5-pregnane-3,20-dione 17-butyrate..CLME:269. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21trihydroxy-16o:-methyl- 5o:-pregnane-3,20-dione 17-valerate..CLME:270. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21trihydroxy-16o:-methyl- 5o:-pregnane-3,20-dione 17-benzoate. 10 271. A compound according to Claim 1 which is 9c-fluoro-11/3,17o:,21 otrihydroxy-5o:-pregnane- 3,20-dione 17-acetate..CLME:272. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21trihydroxy-5ol-pregnane- 3,20-dione 17-propionate..CLME:273. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21 trihydroxy-5o:-pregnane- 15 3,20-dione 17-butyrate..CLME:274. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21trihydroxy-5o:-pregnane- 3,20-dione 17-valerate..CLME:275. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21trihydroxy-5o:-pregnane- 3,20-dione 17-benzoate. 20 276. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21- trihydroxy-I 6./3-methyl- 5o:-pregnane-3,20-dione 17-propionate 21-dihydrogen phosphate..CLME:277. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21trihydroxy-16/-methyl- 5-pregnane-3,20-dione 17-acetate 21 -dihydrogen phosphate..CLME:278. A compound according to Clafm 1 which is 9o:-fluoro-11/3,17o:,21trfhydroxy-16/3-methyl- 25 5o:-pregnane-3,20-dione 17-butyrate 21 -dihydrogen phosphate..CLME:279. A compound according to Claim 1 which is 9-fluoro-11/3,17o:,21trihydroxy-16/3-methyl- 5o:-pregnane-3,20-dione 17-valerate 21 -dihydrogen phosphate..CLME:280. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21trihydroxy-16/3-methyl- 5o:-pregnane-3,20-dione 17-benzoate 21-dihydrogen phosphate. 30 281. A compound according to Claim 1 which is 9-fluoro-11/3,17,21- trihydroxy-16o:-methyl- 5o:-pregnane-3,20-dione 17-acetate 21-dihydrogen phosphate..CLME:282. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21trihydroxy-16o:-methyl- 5o:-pregnane-3,20-dione 17-propionate 21-dihydl'0gen phosphate. _ 283. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21- trihydroxy-16C-methyl- 35 5o:-pregnane-3,20-dione 17-butyrate 21 -dihydrogen phosphate..CLME:284. A compound according to Claim 1 which is 9ó-fluoro- 11/3,17,21trihydroxy- 16ó-methyl- 5o:-pregnane-3,20-dione 17-valerate 21-dihydrogen phosphate..CLME:9o:-fluoro- 11/3,17cz,21 -trihydroxy- 16o:-methyl- phosphate. 40 9o:-fluoro- 11/3,17o:,21-trihydroxy-5o:-pregnane- 285. A compound according to Claim 1 which is 5ó-pregnane-3,20-dione 17-benzoate 21-dihydrogen 286. A compound according to Claim 1 which is 3,20-dione 17-acetate 21-dihydrogen phosphate..CLME:287. A compound according to Claim 1 which is 3,20-dione 17-propionate 21 -dihydrogen phosphate..CLME:288. A compound according to Claim 1 which is 3,20-dione 17-butyrate 21-dihydrogen phosphate..CLME:9 o:-fluoro- 11/3,17,21-trihydroxy-5o:-pregnane- 9o:-fluoro11/3,17,21-trihydroxy-5z-pregnane- 45 289. A compound according to Claim 1 which is 9-fluoro-11/3,17z,21 - trihydroxy-5o:-pregnane- 3,20-dione 17-valerate 21-dihydrogen phosphate..CLME:290. A compound according to Claim 1 which is 9-fluoro-11/3,17z,21trihydroxy-5o:-pregnane- 3,20-dione 17-benzoate 21-dihydrogen phosphate. 50 291. A compound according to Claim 1 which is 9z-fluoro-11/3,17o:,21trihydroxy-16/3-methyl- 5o:-pregnane-3,20-dione 17-propionate 21-disodium phosphate..CLME:292. A compound according to Claim 1 which is 9ó-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5-pregnane-3,20-dione 17-acetate 21-disodium phosphate..CLME:293. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21trihydroxy-16/3-methyl- 55 5ó-pregnane-3,20-dione 17-butyrate 21-disodium phosphate..CLME:294. A compound according to Claim 1 which is 9-fluoro-11/3,17o:,21trihydroxy-16/3-methyl- 5o:-pregnane-3,20-dione 17-valerate 21-disodium phosphate.*.CLME:295. A compound according to Claim 1 which is 9o-fluoro- 11/3,17,21trihydroxy-16/3-methyl- 5o:-pregnane-3,20-dione 17-benzoate 21-disodium phosphate. 60 296. A compound according to Claim 1 which is 9o-fluoro-1 I/3,17o:,21- trihydroxy-I 6o:-methyl- 5o:-pregnane-3,20-dione 17-acetate 21-disodium phosphate..CLME:297. A compound according to Claim 1 which is 9o:-fluoro-11/3,17o:,21 trihydroxy-16o:-methyl- 5o-pregnane-3,20-dione 17-propionate 21-disodium phosphate..CLME:48 GB 2 070 016 A 48 298. A compound according to Claim 1 which is 9o-fluoro-11/3,17o,21- trihydroxy-16z-methyl- 5c-pregnane-3,20-dione 17-butyrate 21-disodium phosphate..CLME:299. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-16o-methyl- 5-pregnane-3,20-dione 17-valerate 21-disodium phosphate..CLME:300. A compound according to Claim 1 which is 9-fluoro-11/3,17a,21trihydroxy-16-methyl- 5c-pregnane-3,20-dione 17-benzoate 21-disodium phosphate..CLME:301. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-5a-pregnane- 3,20-dione 17-acetate 21-disodium phosphate..CLME:302. A compound according to Claim 1 which is 9a-fluoro-11/3,17o,21trihydroxy-5o-pregnane- 3,20-dione 17-propionate 21-disodium phosphate..CLME:303. A compound according to Claim 1 which is 9o-fluoro-11/3,17o,21 trihydroxy-5-pregnane- 3,20-dione 17-butyrat8 2 l-disodium phosphate..CLME:304. A compound according to Claim 1 which is 9o-fluoro-11/3,17,21trihydroxy-5-pregnane- 3,20-dione 17-valerate 21-disodium phosphate..CLME:305. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-5o-pregnane- 3,20-dione 17-disodium phosphate..CLME:306. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5c-pregnane-3,20-dione 17-propionate 21 -hemisuccinate..CLME:307. A compound according to Claim 1 which is 9o-fluoro-11/3,17o,21trihydroxy-16/3-methyl- 5ot-pregnane-3,20-dione 17-acetate 21-hemisuccinate..CLME:308. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5-pregnane-3,20-dione 17-butyrate 21-hemisuccinate..CLME:309. A compound according to Claim 1 which is 9a-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5c-pregnane-3,20-dione 17-valerate 21 -hemisuccinate..CLME:310. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5-pregnane-3,20-dione 17-benzoate 21-hemisuccinate..CLME:311. A compound according to Claim 1 which is 9o-fluoro-11/3,17a,21trihydroxy-16o-methyl- 5-pregnane-3,20-dione 17-acetate 21-hemisuccinate..CLME:312. A compound according to Claim 1 which is 9-fluoro-11/3,17,21 trihydroxy-16o-methyl- 5-pregnane-3,20-dione 17-propionate 21-hemisuccinate..CLME:313. A compound according to Claim 1 which is 9-fluoro-11/3,17,21 trihydroxy-16-methyl- 5-pregnane-3,20-dione 17-butyrate 21-hemisuccinate..CLME:314. A compound according to Claim 1 which is 9-fluoro-11/3,17,21 trihydroxy-16-methyl- 5oL-pregnane-3,20-dione 17-valerate 2 l-hemisuccinate..CLME:315. A compound according to CJaim 1 which is 9o-fluoro-11/3,17,21trihydroxy-16ol-methyl- 5-pregnane-3,20-diene 17-benzoate 21-hemisuccinate..CLME:316. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-5o-pregnane- 3,20-dione 17-acetate 21 -hemisuccinate..CLME:317. A compound according to Claim 1 which is 9z-fluoro-11/3,17oz,21trihydroxy-5ó-pregnane- 3,20-dione 17-propionate 21-hemisuccinate..CLME:318. A compound according to claim 1 which is 9ó-fluoro-11/3,17ó,21trihydroxy-5-pregnane3,20-dione 17-butyrate 21 -hemisuccinate..CLME:319. A compound according to Claim 1 which is 9-fluoro-11/3,170,21trihydroxy-5o-preqnane3,20-dione 17-valerate 21-hemisuccinate..CLME:320. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-5-pregnane- 3,20-dione 17-benzoate 21-hemisuccinate..CLME:321. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5c-pregnane-3,20-dione 17-propionate 21-sodium hemisuccinate..CLME:322. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-16/-methyl- "5c-pregnane-3,20-dione 17-acetate 21-sodium hemisuccinate..CLME:323. A compound according to Claim 1 which is 9c-fluoro-11/3,17o, 214rihydroxy-16/3-methyl- 5-pregnane-3,20-dione 17-butyrate 21-sodium hemisuccinate..CLME:324. A compound according to Claim 1 which is 9o-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5c-pregnane-3,20-dione 17-valerate 21-sodium hemisuccinate..CLME:325. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-16/3-methyl- 5-pregnane-3,20-dione 17-benzoate 21-sodium hemisuccinate..CLME:326. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-16o-methyl- 5-pregnane-3,20-dione 17-acetate 21-sodium hemisuccinate..CLME:327. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-16o-methyl- 5o-pregnane-3,20-dione 17-propionate 21-sodium hemisuccinate..CLME:328. A compound according to Claim 1 which is 9-fluoro-11/3,17,21trihydroxy-16-methyl- 5-pregnane-3,20-dione 17-butyrate 21-sodium hemisuccinate..CLME:329. A compound according to Claim 1 which is 9z-fluoro-11/3,17,21trihydroxy-16z-methyl- 5o-pregnane-3,20-dione 17-valerate 21-sodium hemisuccinate..CLME:-" 49 GB 2 070 016 A 49 330. A compound according to Claim 1 which is 9o-fluoro-11/3,17,21 - trihydroxy- 16e-methyl5-pregnane-3,20-dione 17-benzoate 21-sodium hemisuccinate..CLME:331. A compound according to Claim 1 which is 9o-fluoro-11/3,17,21 trihydroxy-5-pregnane- 3,20-dione 17-acetate 21-sodium hemisuccinate..CLME:332. A compound according to Claim 1 which is 3,20-dione 17-propionate 21 -sodium hemisuccinate..CLME:333. A compound according to Claim I which is 3,20-dione 17-butyrate 21-sodium hemisuccinate..CLME:334. A compound according to Claim 1 which is 3,20-dione 17-valerate 21-sodium hemisuccinate..CLME:335. A compound according to Claim 1 which is 3,20-dione 17-benzoate 2 l-sodium hemisuccinate..CLME:9-fluoro-11/3,17o,21-trihydroxy-5a-pregnane- 5 9-fluoro11/3,17,21-trihydroxy-5-pregnane- 9-fluoro- 11/3,17e,21 -trihydroxy-5 -pregna ne- 9-fl uoro- 11/3,17,21 -trihydroxy-5 a-pregna ne- 336. A compound according to Claim 1 which is 9,11/3-dichloro-17,21dihydroxy-16/3- methyl-5-pregnane-3,20-dione 17-propionate 21-acetate..CLME:337. A compound according to Claim 1 which is 9c,11/3-dichloro-17,21 dihydroxy-16/3- 15 methyl-5o-pregnane-3,20-dione 17,21-dipropionate..CLME:338. A compound according to Claim 1 which is 9,11/3-dichloro-17,21dihydroxy-16/3- methyl-5-pregnane-3,20-dione 17-butyrate 21-acetate..CLME:339. A compound according to Claim 1 which is 9oL,11/3-dichloro-17,21dihy.droxy.-16- methyl-6-pregnane-3,20-dione 17-propionate 21-acetate. 20 340. A compound according to Claim 1 which is 9c,11/3-dichloro-17c,21dihydroxy-16- methyl-5-pregnane-3,20-dione 17,21-dipropionate..CLME:341. A compound according to Claim 1 which is 9,11/3-dichloro-17,21dihydroxy-16- methyl-5-pregnane-3,20-dione 17-butyrate 21-acetate..CLME:342. A compound according to Claim 1 which is 9,11/3-dichloro-17,21dihydroxy-5- 25 pregnane-3,20-dione 17-propionate 21-acetate..CLME:343. A compound according to Claim 1 which is 9,11/3-dichloro-17,21dihydroxy-5- pregnane-3,20-dione 17,21 -dipropionate..CLME:344. A compound according to Claim 1 which is 9c,11/3-dichloro-17c,21dihydroxy-5o- pregnane-3,20-dione 17-butyrate 21-acetate. 30 345. A compound according to Claim 1 which is 11/3,17c,21-trihydroxy-16/3methyl-5- pregnane-3,20-dione 17,21 -dipropionate..CLME:346. A compound according to Claim 1 which is 11/3,17,21-trihydroxy-16/3methyl-5- pregnane-3,20-dione 17-propionate 21-acetate..CLME:347. A compound according to Claim 1 which is 11/3,17oL,21-trihydroxy16/3-methyl-5- 35 pregnane-3,20-dione 17-butyrate 21 -acetate..CLME:348. A compound according to Claim 1 which is 11/3,17,21-tril'iydroxy-16methyl-5- pregnane-3,20-dione 17-propionate 21-acetate..CLME:349. A compound according to Claim 1 which is 11/3,17,21-trihydroxy-16methyl-5- pregnane-3,20-dione 17,21-dipropionate. 40 350. A compound according to Claim 1 which is 11/3,17a,21-trihydroxy-16- methyl-5pregnane-3,20-dione 17-butyrate 21-acetate..CLME:351. A compound according to Claim 1 which is 11/3,17,21 -trihydroxy-5pregnane-3,20- dione 17-propionate 21 -acetate..CLME:352. A compound according to Claim 1 which is 11/3,17,21-trihydroxy-5pregnane-3,20- 45 dione 17,21 -dipropionate..CLME:353. A compound according to Claim 1 which is 11/3,17,21-trihydroxy-5pregnane-3,20- dione 17-butyrate 21-acetate..CLME:354. A compound according to Claim 1 which is 21-chloro-11/3,17-dihydroxy16/3-methyl-5- pregnane-3,20-dione 17-propionate. 50 355. A compound according to Claim 1 which is 21-chloro-11/3,17a- dihydroxy-16/3-methyl-5pregnane-3,20-dione 17-acetate..CLME:356. A compound according to Claim 1 which is 21-chloro-11/3,17-dihydroxy16/3-methyl-Sc- pregnane-3,20-dione 17-butyrate..CLME:357. A compound according to Claim 1 which is 21-chloro-11/3,17-dihydroxy16/3-methyl-5- 55 pregnane-3,20-dione 17-valerate..CLME:358. A compound according to Claim 1 which is 21-chloro-11/3,17adihydroxy-16/3-methyl-5- pregnane-3,20-dione 17-benzoate..CLME:359. A compound according to Caim 1 which is 21-chloro-11/3,17-dihydroxyI 6-methyl-5- pregnane-3,20-dione 17-acetate. 60 360. A compound according to Claim 1 which is 21-chloro-11/3,17-dihydroxy- 16-methyl-5pregnane-3,20-dione 17-propionate..CLME:361. A compound according to Claim 1 which is 21-chloro-11/3,17-dihydroxy16o:-methyl-5- pregnane-3,20-dione 17-butyrate..CLME:GB 2 070 O16 A 50 362. A compound according to Claim 1 which is 21-chloro-11/3,17oL- dihydroxy-16o-methyl-5ó- pregnane-3,20-dione 17-valerate..CLME:363. A compound according to Claim 1 which is 21-chloro-11/3,17-dihydroxy16-methyl-5- pregnane-3,20-dione 17-benzoate..CLME:364. A compound according to Claim 1 which is 21-chloro-11/3,17ódihydroxy-5o-pregnane- 5 3,20-dione 17-acetate..CLME:365. A cpmpound according to Claim 1 which is 21-chloro-11/3,17-dihydroxy5-pregnane- 3,20-dione 17-propionate..CLME:366. A compound according to Claim 1 which is 21-chloro-11/3,17ódihydroxy-5ó-pregnane- 3,20-dione 17-butyrate. 10 367. A compound according to Claim 1 which is 21-chloro-11/3,17-dihydroxy- 5ó-pregnane3,20-dione 17-valerate..CLME:368. A compound according to Claim 1 which is 21 -chloro-11/3,17ódihydroxy-5ó-pregnane- 3,20-dione 17-benzoate..CLME:369. A compound according to Claim 1 which is 21 -chloro-6ó,9ó-difluoro11/3,17-dihydroxy- 15 16/3-methyl-5/3-pregnane-3,20-dione 17-propionate..CLME:370. A compound according to Claim 1 which is 6,9-difluoro-11/3,17o,21 trihydroxy-16/3- methyl-5-pregnane-3,20-dione 17,21 -dipropionate..CLME:371. A 5/3-9,11-epoxy steroid of the formula:.CLME:wherein R2, Re, R7, Rle=, Rle, R17, Rz1 and,,- are as defined in Claim 1; or a pharmaceutically acceptable salt of an acid form thereof..CLME:372.21-chloro-9,11 -epoxy-17o-hydroxy-5/3-pregnane-3,20-dione 17propionate..CLME:3"1% 21 -chloro:9,11 -epoxy- 17-hydroxy-16/3-methyl-5/3-pregnane-3,20dione 17-propionate. 374. 21-chloro-9,11-epoxy-17ó-hydroxy-16-methyl-5/3pregnane-3,20-dione 17-dione. 375.9,11 -epoxy-17,21-dihydroxy-16/3-methyl5/3-pregnane-3,20-dione 17,20-dipropionate. 376. A 5/3-A9tllLsteroid of the formula O--CO--R.? !! I | -R,s R= 0 (Ill) -- R-] H - R6 wherein R2, Rs, RT,Re,,, Re, R7, R21, and, are as defined in Claim 1; or a pharmaceutically acceptable salt of an acid form thereof..CLME:377.17,21-dihydroxy-16/3-methyl-5/3-pregn-9(11)ene-3,20-dione 17,21 dipropionate..CLME:51 GB 2 070 016 A 51 378.17m21-dihydroxy-16o-methyl-5/%pregn-9(11)ene-3,20-dione 17,21 dipropionate..CLME:379.17o(,21 -dihydroxy-5/3-pregn-9( 11)ene-3,20-dione 17,21 -dipropionate..CLME:380. 17,21 -dihydroxy-16/3-methyl-5/-pregn-9(11)ene-3,20-dione 17propionate 21 -mesylate..CLME:381.17ol,21 -dihydroxy-16-methyl-5/3-pregna-9(11)ene-3,20- dione 17propionate 21 - mesylate. 5 382.17,21 -dihydroxy-5/3-pregna-9(11)ene-3,20-dione 17-propionate 21 - mesylate..CLME:383.21 -chloro-17-hydroxy- 16/-methyl-5/3-pregn-9(11)ene-3,20-dione 17propionate..CLME:384. 21 -chloro-17-hydroxy-16-methyl-5/-pregn-9(11)ene-3,20-dione 17.propionate..CLME:385.21 -chloro-17-hydroxy-5/3-pregn-9(11)ene-3,20-dione 17-propionate..CLME:386. A 5-6(11}-21 -hydroxy-steroid of the formula 10 wherein R2, R6, R16=, R6, R7 and,- are as defined in Claim 1; or a pharmaceutically acceptable salt of an acid form thereof..CLME:387. A compound according to Claim 386 wherein R2 and R7 are each hydrogen and R6 is methyl. 15 388. 17e,21 -dihydroxy-16/}-methyl-5(z-pregn-9(11)ene-3,20-dione in the form of its 17- propionate, 17-propionate 21-mesylate, 17-acetate, 17-butyrate, 17valerate or 17-benzoate..CLME:389. A compound according to Claim 386 wherein R2 and R7 are each hydrogen and Re is methyl..CLME: 390. 17(,21 -dihydroxy-16ó-methyl-5(-pregn-9(11)ene-3,20-dione in the formof its 17- 20 acetate, 17-propionate, 17-butyrate, 17-valerate or 17-benzoate..CLME:391. A compound according to Claim 386 wherein R2, R7, R16= and R6 are each hydrogen..CLME:392.17,21 -dihydroxy-5(-pregn-9(11)ene-3,20-dione in the form of its 17acetate, 17- propionate, 17-butyrate, 17-valerate or 17-benzoate..CLME:393. A process for preparing a compound according to any of Claims 1 to 392, which comprises 25 hydrogenating the corresponding pregn-4-ene or pregn-1,4-diene in the presence of a catalyst and, if desired, separating the 5 and 5/} isomers..CLME:394. A process according to Claim 393 wherein the catalyst is palladium supported on carbon, barium carbonate or calcium carbonate, platinum-on-carbon or platinum dioxide..CLME:395. A process for preparing a 5-17ó,21-dihydroxy-steroid of the formula 30 wherein R2, R6, R7, R6,, and R6 are as defined in Claim 1, which comprises 52 GB 2 070 016 A 52 (1) reaction a A"-I 7o,2 ldihydroxy-steroid of the formula wherein R2, R6. R7, Rje.. and Bt6 are as defined above, with an aldehyde of the formula RCHO wherein R is hydrogen or C_, alkyl, to give a blocked steroid of the formula (IVB) (2) reducing the &4-double bond of the compound of formula IVB by reaction with a metal-amine to give a 5ó-17z,21-blocked steroid of the formula..CLME:and (zvc) (3) removing the side chain-blocking group. 10 396. A process according to Claim 395 wherein R16= is methyl..CLME:397. A process according to Claim 395 wherein R16 is methyl..CLME:398. A process according to Claim 395 wherein Rle= and Rle are each hydrogen..CLME:399. A process according to any of Claims 395 to 398 wherein R and R7 are each hydrogen..CLME:400. A process according to any of Claims 395 to 399 wherein the 17,21 blocking group is 15 removed with dilute acid..CLME:401. A process according to any of Claims 395 to 400 wherein the lithiumammonia reduction is performed at less than --35 C..CLME:402. A process according to any of Claims 395 to 401 wherein the metal of the metalamine is lithium or sodium. 20 403. A process according to Claim 402 wherein the metal is lithium..CLME:53 GB 2 070 016 A 53, 404. A process according to any of Claims 395 to 403 wherein the amine of the metal-amine is ammonia, methylamine, ethylamine or ethylenediamine..CLME:405. A process according to Claim 404 wherein the amine is ammonia..CLME:406. A process according to Claim 402 wherein the amine is ammonia..CLME:407. A process according to any of Claims 395 to 406 wherein the aldehyde is formaldehyde. 408. A compound or process substantially as herein described..CLME:409. A pharmaceutical composition comprising a compound as claimed in any preceding compound claim in association with a physiologically acceptable excipient..CLME:Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1981. Published by the Patent Office, Southampton Buildings, London, WC2A lAY, from which copies may be obtained..CLME:
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/117,401 US4318853A (en) | 1980-01-31 | 1980-01-31 | 9β,11β-Epoxy-5β-corticoids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB2070016A true GB2070016A (en) | 1981-09-03 |
| GB2070016B GB2070016B (en) | 1983-09-14 |
Family
ID=22372732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8101407A Expired GB2070016B (en) | 1980-01-31 | 1981-01-16 | 17-acyloxy-5-corticoids and 17-acyloxy-5-corticoids |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4318853A (en) |
| JP (1) | JPS56122398A (en) |
| KR (1) | KR850001208B1 (en) |
| AU (1) | AU538883B2 (en) |
| BE (1) | BE887323A (en) |
| CA (1) | CA1155108A (en) |
| CH (1) | CH644614A5 (en) |
| DE (1) | DE3102397A1 (en) |
| DK (1) | DK39281A (en) |
| ES (1) | ES8300342A1 (en) |
| FR (1) | FR2475048A1 (en) |
| GB (1) | GB2070016B (en) |
| GR (1) | GR73511B (en) |
| IT (1) | IT1193576B (en) |
| NL (1) | NL8100467A (en) |
| PH (2) | PH16525A (en) |
| SE (1) | SE8100563L (en) |
| ZA (1) | ZA8118B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2302807A (en) * | 1995-07-04 | 1997-02-05 | Surtech Int Ltd | Method and composition for treating atopic eczema |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3243482A1 (en) * | 1982-11-22 | 1984-05-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | NEW 6 (ALPHA) METHYL CORTICOIDS, THEIR PRODUCTION AND USE |
| DE3680788D1 (en) * | 1985-10-23 | 1991-09-12 | Upjohn Co | ANGIOSTATIC STEROIDS. |
| NL8900507A (en) * | 1989-03-02 | 1990-10-01 | Philips Nv | AMPLIFIER CIRCUIT WITH SATURATION DETECTION. |
| CA2139549A1 (en) * | 1994-01-28 | 1995-07-29 | Kazumi Ogata | Corticoid derivatives and pharmaceutical and cosmetic compositions |
| DE19737348C2 (en) * | 1997-08-27 | 2002-07-25 | Dan-Gabriel Vulpescu | Pharmaceutical composition containing clindamycin and clotrimazole |
| SI2805720T1 (en) | 2008-05-28 | 2019-11-29 | Reveragen Biopharma Inc | Non-hormonal steroid modulators of NF-KB for treatment of disease |
| US9198921B2 (en) | 2010-04-05 | 2015-12-01 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
| CN102225959B (en) * | 2011-04-29 | 2012-11-07 | 中国科学院上海有机化学研究所 | 16beta-methyl-17alpha-hydroxypreg-3, 20- diketone compound and synthesis thereof |
| US10799514B2 (en) | 2015-06-29 | 2020-10-13 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease |
| US11382922B2 (en) | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2831874A (en) * | 1954-04-20 | 1958-04-22 | Gnrd Patent Holdings Ltd | Improvements in the preparation of 17:21-diacyloxy-2:4-dibromo-3:11:20-triketoallopregnanes |
| US2854465A (en) * | 1955-02-18 | 1958-09-30 | Ciba Pharm Prod Inc | Process for the manufacture of halogen-pregnanes and dehalogenation products thereof |
| DE1195748B (en) * | 1961-06-24 | 1965-07-01 | Vismara Francesco Spa | Process for the preparation of 1'-substituted 17alpha, 21- (1'-alkoxy) -methylenedioxysteriodes |
| US3681410A (en) * | 1970-08-07 | 1972-08-01 | Syntex Corp | Process for preparing 17{60 -hydroxy-20-keto and 17{60 ,21-dihydroxy-20-keto pregnanes and derivatives and intermediates thereof |
-
1980
- 1980-01-31 US US06/117,401 patent/US4318853A/en not_active Expired - Lifetime
-
1981
- 1981-01-02 ZA ZA00810018A patent/ZA8118B/en unknown
- 1981-01-16 GB GB8101407A patent/GB2070016B/en not_active Expired
- 1981-01-16 CA CA000368713A patent/CA1155108A/en not_active Expired
- 1981-01-21 AU AU66513/81A patent/AU538883B2/en not_active Ceased
- 1981-01-24 PH PH25134A patent/PH16525A/en unknown
- 1981-01-26 DE DE3102397A patent/DE3102397A1/en not_active Withdrawn
- 1981-01-26 GR GR63960A patent/GR73511B/el unknown
- 1981-01-27 IT IT19360/81A patent/IT1193576B/en active
- 1981-01-28 SE SE8100563A patent/SE8100563L/en not_active Application Discontinuation
- 1981-01-29 DK DK39281A patent/DK39281A/en not_active Application Discontinuation
- 1981-01-29 ES ES498938A patent/ES8300342A1/en not_active Expired
- 1981-01-30 NL NL8100467A patent/NL8100467A/en not_active Application Discontinuation
- 1981-01-30 BE BE0/203661A patent/BE887323A/en not_active IP Right Cessation
- 1981-01-30 JP JP1178381A patent/JPS56122398A/en active Pending
- 1981-01-30 FR FR8101828A patent/FR2475048A1/en active Granted
- 1981-01-30 KR KR1019810000285A patent/KR850001208B1/en active IP Right Grant
- 1981-01-30 CH CH62681A patent/CH644614A5/en not_active IP Right Cessation
-
1983
- 1983-06-21 PH PH29092A patent/PH19579A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2302807A (en) * | 1995-07-04 | 1997-02-05 | Surtech Int Ltd | Method and composition for treating atopic eczema |
Also Published As
| Publication number | Publication date |
|---|---|
| GR73511B (en) | 1984-03-07 |
| KR830005263A (en) | 1983-08-03 |
| PH16525A (en) | 1983-11-10 |
| ZA8118B (en) | 1982-01-27 |
| KR850001208B1 (en) | 1985-08-20 |
| ES498938A0 (en) | 1982-11-01 |
| PH19579A (en) | 1986-05-26 |
| US4318853A (en) | 1982-03-09 |
| ES8300342A1 (en) | 1982-11-01 |
| BE887323A (en) | 1981-07-30 |
| IT8119360A0 (en) | 1981-01-27 |
| FR2475048A1 (en) | 1981-08-07 |
| SE8100563L (en) | 1981-08-01 |
| CH644614A5 (en) | 1984-08-15 |
| FR2475048B1 (en) | 1984-11-16 |
| AU6651381A (en) | 1981-08-06 |
| NL8100467A (en) | 1981-09-01 |
| GB2070016B (en) | 1983-09-14 |
| AU538883B2 (en) | 1984-08-30 |
| IT1193576B (en) | 1988-07-08 |
| CA1155108A (en) | 1983-10-11 |
| JPS56122398A (en) | 1981-09-25 |
| DK39281A (en) | 1981-08-01 |
| DE3102397A1 (en) | 1981-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4124707A (en) | 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor | |
| US4267173A (en) | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor | |
| US4172132A (en) | 1,3,5(10),6,8,14-19-Nor-pregnahexaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor | |
| CA1099254A (en) | PROCESS FOR THE PREPARATION OF 7 .alpha.-HALOGENO-3-OXO-4- DEHYDRO STEROIDS AND NOVEL 7.alpha.-HALOGENO DERIVATIVES PRODUCED THEREBY | |
| US4336200A (en) | 17α-Acyloxy-5β-corticoids | |
| US4036831A (en) | Trimethyl siloxane steroid intermediates | |
| US4318853A (en) | 9β,11β-Epoxy-5β-corticoids | |
| IE50829B1 (en) | 6alpha-fluoro-9alpha-chloro-prednisolone-17,21 diesters,pharmaceutical compositions containing them and intermediates | |
| CA1065848A (en) | 16-METHYL-9.alpha.-HALO STEROID ESTERS, ETHERS AND PREPARATION THEREOF | |
| US4201778A (en) | 6-Acyloxy-1,4,6-pregnatrienes, their use as anti-inflammatory agents, methods for their manufacture, and 6-oxo-1,4-pregnadiene intermediates | |
| US4427591A (en) | Reduced A ring-Δ9(11) -corticoids | |
| CA1251784A (en) | Steroids esterified in position 17 and thioesterified in position 21, a process for preparing them and their use as medicaments | |
| CA1160623A (en) | Alkylated pregnanes, processes for their preparation and pharmaceutical compositions containing same | |
| US4207316A (en) | Novel 17-substituted 11 β-hydroxy steroids of the pregnane series, their manufacture, preparation and use | |
| US4185101A (en) | 1,3,5(10),6,8-19-Nor-pregnapentaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor | |
| Ayer et al. | Reduced A ring-Δ 9 (11)-corticoids | |
| US3933799A (en) | 11β-Halo-9,12-unsubstituted-C19 -steroids | |
| US3980680A (en) | Process for the preparation of 21-desoxy-17-acyloxy-4-pregnenes and of 21-iodo-21-desoxy-17-acyl oxy-4-pregnene intermediates useful therein | |
| EP0000609B1 (en) | Novel 19-nor-pregnahexaenes, process for the preparation thereof, and pharmaceutical compositions containing them | |
| US3931167A (en) | Process for the manufacture of 3-keto-6-azido-4,6-bis-dehydro-steroids and intermediates useful therein | |
| KR810000311B1 (en) | Process for the preparation of 7-halogeno-3,20-dioxo-1,4-pregnadienes and 4-pregnen | |
| JPH0518838B2 (en) | ||
| KR840000154B1 (en) | Novel 6 -fluoro-prednisolone 17,21-diesters | |
| Phillipps et al. | 11β-Halo-9, 12-unsubstituted-C 19-steroids | |
| US3842075A (en) | Ethers of the pregnane series |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |